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“Finding truth is difficult and the road to it is rough. 
As seekers after truth you will be wise to withhold 
judgment and not simply put your trust in the 
writings of the ancients. You must question and 
examine those writings from every side. You must 
submit only to argument and experiment and not to 
the sayings of any person. For every human being is 
vulnerable to all kinds of imperfection. As seekers of 
the truth we must also suspect and question our own 
ideas as we perform our investigation to avoid 
falling into prejudice or careless thinking. Take this 
course and truth will be revealed to you.” 
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Introduction: Adipose-derived stem cells (ADSC) have been investigated as a potential 
therapy for de novo bone formation around titanium devices. However, the osteogenic 
behaviour of ADSC grown in a clinical grade serum-free medium used for de novo bone 
formation in the presence of titanium devices is unknown. Moreover, the impact of the 
titanium surface on these cells remains elusive. Human ADSC (hADSC) and autologous 
ovine ADSC (oADSC) were cultured in serum-free conditions and used to evaluate in 
vitro and in vivo their de novo bone formation capacity on titanium discs with different 
roughness.  
Hypothesis and research questions: This thesis presented the hypothesis that ADSC 
grown in serum-free conditions would promote de novo bone formation in the presence 
of titanium devices. Moreover, that titanium with micro-rough surfaces would further 
improve the de novo formation of bone. To address this hypothesis two main questions 
were formulated: 1. Do ADSC grown in serum-free conditions have the potential to 
regenerate bone in the presence titanium devices? 2. Does surface 
topography/roughness of titanium devices influence the amount of bone produced by 
serum-free grown ADSC?  
Methods: A number of techniques were employed to answer the proposed questions. 
The machined (MTi) and alumina-blasted (ABTi) titanium surfaces were characterised 
using scanning electron microscopy, energy-dispersive x-ray spectroscopy, and contact 
angle analysis (goniometer). The human and ovine ADSC were cultured using serum-
free and osteogenic conditions. The in vitro growth and osteogenic behaviour of these 
cells were analysed using cell proliferation and extracellular matrix mineralisation. The 
hADSC were further analysed in vitro using immunofluorescence for protein production 
and relative gene expression for genes associated to cell attachment (ITGA1, ITGA5, 
ITGAV, ITGB1, ITGB3), pluripotency and self-renewal (OCT-4 and TERT), and 
osteogenesis (MSX2, RUNX2, and BGLAP). The osteogenic capacity of autologous 
oADSC was further evaluated in vivo using a femur epicondyle de novo bone formation 
model containing titanium devices. This model included the in vivo tracking of oADSC 
using PKH26 cell tracking dye and the de novo bone formation in the defect sites using 
histology and histomorphometry. 
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Results: hOS-ADSC (osteogenically differentiated hADSC) proliferated less than 
hADSC and also produced more mineralised matrix. The immunofluorescence assays 
showed that hADSC cultured in serum-free and osteogenic conditions produced Runx-2 
on titanium surfaces with different roughness, while only hOS-ADSC produced 
osteocalcin as shown by immunofluorescence. The gene expression analysis of hADSC 
demonstrated the stable relative gene expression of RUNX2, MSX2, and BGLAP over 
time. ITGA1, ITGB5, and ITGB1 were all highly expressed at day 0 in hADSC. 
However, only the expression of ITGAV and ITGB3 tended to increase over time in 
hADSC. In contrast, only hOS-ADSC showed an increased expression of ITGA1 over 
time. oADSC cultured in serum-free conditions showed variability in their in vitro 
differentiation potential with cells from only five out of seven animals differentiated 
into osteoblast-like cells. There was no statistically significant difference on the in vitro 
proliferation and mineralisation matrix deposition between oADSC and osteogenically 
induced oADSC (oOS-ADSC) regardless of surface type. The in vivo femoral 
epicondyle model showed that oADSC labelled with PKH26 remained at the defect site 
after one month of healing. However, there was no difference in de novo bone 
formation between the bone defects treated with oADSC and the ones with only blood 
clot after one month.  
Conclusions: In summary, the culture condition had more effect on the osteogenic 
behaviour of hADSC than the titanium surface roughness. Also, the use in vivo of 
autologous oADSC did not improve the de novo bone formation in defects containing 
titanium discs with different surfaces after a period of 1 month. 
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1.1 Introduction and Literature Review 
This thesis aimed to assess the suitability of the use of adipose-derived stem 
cells (ADSC) grown in an especially formulated serum-free medium for de novo bone 
formation in the presence titanium devices with different surfaces. A combination of in 
vitro experiments and a large animal model were used. Although of interest to any field 
of knowledge where de novo bone formation/regeneration on titanium implants/devices 
is important (e.g. Implant Dentistry, Orthopaedic Surgery, Neurosurgery, and Plastic 
Surgery), this thesis focused on Implant Dentistry. Each chapter of this thesis, with the 
exception of the introduction, was written in a manuscript-like fashion to facilitate its 
peer-reviewing. Whenever necessary, the reader will find detailed information on the 
experimental methods and supportive materials (i.e. raw data) in the appendices. 
This chapter provides an introduction and brief literature review on the problem 
and the gap in the scientific knowledge that this thesis addresses. The inclusion of 
clinical scenarios is merely to exemplify areas that could benefit from the work done in 
this thesis. There was no intention in providing a clinical application to the research 
done. 
1.1.1 	Titanium	implants	
Titanium implants are devices made of commercially pure titanium that are 
presented as screws. These implants are placed into the jawbones in direct contact with 
the hosting bone and have been successfully used to replace missing teeth. The 
placement and long-term maintenance of titanium implants/devices requires sufficient 
amounts of bone for anchorage and support. Insufficient quantity/quality for anchoring 
titanium implants is generally due to the placement of implants in large alveolus or 
narrow bone ridges, the immediate or late presence of dehiscence type bone defects post 
implant placement, and an infectious disease called periimplantitis (Zuffetti et al., 2013, 
Aghaloo and Moy, 2007, Elangovan, 2013). 
Titanium implants are available in a number of shapes, sizes, and surfaces. 
Currently, most available titanium implants have machined surface or micro-roughened 
surfaces formed by anodisation, or particle blasting, and/or acid etching (Wennerberg 
and Albrektsson, 2009). These micro-roughened topographies exert important 
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biological effect. Titanium surfaces with different topographies and roughness are 
known to interact in a unique way with adhesion proteins from the extracellular matrix 
(e.g. fibronectin, vitronectin, and albumin) (Sela et al., 2007, Wilson et al., 2005, Jimbo 
et al., 2010). Surfaces with increased roughness have been shown to adsorb more 
protein than smoother counterparts (Protivinsky et al., 2007, Sela et al., 2007). 
However, others have shown that when corrected for the total surface area this 
difference was inversed (Francois et al., 1997). Also, surfaces with increased roughness 
are shown to improve osteoblast adhesion and osteogenesis in vitro, and bone-to-
implant contact in vivo (Yang et al., 2003, Le Guehennec et al., 2007). 
1.1.2 	Forming/Regenerating	 bone	 in	 the	 presence	 titanium	
implants	
A number of clinical procedures done in the dental and medical fields aim for 
the regeneration of bone around titanium. The list is extensive and for this reason only a 
few examples of procedures done in the author’s field of interest are described below.  
Once a tooth is extracted, the clinician decides whether to place an implant 
immediately (immediate implant), between two weeks and two months (immediate-
delayed implant), or at a later stage (>2 months post-extraction, delayed implant) 
(Esposito et al., 2010). The rationale for placing immediate implants included the 
reduction of the treatment time, the preservation of the bone dimensions in post-
extraction sockets, and the improvement of the axial implant positioning thus improving 
bone to implant support and aesthetics (Ashman, 1990, Werbitt and Goldberg, 1992). 
However, current research shows no evidence to support that immediate implant 
placement preserves the bone ridge dimensions (Paolantonio et al., 2001, Esposito et al., 
2010). 
Dehiscence bone defects generally occur in the narrow alveolar ridge on the 
buccal plate of the bone where implants are placed and may lead to compromised 
aesthetics and/or function (Konstantinidis et al., 2014). Such defects can also develop 
during bone healing/remodelling post implant placement (Schropp et al., 2003). The use 
of regenerative techniques (e.g. guided bone regeneration – GBR) to regenerate bone at 
the dehiscence sites does not typically lead to complete regeneration of the defects 
(Chiapasco and Zaniboni, 2009, Dahlin et al., 1995, Becker et al., 1999).  
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Periimplantitis is an infectious disease that is presented as an inflammatory 
lesion affecting the supporting bone of dental implants (Lindhe et al., 2008). It affects a 
large number of implants with reports showing 28% prevalence in patients after 5 years 
(Fransson et al., 2005). Periimplantitis results in the resorption of bone and consequent 
establishment of a bone defect surrounding the implant. These defects vary in shape and 
size with the most common being a chalice-like lesion where the buccal and 
lingual/palatal bone walls remain intact (class Ie) (Figure 1) (Schwarz et al., 2007). The 
different lesions generated by periimplantitis often respond with different degrees of 
success to bone regeneration procedures although none with complete regeneration. 
Research by Schwarz and co-workers (2010) and Elangovan and co-workers (2013) 
indicates that the chalice-like defects (1e) have the best outcomes for regenerative 
procedures when compared to classes Ib and Ic defects. 
 
 
Figure 1 – Periimplantitis bone defects classification (Adapted from Schwarz and co-workers 
(2007)). Dark brown: bone resorption; light brown: native bone ridge. Class Ib – buccal dehiscence 
with semi-circular bone resorption to the middle of the implant body. Class Ic – buccal dehiscence 
with circular bone resorption, but with maintenance of the lingual bone wall. Class Ie – chalice-like 
bone resorption without the loss of the buccal or lingual/palatal bone walls. 
1.1.3 	 	Regenerative	materials	
Considering the previously mentioned problems, de novo bone 
formation/regeneration using graft materials is a step often necessary to support the 
implant. To predictably regenerate bone on titanium implants is a challenging task. The 
gold standard material that has been used for this purpose is the autogenous bone graft 
(Oppenheimer et al., 2008). However, limitations on autogenous bone graft quantity, 
donor site morbidity, and patient acceptance have been raised as disadvantages of its 
use (Nkenke and Neukam, 2014). For these reasons, a number of materials are currently 
being used to replace autogenous bone when augmenting or regenerating the missing 
tissue. These materials are classified as allografts, xenografts, and alloplastic grafts. 
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Although, these materials have been used with some success, they lack the “golden 
trinity” characteristics found in autogenous bone grafts; osteoconduction, 
osteoinduction, and osteogenesis (Becker et al., 1999, Oppenheimer et al., 2008, 
Khoshkam et al., 2013, Chan et al., 2014). Hence, alternative grafting materials with the 
same characteristics of autogenous bone grafts have been sought. 
1.1.4 	Mesenchymal	progenitor	cells	
The use of mesenchymal progenitor cells, so called mesenchymal stem cells 
(MSC), has arisen as an important tool for regenerative procedures including bone. 
MSC are progenitor cells with regenerative potential living in virtually every tissue of 
mesenchymal origin. These cells have been isolated from multiple tissues including but 
not limited to bone marrow, fat, periosteum, gingival connective tissue, dental pulp, and 
periodontal ligament (Pittenger et al., 1999, Zuk et al., 2001, Roberts et al., 2014, Jin et 
al., 2014, Gronthos et al., 2000, Seo et al., 2004). MSC have shown the capacity to 
differentiate into multiple cell types (e.g. osteoblasts, chondroblasts, and adipocytes) 
and to collaborate with the regeneration process of tissues through different 
mechanisms (Figure 2) (Raynaud and Rafii, 2013).  
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Figure 2 – Adapted from Raynaud and Rafii (2013). MSC contribute to the regeneration of tissues 
through different mechanisms. 
 
1.1.4.1 	Adipose	derived	stem	cells	 	
A major source of MSC is the fat deposits found throughout the human body 
from where adipose-derived progenitor cells can be isolated. These cells, called 
adipose-derived stem cells (ADSC), are thought to be located in the peri-vasculature of 
the fat tissues and to present distinct cell populations (Zannettino et al., 2008, Traktuev 
et al., 2008, Tsuji et al., 2014, Li et al., 2011). The use of ADSC is advantageous 
because of their abundance, easy isolation, and multi-lineage differentiation capacity 
(Zuk et al., 2001). ADSC are plastic adherent and been shown to present cell surface 
markers such as CD29, CD44, CD73, CD90, CD105, CD146, CD166, STRO-1. Also 
ADSC do not express CD14, CD31, CD45, CD106, and CD144. Moreover, ADSC can 
differentiate into multiple effector cell lines such as adipocytes, chondroblasts, and 
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osteoblasts (Zuk et al., 2001, Strem et al., 2005, Fraser et al., 2006, Eto et al., 2009). For 
having these characteristics ADSC have shown great potential for de novo bone 
formation/regeneration. Since Zuk and co-workers published their discovery in 2001, 
ADSC has been widely investigated in vitro and in vivo for de novo bone 
formation/regeneration (Tsuji et al., 2014, Romagnoli and Brandi, 2014). However, 
there are still issues associated with the expansion and clinical application of MSC. 
1.1.4.2 	Serum-free	conditions	
One of the major issues regarding the culture of ADSC for clinical application is 
the routine usage of serum of animal origin. Serum of animal origin (i.e. foetal bovine 
serum – FBS) has been traditionally used to provide nutrients and adhesion proteins to 
MSC. However, there is lot-to-lot variation between FBS batches, which affects the 
proliferation and differentiation potential of ADSC. Also, unknown serum proteins have 
an elusive effect on ADSC.  
There is an inherent risk of FBS being contaminated with mycoplasma, prions, 
and viruses; which pose safety concerns for clinical use (Santos et al., 2011, Wang et 
al., 2012, Brunner et al., 2010, Shahdadfar et al., 2005). For these reasons, it is of 
utmost importance that ADSC be cultured in a xeno-free serum-free especially 
formulated medium (Life technologies, Cat. No. 1067501). Moreover, serum-free media 
has been shown not to significantly affect the overall characteristics of ADSC, 
especially their osteogenic differentiation potential (Patrikoski et al., 2013).  
1.1.5 	Titanium	implants	and	ADSC	
The effect of titanium surfaces on ADSC has been investigated over the past 
years (Table 1). Five structural types of titanium were used in the published literature, 
solid flat surfaces (Tognarini et al., 2008, Haslauer et al., 2010, Lopa et al., 2011, Pozio 
et al., 2012, Lee et al., 2013, Marycz et al., 2013, Niada et al., 2013, Tatrai et al., 2013, 
Bennazo et al., 2014, Liu et al., 2014, Marycz et al., 2014, Park et al., 2014), trabecular 
titanium scaffolds (Asti et al., 2010, Gastaldi et al., 2010, Haslauer et al., 2010, Benazzo 
et al., 2014, Ma et al., 2014), titanium screws (De Girolamo et al., 2008, Pieri et al., 
2010, Zollino et al., 2012), porous granules of titanium oxide TiO2 (Dahl et al., 2013), 
and porous TiO2 scaffolds (Pullisaar et al., 2014). This thesis was mostly focused in the 
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solid flat surface of titanium discs to avoid misinterpretations when comparing studies. 
ADSC grown on flat surfaces behave differently than those grown on 3D scaffolds. 
Benazzo and co-workers (2014) demonstrated that undifferentiated human ADSC 
grown on 3D scaffolds have similar expression of the osteogenic related genes ALP and 
RUNX-2 compared to osteogenically differentiated ADSC. In contrast, for cells grown 
on titanium plates, a high expression of ALP and RUNX-2 was only found for 
osteogenically differentiated human ADSC. 
Different types of titanium were used in the experiments with ADSC presented 
in Table 1. The two main types of titanium used for dental/medical reasons are 
commercially pure titanium and Ti6Al4V titanium alloy (Ti6Al4V). In dentistry, the 
material of choice is commercially pure titanium (CpTi) for its purity while in medicine 
is Ti6Al4V for its higher load bearing strength (Wataha, 1996). Ti6Al4V was the 
material of choice used in the majority of the work done with titanium materials and 
ADSC (Tognarini et al., 2008, Asti et al., 2010, Gastaldi et al., 2010, Haslauer et al., 
2010, Maycz et al., 2013, Tatrai et al., 2013, Benazzo et al., 2014). In the work done for 
this thesis, I used commercially pure titanium. The direct comparison of studies using 
cells grown on CpTi and Ti6Al4V has to be done with care. The cellular response of 
cells grown on the two surfaces has been shown to differ significantly, with MG63 cells 
grown on CpTi showing increased osteogenic differentiation compared to cells grown 
on Ti6Al4V (Links et al., 1998). Moreover, CpTi has been shown to present increased 
in vivo osseointegration than Ti6Al4V (Han et al., 1998).  
Tognarini and co-workers (2008) and De Girolamo and co-workers (2008) were 
the first to investigate the behaviour of ADSC seeded on titanium. They demonstrated 
that ADSC could attach and grow successfully on titanium. Moreover, De Girolamo et 
al. (2008) showed the pro-osteogenic effect of titanium on ADSC when compared to 
tissue culture polystyrene (TCPS). Their results showed that osteogenically 
differentiated ADSC cultured on titanium had a 106% increase in the mineralised 
extracellular matrix deposition compared to TCPS. Others reported similar pro-




 The surface of titanium devices has been shown to play an important role in the 
behavior of ADSC. These surfaces have been shown to influence the proliferative and 
osteogenic behavior of ADSC (Table 1). More than a third of the published work on 
ADSC and titanium investigated the modification of the titanium surface and its impact 
on ADSC adhesion, proliferation, and osteogenesis. These modifications included acid 
etching, particle blasting, anodisation, colloidal suspension impregnation, growth factor, 
peptides, and chemical immobilisation, ascorbic acid functionalisation, and titanium 
oxide functionalisation (Lopa et al., 2011, Pozio et al., 2012, Zollino et al., 2012, Lee et 
al., 2013, Marycz et al., 2013, Tatrai et al., 2013, Liu et al., 2014). Generally these 
modifications led to an improvement in adhesion and osteogenic differentiation of 
ADSC. As an example, Tatrai and collaborators (2013) have shown that titanium 
functionalised with a polymer containing a cyclic RGD peptide (Arg-Gly-Asp) or 
fibronectin, improved the adhesion of ADSC adapted to serum-free conditions after 45 
minutes in culture. Also, the same authors have shown a markedly improved 
mineralised matrix production by serum cultured/osteogenically differentiated ADSC 
on the RGD coated titanium compared to untreated titanium. 
 Titanium was shown to have an osteogenic effect on ADSC even without the 
chemical stimulation factors present in the osteogenic medium (i.e. dexamethasone, 
ascorbic acid, and glycerolphosphate). Benazzo and collaborators (2013) tested the 
osteogenic differentiation of ADSC on sandblasted titanium plates without any 
chemical induction of osteogenesis. They found that the protein production and relative 
gene expression of alkaline phosphatase (ALP) and runt-related transcription factor 2 
(RUNX2) were similarly up-regulated in ADSC grown on both titanium surfaces 
compared to TCPS. It is important to note that the up-regulation of ALP and RUNX2 
was significantly higher for osteogenically induced cells compared to undifferentiated 
ADSC. This suggests that the surface characteristics of the titanium device can impact 
in the differentiation of ADSC.  
1.1.5.2 	Titanium	and	serum-free	culture	ADSC	
Only one manuscript addressed the use of serum-free conditions for the culture 
of ADSC on titanium (Tatrai et al., 2013). The authors used cells cultured in serum-free 
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medium to test their ability to adhere to a number of treated titanium surfaces; acid-
etched, RGD peptide coating, and fibronectin coating. The experiment was performed at 
45 minutes post seeding where cells were observed with the aid of time-lapse 
microscopy. After the experimental period of 45 minutes, only cells on titanium coated 
with RGD peptide and fibronectin remained attached to the surfaces. These authors 
demonstrated that ADSC grown in serum-free conditions needed a protein matrix to 
properly attach to the titanium surfaces. A limitation of this paper was that the long-
term attachment and the osteogenic differentiation were not performed for ADSC 
grown in serum-free medium on titanium. 
1.1.5.3 	In	vitro	and	in	vivo	studies	
 The adhesion, proliferative behavior, and osteogenic differentiation of ADSC on 
titanium were mostly investigated in vitro (Table 1). In the majority of studies, the 
adhesion and proliferation of ADSC is higher on TCPS and functionalised (peptide 
coated Ti) than on pure titanium. The only exception was the study performed by De 
Girolamo and collaborators in 2008. They found that the proliferation of cells on 
Ti6Al4V substrates was higher than on TCPS (De Girolamo et al., 2008). The 
osteogenic differentiation of ADSC has been shown to be increased on titanium 
substrates compared to TCPS (De Girolamo., 2008, Lopa et al., 2011, Lee et al., 2013, 
Niada et al., 2013). Niada and collaborators (2013) found a 234% increase in the 
mineralised matrix deposition on titanium substrates compared to TCPS. This 
difference further increased when the titanium substrate was functionalised with a 
peptide or protein such as BMP2 (Lee et al., 2013, Marycz et al., 2013, Tatrai et al., 
2013). The expression of osteogenic related genes such as ALP, RUNX2, BGLAP, 
COL1A1, SPP1 also increased in cells cultured on titanium (Pozio et al., 2012, Zollino 
et al., 2012). The functionalisation of the titanium substrates further increased the 
expression of osteogenic related genes as shown by Zollino and collaborators (2012).  
 As previously discussed, ADSC are affected by the titanium surfaces and its 
modifications in vitro. However, it is not uncommon to find conflicting outcomes 
between in vitro and in vivo investigations. Only one study investigated the use of 
ADSC for de novo bone formation on titanium both in vitro and in vivo (Ma et al., 
2014). The authors reported that osteogenically differentiated ADSC produced large 
amounts of mineralised matrix after 28 days in culture. However, no significant 
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difference in de novo bone formation was found between titanium scaffolds containing 
ADSC and scaffold alone in rat cranial defects after a period of 8 weeks. In contrast, an 
in vivo only study in the calvarium of rabbits showed that the de novo formation of bone 
in contact with titanium implants was improved in a dose-dependant manner using 
ADSC compared to titanium alone (Pieri et al., 2010). 
1.1.6 	Summary	of	literature	and	generation	of	a	hypothesis	
Titanium devices with various shapes, forms, and surface treatments have been 
investigated by researchers who examined new titanium surface treatments for their 
effect on the osteogenic differentiation of ADSC. There are indications that titanium 
would help promoting osteogenesis in ADSC. However, the de novo formation of bone 
using ADSC grown in serum-free conditions on titanium devices with different 
topography and roughness has had little attention. A full understanding on how ADSC 
grown in serum-free conditions interact in vitro and in vivo with widely available 
titanium surfaces would lead to better clinical decisions on their use for de novo bone 
formation/regeneration on titanium implants. It is my hypothesis that ADSC grown in 
serum-free conditions in the presence of titanium devices would promote an increased 
de novo formation of bone. Moreover, titanium with micro-rough surfaces should 
further improve the de novo bone formation compared to machined titanium. To 
evaluate the proposed hypothesis, this thesis addressed two main questions: 
 
1. Do ADSC grown in serum-free conditions have the potential to regenerate bone in 
the presence of titanium devices? 
2. Does surface topography/roughness of titanium devices influence the amount of bone 
produced by ADSC grown in serum-free conditions? 
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This thesis is organised into four chapters containing a general introduction 
(Chapter I), two independent but interconnected experimental chapters in a structure 
similar to a journal article (Chapters II and III), and a final discussion (Chapter IV) 
integrating the experimental chapters and presenting future research directions. Chapter 
I present a brief literature review on the thesis topic, the hypothesis to be tested, and the 
research questions to be addressed. Chapter II analyses the in vitro osteogenic potential 
of human ADSC grown using serum-free medium or osteogenic medium on titanium 
substrates with two different surfaces. Chapter III investigates in a large animal model 
(sheep) the in vitro and in vivo potential of autologous ADSC grown in serum-free 
conditions in the presence of titanium devices with two different surfaces to regenerate 
bone. Chapter IV is a final discussion integrating the knowledge acquired by Chapters II 













Data from this chapter was presented at the IADR/APR 2nd Meeting, Bangkok, 
Thailand, as a poster. This has been published as “Godoy Zanicotti, Diogo, Coates, 
Dawn E, Seymour, Gregory J, Duncan, Warwick J. Human Adipose-derived Stem Cells 
on Titanium Surfaces. J Dent Res Spec Iss 92B, 685, 2013.” 
Comprehensive data from this chapter is under review by the journal Stem Cell 
Research and Therapy: “Godoy Zanicotti, Diogo, Coates, Dawn Elizabeth, Seymour, 
Gregory John, Duncan, Warwick John. Effect of machined and alumina-blasted 
titanium surfaces on the osteogenic differentiation of human adipose-derived stem 
cells.” 
Before clinically testing the bone regenerative potential of serum-free cultured 
ADSC in bone defects containing titanium devices it is important to thoroughly 
investigate this in vitro and in vivo. This would secure the proper clinical use of these 
cells in the future. This chapter aimed to investigate the in vitro osteogenic capacity of 
human ADSC grown in serum free conditions on titanium substrates with two different 
surface characteristics. This was the first step in addressing the hypothesis that that 
ADSC grown in serum-free conditions on titanium devices would promote an increased 
de novo formation of bone.  
The introduction of this chapter contains information already presented in the 
previous chapter, but will help orient the reader presenting relevant information like 
those found in the introduction of a manuscript. The reader will find detailed methods 
and raw data in the appendices section. 
2.1 Introduction 
 Dental implants are commonly used in oral rehabilitations to replace missing 
teeth (Emami et al., 2009). The presence of sufficient bone to anchor these implants is 
paramount. If insufficient bone exists the implant site may be simultaneously 
augmented using bone replacement grafting or other regenerative technologies. Similar 
approaches may be employed to regenerate bone around implants where infection or 
inflammation has caused progressive bone loss. However, evidence suggests that 
grafted material may not completely support de novo bone formation/regeneration 
(Esposito et al., 2009). Esposito and collaborators (2009) did a comprehensive analysis 
 32 
of the bone augmentation techniques used in implant dentistry. They found that 
especially for vertical augmentation around implants, there was a higher incidence of 
complications and limited bone regeneration. New strategies are therefore being sought 
to augment or replace missing bone adjacent to titanium implants. The ideal approach 
would be to augment osseous defects by the surgical implantation of cells with bone 
regenerative capacity. This technique requires an understanding of the interaction 
between the medical device, in this case a titanium dental implant, and the implanted 
cells. 
Dental implants are made mostly of commercially pure titanium (Ti) and vary 
greatly in shape, size, and surface characteristics. Surface topography and roughness are 
dictated by the manufacturing method. Titanium dental implants are initially milled 
using CNC lathes, which results in minimally-rough "machined" surfaces (Ra between 
0.1 and 0.99µm), however most modern dental implants have micro-roughened surfaces 
(Ra = 1.0 to 2.0µm) formed by particle blasting and/or acid etching (Wennerberg and 
Albrektsson, 2009). In vitro studies have shown improved deposition of osteoblasts 
derived mineralised matrix on micro-rough titanium surfaces as compared to smooth 
surfaces (Ra = 0.60 or mirror-like smoothness) (Boyan et al., 2002, Wall et al., 2009). 
Roughened surfaces have also been shown to improve bone-to-implant contact and 
implant survival rates in humans (Le Guehennec et al., 2007, Herrero-Climent et al., 
2013). 
 A promising new technique is the implantation of mesenchymal progenitor cells 
also-called mesenchymal ‘stem cells’ (MSC) to directly replace missing tissue (Kon et 
al., 2012). Tissue regeneration using autologous MSC aims to restore tissue volume and 
function thus maximising stability around titanium implants. Moreover, MSC can 
modulate the immune response and may thus benefit the regeneration process (Calderon 
et al., 2012). MSC can be derived from different sources, including bone marrow, dental 
pulp, and fat (Garcia-Gomez et al., 2010, Hass et al., 2011, Huang et al., 2009). 
Typically MSC constitute up to 2% of the nucleated cells in these tissues and exert 
important roles in tissue homeostasis and repair. These cells retain the ability to 
differentiate into multiple effector cell types, which presents exciting avenues for tissue 
engineering (Strem et al., 2005, Garcia-Gomez et al., 2010). Adipose tissue is a 
particularly attractive source of MSC because it is abundant and easily accessible in the 
human body. Human adipose-derived MSC (hADSC) can differentiate into adipocytes, 
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chondroblasts, and osteoblasts in vitro and have been used for different clinical 
applications, including skeletal tissue repair (Zuk et al., 2002, Bunnell et al., 2008, 
Gronthos and Zannettino, 2011, Sandor et al., 2014). Recent work has also 
demonstrated that these cells can proliferate and differentiate into osteoblasts in contact 
with titanium in vitro (De Girolamo et al., 2008, Tognarini et al., 2008). 
 ADSC adhesion to titanium is mediated via cell-substrate interactions through 
cell adhesion molecules called integrins. These are composed of two non-covalently 
associated transmembrane glycoprotein subunits called α and β integrin subunits 
(Takada et al., 2007, van der Flier and Sonnenberg, 2001). Various integrin subunit 
combinations are known to bind and respond to extracellular matrix (ECM) proteins 
previously absorbed by titanium substrates (Olivares-Navarrete et al., 2011, Olivares-
Navarrete et al., 2010, Wilson et al., 2005). One of the most important titanium-
substrate interactions is the one between integrins and fibronectin. Integrins interact 
with fibronectin through a specific RGD sequence (arginine-glycine-aspartic acid), 
which is likely to influence cell growth and differentiation (Martino et al., 2009, Verrier 
et al., 2002). Important integrins involved in this process are the β1 and β3 subunits. 
The β1 integrin is known to form multiple fibronectin binding heterodimers with varied 
alpha subunits (e.g. α5β1 and αvβ1 integrins) with significant effects over MSC 
proliferation and osteogenic differentiation. Previous studies have shown that blocking 
the β1 subunit in osteoblast-like cells (derived from MSC) compromised their ability to 
produce a mineralised matrix in vitro (Gronthos et al., 2001, Keselowsky et al., 2005). 
In contrast, impairing the function of the β3 integrin subunit may increase the 
deposition of mineralised matrix by osteoblasts-like MC3T3-E1 cells (Keselowsky et 
al., 2005).  
 Although MSC have real potential for tissue engineering, their safety for clinical 
application remains unclear. A significant safety issue is the in vitro culture of these 
cells using serum of animal origin. This presents a potential risk for the transmission of 
diseases such as from mycoplasmas, viruses, and prions. Also, due to batch-to-batch 
variation, animal serum has an unpredictable effect on cell growth and on osteogenesis 
in particular. Therefore, the use of xeno-free serum-free medium may be beneficial for 
the safe and controlled growth of MSC for clinical applications (Santos et al., 2011, 
Wang et al., 2012, Brunner et al., 2010). Unknown proteins in the serum may also 
impact on in vitro cellular behaviour of MSC particularly during attachment and 
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differentiation (Shahdadfar et al., 2005). Therefore, serum free medium could contribute 
to the removal of unknown factors that may lead to misinterpreting in vitro experiment 
results.   
 For this chapter I hypothesised that hADSC, grown in serum-free xeno-free 
media, can form a functional mineralised matrix on titanium substrates and further, that 
roughened titanium surface would have a different effect on this process as compared to 
a “machined” surface. To test this hypothesis, this study aimed to evaluate in vitro the 
behaviour of hADSC, grown in serum-free vs osteogenic medium (positive control 
media), on alumina-blasted (ABTi) and machined (MTi) titanium discs.  
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2.2 Materials and Methods 
2.2.1 	Titanium	discs	
ASTM-F67-95 Grade IV pure titanium (Ti) discs measuring 10mm x 1.5mm 
(diameter x thickness) were donated by and also purchased from Southern Implants 
(Irene, South Africa). The surface of the discs was rutile titanium with either a 
machined titanium surface (MTi) or a surface blasted using alumina (Al2O3) particles 
(ABTi). Discs were sterilised by gamma irradiation by the manufacturer.  
2.2.2 	Surface	characterisation	of	the	Ti	discs	
Fibronectin (from human plasma, Sigma-Aldrich, Cat# F0895) coated and non-
coated titanium discs were used. The former were coated with fibronectin at a 
concentration of 2µg/cm2 for 1hr at RT. The fibronectin solution was discarded and the 
discs used immediately. For the surface characterisation experiments coated discs were 
fixed with 10% neutral buffered formalin (Labserv, Cat# BSPFS426.2.5) for 30min. 
The coated discs were then air-dried and carbon coated for SEM imaging and EDS 
analysis. Surface topography was recorded using field emission scanning electron 
microscopy at 5000x, 8.5µA, and 15KeV (FE-SEM, JEOL 6700F, JOEL Ltd, Tokyo, 
Japan). Elemental analysis was performed by relative quantitation, with the same 
equipment, using energy dispersive x-ray spectroscopy (EDS) at 5000x, 12µA, and 
25KeV for 100sec/area. Contact angle measurement was performed with a goniometer 
fitted with an APPRO B/W camera. Distilled water (5µL) was applied to the surface 
and the contact angle measurement performed after 30sec. The centre and edges of the 
discs were avoided. The contact angle was analysed with FTA 32 version 2.0 software 
(First Ten Ångstroms, Inc., Portsmouth, Virginia, USA).  
 Surface roughness was measured by confocal laser microscopy (LSM510, 
Axioplan 2 imaging, Zeiss, Jena, Germany) as a modification of a previously reported 
technique by Safdar and collaborators (Safdar et al., 2012). An argon laser was used at 
an emission wavelength of 488nm (10%), stack multi-track 8 bit scan mode, pinhole of 
67µm (optical size < 40.2µm), and 20x objective. Stack images were obtained and 
processed in the software FIJI (Schindelin et al., 2012). Using the plug-in Extended 
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depth of field (Forster et al., 2004), a surface-height map was generated and roughness 
analysed with the plug-in SurfCharJ (Chinga et al., 2007). Detailed information on the 
settings used can be found in Appendix 1. Surface roughness analysis displayed Ra 
(arithmetical mean), Rq (root mean square deviation), Rku (kurtosis of the assessed 
profile), Rsk (skewness of the assessed profile), Rv (lowest valley), Rp (highest peak), 
Rt (the total height of the profile), and SA (surface area, calibrated in mm2) in 
accordance to the ISO4287/2000 standard. 
2.2.3 	Cell	culture	
 hADSC (n=3) were purchased from Life Technologies (StemPro hADSC, Cat# 
510070, Lot# 2152, 2033, and 2117) (Appendix 2). These originated from the fat tissue 
harvested from the abdomen of male and female donors aged 39, 63, and 49 years. All 
experiments using hADSC were performed in biological triplicate. The cells were 
cultured according to the manufacturer instructions. A more detailed cell culture 
procedure is presented in Appendix 3. All media used are described in Appendix 17. All 
products used for cell culture were purchased from Life Technologies, USA unless 
stated otherwise. Briefly, hADSC were cultured in 75cm2 tissue culture flasks (T75, 
Greiner Bio-one, Cat# 658175) coated for 1 hour (in humidified atmosphere at 37°C 
and 5% CO2) with CELLstart CTS (Cat# A10142) 1:100 solution in PBS (Cat# 
SALB010). Serum-free medium (SFM, StemPro MSC SFM Xeno-free KIT, Cat# 
A1067501) was used for the cell culture. This serum-free medium (SFM) was also 
supplemented with 1% GlutaMAX-I CTS (Cat# A12860), 0.05% gentamycin 
(10mg/mL) (Cat# 15710064), and 1% antibiotic-antimycotic (Cat#15240). Cells were 
plated at 5x103 cells/cm2 and expanded until 90% confluence in humidified atmosphere 
at 37°C and 5% CO2. Medium was replaced after 24 hours and then every 2 days. Cells 
were passaged with TrypLE Express (Cat# 12604012). In all endpoint assays cells were 
used at the 4th passage. 
2.2.4 	hADSC	 tri-lineage	 differentiation	 (osteogenesis,	
adipogenesis,	and	chondrogenesis)	
 The manufacturer had characterised the hADSC demonstrating plastic adherence 
and positive expression ≥ 95% for the cell surface antigens CD29, CD44, CD73, CD90, 
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CD105, and CD166 (Appendix 2). Also, the purchased hADSC showed negative 
expression ≤ 2% for the cell surface antigens CD14, CD31, and CD45. To confirm 
hADSC multipotency, a tri-lineage differentiation assay for osteogenesis, adipogenesis, 
and chondrogenesis was conducted. Eight-well glass chamber slides (Labtek, Cat# 
NUN154534) were coated with human fibronectin (Sigma Aldrich, Cat# F0895) for 1hr 
at a concentration of 2µg/cm2. The culture conditions followed the manufacturer’s 
recommendations (Appendix 4). Cells were plated on each well at a concentration of 
1x104 cells/cm2 in complete SFM for the osteogenesis and adipogenesis assays. For the 
chondrogenesis assay, cells were plated in a single 5µL droplet at a concentration of 
8x104 cells/droplet (micromass). The micromass was cultured in 100% humidity at 
37ºC and 5% CO2 for 2 hours and then the chondrogenesis medium was added. In all 
other assays, a specialised differentiation medium replaced the SFM after 24 hours and 
was subsequently replaced every 3 days. In each case wells containing SFM as control 
for the differentiation were included. 
 Detailed methods for tri-lineage differentiation and staining are presented in 
Appendix 4. Cells for the osteogenesis assay were cultured in StemPro Osteogenic 
differentiation kit medium (OM) (Cat# A10072-01) for 21 days. This kit contained the 
StemPro Osteocyte/Chondrocyte differentiation basal medium (Cat# A10069-01) and 
the StemPro Osteogenesis supplement (Cat# A10066-01). The osteogenesis supplement 
contained 10% foetal bovine serum (FBS), dexamethasone, L-ascorbic acid, and β-
glycerophosphate.  
 Cell for the adipogenesis assay cells were cultured in StemPro Adipogenesis 
differentiation kit medium (AD) (Cat# A10070-01). This kit contained the StemPro 
Adipocyte differentiation basal medium (Cat# A10410-01) and the StemPro 
Adipogenesis supplement (Cat# A10065-01). The adipogenesis supplement contained 
10% (FBS), human insulin, dexamethasone, indomethacin, and IBMX (3-isobutyl-1-
methylxanthine).  
 Cells for the chondrogenesis assay were cultured in StemPro Chondrogenesis 
differentiation kit medium (CD) (Cat# A10071-01). This kit contained the StemPro 
Osteocyte/Chondrocyte differentiation basal medium (Cat# A10069-01) and the 
StemPro Chondrogenesis supplement (Cat# A10064-01). The chondrogenesis 
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supplement contained ITS plus (insulin, human transferrin, and selenous acid), L-
ascorbic acid, L-proline, dexamethasone, and recombinant human TGFβ-3.  
  All differentiation media was also supplemented with 0.05% gentamycin 
(10mg/mL), and 1% antibiotic-antimycotic. 
 After the given culture periods for each of the tri-lineage assays, cells were 
washed in PBS and then fixed in 70% ethanol for 1 hour (osteogenesis) or 10% neutral 
buffered formalin for 30 minutes (adipogenesis and chondrogenesis). Osteogenesis, 
chondrogenesis, and adipogenesis were accessed through staining with Alizarin red S, 
alcian blue, and oil red O respectively. Alizarin red S and Alcian Blue staining methods 
followed the protocol found at the differentiation kits manuals. Oil red O followed the 
protocol proposed by Lillie and Ashburn in 1943 (Ellis, 2014) (Appendix 3). 
2.2.5 	Experiments	with	hADSC	and	titanium	discs	
 Experiments involving titanium discs were performed in tissue culture 
polystyrene (TCPS) 48-well plates with a well diameter of 1.2 cm (Cellstar, Greiner 
Bio-one, Cat# 677180) The only exception was the immunofluorescence experiment 
where 8-well glass slides (Labtek, Cat# NUN154534) were used as a control substrate 
to avoid the fluorescent background signal commonly found in TCPS. Undifferentiated 
hADSC (hADSC; n=3) that had been cultured in SFM and hADSC that had been grown 
in osteogenic differentiation medium (hOS-ADSC) were used in these experiments. 
MTi/hADSC, MTi/hOS-ADSC, ABTi/hADSC, and ABTi/hOS-ADSC were randomly 
allocated to the wells of 48-well plates. TCPS with either hADSC or hOS-ADSC were 
used as controls. Test and controls were conducted in triplicate. Each well was coated 
with human fibronectin (Sigma-Aldrich, Cat# F0895) at a concentration of 2µg/cm2 for 
1 hour prior to cell plating. Cells were plated at a concentration of 5x103 cells/cm2. For 
the osteogenic differentiation (hOS-ADSC), cells were initially cultured on each 
substrate in SFM for 24 hours and then in OM medium for the rest of the experiment. 
Medium was replaced after 24 hours and then every 3 days. 
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Table 2 – Groups included in the experiments with hADSC and titanium discs. 
Group Name Substrate Cells 
hADSC / TCPS TCPS hADSC 
hADSC / MTi MTi hADSC 
hADSC / ABTi ABTi hADSC 
hOS-ADSC / TCPS TCPS hOS-ADSC 
hOS-ADSC / MTi MTi hOS-ADSC 
hOS-ADSC / ABTi ABTi hOS-ADSC 
 
2.2.5.1 	Proliferation	of	hADSC	on	titanium	
 ADSC proliferation on titanium was evaluated at 2, 6, 12, and 24 hours using 
the AlamarBlue assay (Life Technologies, Cat# DAL1025) according to the 
manufacturer’s instructions. A detailed method can be found in Appendix 5. Briefly, at 
baseline (24 hours after plating) the culture medium (SFM) was replaced by 1mL of 
SFM or OM medium containing 10% AlamarBlue. Controls included a 100% reduced 
alamarBlue (no cells, SFM or OM with 10% alamarBlue autoclaved at 121°C for 
15min) and 0% reduced alamarBlue (no cells, SFM or OM with 10% alamarBlue). At 
each of the time-points, 100µL of medium with alamarBlue from each sample was 
retrieved, placed in a 96-well plate, and read. The fluorescent signal was measured in a 
Synergy 3 microplate reader (Biotek Instruments, USA) at a wavelength of 530-560nm 




Equation 1 – %Reduction of AlamarBlue 
% Reduction = Fx – F0% red / F100% red – F0% red. 
Fx = fluorescence signal from sample  
F0% red = fluorescence signal from 0% reduced alamarBlue 
F100% red = fluorescence from 100% reduced alamarBlue control 
 
2.2.5.2 	hADSC	and	the	production	of	Runx-2	and	Osteocalcin	on	titanium	
 hADSC and hOS-ADSC that had been grown on titanium discs were then 
washed with PBS and fixed with ice-cold acetone for 10 minutes. The discs were glued 
with clear epoxy resin (Araldite, Selleys, New Zealand) onto glass slides. Protein 
production of Runt-related transcription factor 2 (Runx-2) and Osteocalcin were 
evaluated on both titanium and glass by immunofluorescence at 7 and 21 days 
respectively. The detailed immunofluorescence procedures can be found in Appendix 6. 
Immunofluorescence for Runx-2 was performed using a mouse monoclonal anti-human 
Runx-2 antibody (clone: MAAG6111, Creative Biomart, Cat# CAB-8176MH) at 
5µg/mL. Mouse IgG (Santa Cruz, Cat# sc2025) at 5µg/mL was used as negative control 
antibody. Cells were fixed in ice-cold acetone for 10 minutes. Antigen retrieval and 
membrane permeabilisation were performed by incubating fixed cells with PBS 
containing 0.25% Triton X-100 for 10 minutes. Alexa 488 anti-mouse (Life 
Technologies, Cat# A11059) was used at 5µg/mL. 
Immunofluorescence for Osteocalcin was performed using the mouse 
monoclonal anti-human antibody to Osteocalcin (clone: OCG4, abcam, ab13421) at 
2.5µg/mL. Mouse IgG (Santa Cruz, Cat# sc2025) at 2.5µg/mL was used as negative 
control antibody. Alexa 488 anti-mouse (Life Technologies, Cat# A11059) was used as 
secondary antibody at 5µg/mL. 
A 1% non-fat milk wash in PBS was used between the primary and secondary 
antibodies to reduce background fluorescence. 
Cells were counterstained with a mounting medium containing DAPI (Vector 
Laboratories, Cat# H-1200). Images were obtained with a Leica DM5000B microscope 
at an augmentation of 400x using a Spot camera and software (version 5.2). The 
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software ImageJ (version 2.0.0-rc-14/1.49g) and Photoshop CS6 (version 13.0 x64 
Extended) were used for image processing and analysis. 
2.2.5.3 	hADSC	mineralised	matrix	deposition	on	titanium	
The mineralised matrix assay was an adaptation of previously published 
protocols (Gregory et al., 2004, Stanford et al., 1995). Mineralised matrix deposition by 
hADSC and hOS-ADSC on TCPS, MTi, and ABTi was evaluated by measuring the 
absorbance of Alizarin red S staining extracted with cetylpyridinium chloride after 21 
days of culture. Detailed information can be found in Appendix 7. Alizarin red S binds 
approximately 2mol of Ca++/mol of dye in solution (Puchtler et al., 1969, Stanford et al., 
1995). Briefly, cells were stained for 10 minutes with 500µL of 40mM Alizarin red S, 
pH 4.2 (Sigma-Aldrich, Cat# A5533) at room temperature (RT) with gentle shaking. 
Stained cells were washed with PBS and then incubated with 1mL of 10% (w/v) 
cetylpyridinium chloride (Sigma Aldrich, Cat# C0732) in 10mM sodium phosphate, pH 
7.0, for 20 minutes at RT with gentle shaking. Duplicate aliquots (200µL) from each 
sample were transferred to a 96-well plate and read with a Synergy 3 microplate reader. 
Absorbance was measured at a wavelength of 570nm. An Alizarin red S standard curve 
was generated to determine the actual concentration according to the protocol from 
Millipore for the Osteogenesis assay kit (Cat# ECM815). Briefly, a 2-fold serial dilution 
with a range between 2000 and 1.8µM was constructed. 
2.2.5.4 	hADSC	and	the	expression	of	genes	associated	with	pluripotency,	
osteogenesis,	and	cell	attachment		
 The design for the gene expression experiments is presented in Figure 1. Single 
gene assays were performed by quantitative reverse transcriptase real-time PCR 
(RT2qPCR) for genes associated with pluripotency and cellular self-renewal, cell 
attachment, and osteogenesis. These were evaluated for hADSC and hOS-ADSC at 
baseline (24 hours after plating), 7 and 21days. These time-points were selected to 
incorporate an early and a later stage of osteogenic differentiation. Detailed methods 
and raw data can be found in Appendix 8. Total RNA from cells grown on both 
titanium substrates and TCPS was extracted with TRIzol reagent (Life Technologies, 
Cat# 15596-026). The RNA was purified with a PureLink RNA mini kit (Life 
Technologies, Cat# 12183025). Genomic DNA (gDNA) contamination was removed 
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with On-column PureLink DNase treatment (Ambion, Life Technologies, Cat# 
12185010). Then, cDNA was synthesised from 500ng of RNA using the High Capacity 
cDNA Reverse Transcription kit (Life Technologies, Cat# 4368813). Quantitative 
RT2PCR was performed according to the manufacturer instructions with SYBR green 
assays (SABiosciences) (Table 3). 
 
 
Figure 3 – Gene expression experiment design. Each sample was compared to its matched surface 
at baseline (24 hours after plating). The surfaces investigated were TCPS (tissue culture 
polystyrene), MTi (machined titanium) and ABTi (alumina (Al2O3)-blasted titanium). Note that 
because the OM (osteogenic medium) was used for the first time 24 hours after plating the baseline 
groups were all in SFM (serum-free medium). 
 
Table 3 – Single gene assays (SA Biosciences). 
Group Gene Ref. Seq. Cat # 
Reference 
(Housekeeping) 
PGK1 NM_000291 PPH02049A 
Pluripotency and Self-
renewal 
POU5F1  NM_002701 PPH02394E 
Pluripotency and Self-
renewal 
TERT NM_198253 PPH00995E 
Osteogenesis MSX2 NM_002449 PPH02139F 
Osteogenesis RUNX2 NM_004348 PPH01897C 
Osteogenesis BGLAP NM_199173 PPH01898A 
Cell attachment ITGA1 NM_181501 PPH00627B 
Cell attachment ITGA5 NM_002205 PPH00176C 
Cell attachment ITGAV NM_002210 PPH00628C 
Cell attachment ITGB1 NM_002211 PPH00650B 
Cell attachment ITGB3 NM_000212 PPH00178D 
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Controls without reverse transcriptase, no template controls, agarose gel 
electrophoresis, and melting curves were used to confirm the lack of gDNA 
contamination and assess the quality of the reactions (Appendix 8). The selection of 
reference gene was made after analysis of results from an array of 32 human reference 
genes (Human endogenous control fast plate, TaqMan Array 96-well plate, Cat# 
4426700, Applied Biosystems, Life Technologies) (Appendix 9). 
The data analysis used the relative quantification method 2-∆∆Cq as described by 
Livak and Schmittgen (2001) (Equation 2). A formula was applied to generate the fold 
change for each sample. Then the data was converted into biologically meaningful 
values to determine up and down-regulation (fold regulation) (Equation 3). 
 
Equation 2 – Fold change formula 
Fold regulation = 2-∆∆Cq 
∆Cq sample - ∆Cq Calibrator* = ∆∆Cq 
∆Cq sample = Cq target gene – Cq reference gene 
∆Cq calibrator = Cq target gene – Cq reference gene 
*Calibrator was the baseline samples for each surface (Baseline/hADSC/TCPS, 
Baseline/hADSC/MTi, and Baseline/hADSC/ABTi) 
 
Equation 3 – Fold regulation transformation formulas 
Values between 0 and 0.99 = -1/x 
Values = 1 = 0 




 Biological triplicates were performed for all experiments with hADSC (n=3). 
One-way ANOVA statistical testing was used for multiple group comparison (Graphpad 
Prism 6). The former was corrected for multiple comparisons with the Tukey post hoc 
test. Statistical significance was established at p≤0.05. For the gene expression 
statistical analysis each sample was compared to its matched surface at baseline (24 
hours after plating). Baseline was established at 24 hours after plating (Figure 3). The 
minimum level for an expressed gene to be considered detected was established at Cq 
value of 35. For a gene to be considered up or down-regulated it was determined a 
threshold of ±2 fold. Data was obtained using the Applied Biosystems 7500 Fast Real-
time PCR system. 
2.3 Results 
2.3.1 	Titanium	discs	surface	characterisation	
 The raw results for the titanium discs characterisation can be found in Appendix 
1. Scanning electron microscopy demonstrated differences in surface topography 
between the MTi and ABTi discs. The MTi surface was shown to be smoother than the 
ABTi surface with parallel grooves caused by the machining process on the MTi 
surface (Figure 4). The roughened ABTi was more heterogeneous in nature and 
characterised by pits and peaks. Elemental analysis by EDS showed titanium to be the 
primarily constituent of both surfaces. Surface contamination of both disc types with 
nitrogen and carbon was identified. A further contamination with aluminium has been 
found only on the ABTi surface (Table 4). When the surfaces were coated with 
fibronectin, EDS analysis showed an increased presence of carbon and oxygen as 
expected for protein coating. 
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Figure 4 – SEM micrographs of non-coated (A, B) and fibronectin coated (C, D) MTi (machined 
titanium) and ABTi (alumina (Al2O3)-blasted titanium) surfaces. Note the distinct patches of 
fibronectin in both surfaces (red patches – fibronectin coated areas were colourised to illustrate the 
adhered protein). Scale bars = 25µm (A, B) and 50µm (C, D). 
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Table 4 – EDS elemental analysis of fibronectin-coated and uncoated MTi (machined titanium) and 
ABTi (alumina (Al2O3)-blasted titanium) surfaces. Semi-quantitative values are expressed in %. 
Elements are presented per their chemical symbols. T = traces of element (<1%). 







C T 3 1 16 
N 3 T 1 - 
O - 17 38 32 
Na - 2 T T 
Al - - 10 10 
Si - - T T 
Ti 97 77 47 42 
Fe - - 2 - 
K - - T - 
P - T - T 
  
 Fibronectin coated surfaces had an interesting and distinct pattern of protein 
adsorption on the surface. On MTi the protein adsorption followed the valleys found 
between the machined grooves while on ABTi the adsorption pattern had a star-like 
shaped pattern (Figure 4C & D).  
 Roughness results are shown on Table 5 The mean surface roughness (Ra) was 
higher for ABTi 2.06 ± 0.19µm (mean ± SD) than for MTi 0.45 ± 0.20µm. The 
increased roughness of ABTi was confirmed by the Rq values, which measures the root-
mean square average of the roughness profile. The skewness of the surface Rsk that 
indicates the predominance of peaks was higher for MTi due to the grooving produced 
by the machining process. For a similar reason the Rsk indicates the presence of very 
high peaks on the MTi surfaces (Table 5). 
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Table 5 – Surface roughness results for MTi (machined titanium) and ABTi (alumina (Al2O3)-
blasted titanium) surfaces. The parameters evaluated for the surface roughness analysis were Ra 
(arithmetical mean), Rq (root mean square deviation), Rku (kurtosis of the assessed profile), Rsk 
(skewness of the assessed profile), Rv (lowest valley), Rp (highest peak), Rt (the total height of the 
profile), and SA (surface area, calibrated in mm2) in accordance to the ISO4287/2000 standard. 
Standard deviation is represented between parentheses. 
 Surface Roughness 




































 The ABTi surface was the most hydrophilic surface tested. The fibronectin 
coating did not affect significantly the contact angle on either surface (Table 6). 
 
Table 6 – Contact angle results for fibronectin coated and non-coated MTi (machined titanium) 





MTi 81.84 (3.39) 73.41 / 90.27 
Coated 
MTi 
83.01 (3.78) 73.62 / 92.40  
ABTi 69.60 (2.88) 62.45 / 76.76 
Coated 
ABTi 




 hADSC (n=3), grown in specialised medium (osteogenic, adipogenic, and 
chondrogenic), were successfully differentiated into osteoblast-like, chondroblast-like, 
and adipocyte-like cells. Cells grown in serum-free medium did not undergo tri-lineage 
differentiation (Figure 5).  
 
 
Figure 5 – Images are representative of 3 independent experiments. hADSC (n=3) were induced 
with specialised medium to differentiate into osteoblasts (A), chondroblasts (C), and adipocytes (E).  
hADSC cultured for the same length of time in SFM did not differentiate (B, D, and F). Cells were 




 The growth of hADSC and hOS-ADSC on the titanium surfaces after 7 and 14 
days reflected the topographical pattern of the surface (Figure 6). Cells on MTi were 
aligned to the grooves created by the machining process. In contrast, cells that attached 
to ABTi demonstrated random orientation.  
 
Figure 6 – Fluorescence panel for hADSC (undifferentiated hADSC) and hOS-ADSC 
(osteogenically differentiated hADSC) stained for F-actin with phalloidin conjugated with a 594 
fluorchrome cultured on MTi (machined titanium) and ABTi (alumina (Al2O3)-blasted titanium) 
surfaces at 7 and 14 days. DAPI counterstaining (Blue). Note the organisation of cells along with 
the machined grooves of MTi and the apparent disorganised distribution of cells on ABTi. Scale 
bar = 50µm. 
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 An AlamarBlue assay showed that hADSC in serum-free medium proliferated 
more than hOS-ADSC regardless of the surface type. This increased proliferation of 
hADSC was statistically significant for hOS-ADSC on ABTi compared to hADSC on 
ABTi, MTi, and TCPS (p=0.04, p=0.02, and p=0.008 respectively) (Figure 7).  
 
 
Figure 7 – Proliferation of hADSC at 2, 6, 12, and 24 hours – undifferentiated cells (Blue) and hOS-
ADSC – osteogenically differentiated cells (Red) cultured on TCPS (1st and 2nd bars), MTi (3rd and 
4th bars), and ABTi (5th and 6th bars) surfaces (n=3). Repeated measures (RM) ANOVA - *p<0.05 
and **p<0.01. Error bars (SEM). 
 
 Immunofluorescence showed that there was no difference in the production of 
protein for the osteogenic related transcription factor Runx-2 on either of the Ti 
surfaces, nor on the control glass slide. The hADSC and hOS-ADSC cells both showed 
nuclear expression of Runx-2 after 7 days of culture (Figure 8). Only hOS-ADSC 
produced Osteocalcin at 21 days and there were no differences between glass and 
titanium substrates (Figure 9). 
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Figure 8 – Immunofluorescence panel for Runx-2 expression in hADSC (undifferentiated cells) and 
hOS-ADSC (osteogenically differentiated cells) grown on glass, MTi (machined titanium), and 




Figure 9 – Immunofluorescence panel for Osteocalcin expression in hADSC (undifferentiated cells) 
and hOS-ADSC (osteogenically differentiated cells) grown on glass, MTi (machined titanium), and 
ABTi (alumina (Al2O3)-blasted titanium) surfaces at 21 days. Scale bar = 25µm. 
 
 The production of mineralised matrix was evaluated by Alizarin red S staining 
after 21 days of culture. TCPS modestly stimulated the production of mineralised 
matrix by hOS-ADSC, but this was not statistically significant when compared to 
hADSC. In contrast the titanium substrates stimulated a higher production of 
mineralised matrix in hOS-ADSC compared to hADSC (p<0.05) (Figure 10). No 
significant difference in mineralised matrix production was found between either 




Figure 10 – Mineralisation assay results. The concentration of Alizarin red S (ARS) was measured 
at 21 days of the culture of hADSC (undifferentiated cells) and hOS-ADSC (osteogenically 
differentiated cells) grown on TCPS (tissue culture polystyrene), MTi (machined titanium), and 
ABTi (alumina (Al2O3)-blasted titanium) surfaces (n=3). ANOVA - *p<0.05, **p<0.01, and 
***p<0.001. Error bars (SEM). 
 
2.3.3.1 	Gene	expression	
 Detailed methodology and raw results for the gene expression experiments can 
be found in Appendix 8. Gene expression revealed the influence of distinct cellular 
phenotypes (hADSC and hOS-ADSC) and substrates in genes linked to pluripotency 
and self-renewal, cell attachment, and osteogenesis. 
 A standard curve analysis was performed for each gene expression assay used. 
This curve analysis was used to determine the efficiency of the assay and to check the 
minimum quantity of cDNA needed for the RT2qPCR reactions. All assays were found 
to have approximate efficiencies ranging between 90 and 110%. The quantity of cDNA 
to be used in the RT2qPCR reactions was found to be sufficient at 5ng. No template 
(NTC) and no reverse transcriptase controls (NORT) had only undetected signals 
(Cq>35). The melting curve analysis was used to check the dynamics of a double cDNA 
strand containing fluorchrome “melting” into single strands; therefore showing the 



























































analysis has shown that whenever the gene expression was detected the fluorescent 
signal for each sample presented a single peak and a smooth decline in the fluorescent 
signal (Cq>35). On the other hand multiple peaks and disturbance of the decline of the 
fluorescent signal were observed in samples where the gene expression was not detected 
(Cq>35). Gel electrophoresis was also used to show the specificity of the gene 
expression assays used. All assays were shown to be very specific amplifying a single 
size of cDNA strand matching the manufacturer’s specifications. 
 The self-renewal associated gene TERT was not expressed in either of the 
investigated cell lines (Cq>35; Appendix 8). The pluripotency associated OCT4 gene 
was highly up-regulated in hOS-ADSC at 21 days on TCPS when compared to hADSC 
(Figure 11) at 21 days on TCPS (p<0.05). Moreover, cells cultured on the MTi surface 
showed a greater variability in its gene expression of OCT4 between cell lines 




Figure 11 – Relative gene expression (2-ΔΔCq) of OCT4 at 7 and 21 days in hADSC (undifferentiated 
cells) and hOS-ADSC (osteogenically differentiated cells) grown on TCPS (tissue culture 
polystyrene), MTi (machined titanium), and ABTi (alumina (Al2O3)-blasted titanium) compared to 
cells grown on its matched surface at Baseline (24 hours after plating) (n=3). Symbols = 
7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC ( ), and 21days/hOS-ADSC ( ). 
ANOVA - *P<0.05. Error bars (SEM). 
 
 The expression of integrin genes varied among cell types and Ti surfaces (Figure 
12, Figure 13, Figure 14, Figure 15, and Figure 16). ITGA1 expression was 
significantly up-regulated in hOS-ADSC at 7 days on all investigated surfaces 
compared with hADSC on all surfaces and time-points (p<0.05), with the exception of 
hADSC on MTi after 7 days. The regulation of ITGA1 in hADSC remained stable for 
cells cultured on all surfaces at both time-points. ITGA5 was down-regulated in all 
groups. Although not significant, there was a pronounced down-regulation of ITGA5 on 
both titanium surfaces at 21 days in cells originated from two patients. ITGAV and 
ITGB3 showed a trend to be up-regulated in all groups (not statistically significant). 





























































































































































surfaces or time-points. However there is a clear tendency towards down-regulation of 
ITGB1 in both cell lines regardless of the surface or time-points. Cells originating from 
two patients showed an important (>10 fold) down-regulation of ITGB1 in hADSC and 
hOS-ADSC on MTi at 21 days. This increased down-regulation was also found at 21 
days for hOS-ADSC culture on ABTi. 
 
 
Figure 12 – Relative gene expression (2-ΔΔCq) of ITGA1 at 7 and 21 days in hADSC 
(undifferentiated cells) and hOS-ADSC (osteogenically differentiated cells) grown on TCPS (tissue 
culture polystyrene), MTi (machined titanium), and ABTi (alumina (Al2O3)-blasted titanium) 
compared to cells grown on its matched surface at Baseline (24 hours after plating) (n=3). Symbols 
= 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC ( ), and 21days/hOS-ADSC ( ). 


































































































































































Figure 13 – Relative gene expression (2-ΔΔCq) of ITGA5 at 7 and 21 days in hADSC 
(undifferentiated cells) and hOS-ADSC (osteogenically differentiated cells) grown on TCPS (tissue 
culture polystyrene), MTi (machined titanium), and ABTi (alumina (Al2O3)-blasted titanium) 
compared to cells grown on its matched surface at Baseline (24 hours after plating) (n=3). Symbols 
= 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC ( ), and 21days/hOS-ADSC ( ). 























































































































































Figure 14 – Relative gene expression of ITGAV in hADSC and hOS-ADSC at 7 and 21 days 
cultured on TCPS, MTi, and ABTi compared to cells grown on its matched surface at Baseline (24 
hours after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC (


























































































































































Figure 15 – Relative gene expression of ITGB1 in hADSC and hOS-ADSC at 7 and 21 days 
cultured on TCPS, MTi, and ABTi compared to cells grown on its matched surface at Baseline (24 
hours after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC (

















































































































































Figure 16 – Relative gene expression of ITGB3 in hADSC and hOS-ADSC at 7 and 21 days 
cultured on TCPS, MTi, and ABTi compared to cells grown on its matched surface at Baseline (24 
hours after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC (
), and 21days/hOS-ADSC ( ). Error bars (SEM). 
 
 The differentiation state of the cells and surface type also modulated the 
expression of the osteogenesis related genes MSX2, RUNX2, and BGLAP 
(Osteocalcin) (Figure 17, Figure 18, and Figure 19). None of the osteogenic related 
genes were significantly up-regulated in either cell line grown on any of the surfaces. 
There was obvious variability on the expression of RUNX2 and BGLAP in 
differentiated cells (hOS-ADSC) from different patients. This variability was not found 

















































































































































Figure 17 – Relative gene expression of MSX2 in hADSC and hOS-ADSC at 7 and 21 days cultured 
on TCPS, MTi, and ABTi compared to cells grown on its matched surface at Baseline (24 hours 
after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC ( ), and 

































































































































































Figure 18 – Relative gene expression of RUNX2 in hADSC and hOS-ADSC at 7 and 21 days 
cultured on TCPS, MTi, and ABTi compared to cells grown on its matched surface at Baseline (24 
hours after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 7days/hOS-ADSC (









































































































































































Figure 19 – Relative gene expression of BGLAP (Osteocalcin) in hADSC and hOS-ADSC at 7 and 
21 days cultured on TCPS, MTi, and ABTi compared to cells grown on its matched surface at 
Baseline (24 hours after plating) (n=3). Symbols = 7days/hADSC ( ), 21days/hADSC ( ), 

































































































































































 This study evaluated the response of hADSC grown in SFM on titanium 
substrates with different topographies (MTi and ABTi) and the effects of osteogenic 
differentiation on these cells. Before testing the hypothesis, the cells (hADSC) were tri-
lineage differentiated to verify multipotency. This validation step aimed to supplement 
the manufacturer’s data confirming the multipotency of the hADSC and to fulfil the 
criteria proposed by the International Society for Cellular Therapy (ISCT) (Dominici et 
al., 2006). The cells used in this study did express the pluripotency-associated gene 
OCT4. Surprisingly, this expression was found to be higher in hOS-ADSC than in 
hADSC. This result may be likely linked to the OCT4 gene assay itself (Wang and Dai, 
2010). The OCT4 primers are mapped to a position that does not discriminate between 
the A and B isoforms of this gene (position 1245, band size 138bp, NM_002701.4). The 
two splice variants of OCT4 are known to have different functions (Wang and Dai, 
2010, Liedtke et al., 2008). OCT4A encodes a protein involved in maintaining 
pluripotency whereas OCT4B has no known function but has been associated with 
multiple cellular events (Wang et al., 2009). Although not tested in this study, the OCT4 
up-regulation detected in hOS-ADSC could be OCT4B and may be associated with 
unknown cellular events linked to osteogenesis.  
 In this study it was hypothesised that hADSC, grown in serum-free media, 
would form a functional mineralised matrix on ABTi and MTi substrates. Instead, I 
found that hADSC cultured in SFM maintained their undifferentiated state, 
independently of the titanium surface roughness, topography, and hydrophilicity. There 
was no significant increase in expression of MSX2, RUNX2, or Osteocalcin RNA or 
protein over time suggesting that the cultured hADSC retained their multipotential 
phenotype. The cells also failed to produce a mineralised matrix over the 21-day time 
frame investigated in this study, regardless of the surface they were cultured on.  
 The effect of titanium surface roughness and topographic features on hADSC is 
not fully understood. Titanium micro-rough surface has been shown to stimulate 
adhesion and proliferation of MSC when compared to MTi (Baschong et al., 2007, 
Mante et al., 2003). In contrast, the results of this study have shown that the surface 
topography had little impact on proliferation rates of hADSC or hOS-ADSC. This is in 
 65 
agreement with previous reports for hADSC on titanium substrates (Haslauer et al., 
2010, Balloni et al., 2009). 
 One of the most accepted concepts, for the substrate influence on cell behaviour, 
involves the adsorption of ECM proteins on the titanium surface. The surface 
hydrophilicity, topography, and roughness determine the adsorption kinetics of proteins, 
influencing both concentration and biological activity (Protivinsky et al., 2007, Yang et 
al., 2013, Chatakun et al., 2013). Subsequent cellular adhesion, proliferation, and 
differentiation are modulated by the pattern of protein adsorption on the titanium 
surface (Yang et al., 2013). According to the results of this study, in which the same 
dose of fibronectin was applied to functionalise all substrates, surface topography had 
little effect on cell growth, even though the pattern of the surface determined the way 
cells adhered to it. Fibronectin was necessary for hADSC attachment using SFM, as 
these cells did not attach to either TCPS or titanium substrates without fibronectin.  
 The contact angle is directly linked to surface wettability. Higher contact angles 
are translated into hydrophobicity whereas the inverse means hydrophilicity (Chow, 
1998, Kanniah et al., 2013). The ABTi surface was found to be more hydrophilic than 
MTi. Moreover, ABTi are known to adsorb higher quantities of ECM proteins 
compared to hydrophobic surfaces (Lee et al., 2012, Vadillo-Rodriguez et al., 2013). 
Consequently cell processes like adhesion, proliferation, and differentiation should be 
affected (Yang et al., 2003, Garcia et al., 1999, Lee et al., 2012). The results of this 
study indicated that the surface had no clear impact on the proliferation of hADSC. 
However, titanium substrates encouraged the production of mineralised matrix at a 
higher rate than TCPS and significantly increased the production of mineralised matrix 
in hOS-ADSC compared to hADSC (p≤0.001 for MTi and p≤0.05 for ABTi). 
Conflicting data on the effect of hydrophilicity have been reported. Olivares-Navarrete 
and collaborators (2010) have shown that titanium micro-rough substrates with 
increased hydrophilicity lead to increased osteogenesis in MSC (Olivares-Navarrete et 
al., 2010). On the other hand others showed no significant impact of titanium 
hydrophilicity on the differentiation of MSC (Wall et al., 2009).  
 The surface characteristics of the plastic and titanium had varied effects on 
integrin gene expression in hADSC and hOS-ADSC as well as other cellular functions. 
This shows that the surface characteristics play an important role in the cell-to-substrate 
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adhesion (Luthen et al., 2005). Cell-to-substrate (ECM) adhesion receptors are shown to 
mediate cell adhesion, surface pattern recognition, and differentiation (Takada et al., 
2007, Garcia et al., 1999, Olivares-Navarrete et al., 2008). Some integrin heterodimers, 
like α5β1, αvβ1, and αvβ3 are known to interact with fibronectin (Takada et al., 2007, 
Keselowsky et al., 2005). The results of this study show that the genes encoding the 
subunits α1, α5, and β1 were expressed in hADSC at baseline at similar levels all 
surfaces. In contrast αv and β3 expressions were down-regulated on titanium substrates 
compared to TCPS (Appendix 8). ITGB1 showed a trend towards down-regulation in 
both hADSC and hOS-ADSC on titanium surfaces after 7 and 21 days. This down-
regulation did not compromise the capacity of hOS-ADSC to produce mineralised 
matrix over time. This differs from previous published work where the blocking of β1 
affected the mineralised matrix deposition by osteoblast-like cells (Keselowsky et al., 
2005, Gronthos et al., 2001). I also observed stable regulation of ITGA5 over time in all 
groups with only two exceptions. A prominent down-regulation of ITGA5 in hOS-
ADSC from two patients after 21 days growth on MTi and ABTi at 21 days suggests 
that ITGA5 is no longer necessary for osteoblastic differentiation once the cells become 
fully mature hOS-ADSC. This result is corroborated by other work showing that α5 
integrin is deeply involved in the differentiation of MSC into osteoblasts; the protein 
level of α5 integrin was constant during osteoblast maturation (Moursi et al., 1997, 
Hamidouche et al., 2009).  
 The results of the present study are also in agreement with the previously 
reported binding competition between α5β1 and αvβ3 for the fibronectin RGD site 
(Danen et al., 1995). All hADSC cell lines had a markedly higher expression at baseline 
of ITGA5 and ITGB1 (mean±CI Cq of 24.54±0.48 and 22.29±0.43 respectively) 
compared to ITGAV and ITGB3 (mean±CI Cq of 25.27±0.38 and 27.72±0.92 
respectively). This preference for the α5β1 interaction with fibronectin was shown to be 
essential for normal osteogenesis as previously discussed (Moursi et al., 1997, 
Hamidouche et al., 2009). To confirm this ITGA5 was shown to be up-regulated during 
the early differentiation of hOS-ADSC (7 days). Interestingly, that is an apparent 
ITGB3 up-regulation in hADSC and hOS-ADSC cultured on all surfaces at 7 and 21 
days. I believe that this up-regulation could be the result of a shift by our cells to use the 
integrin heterodimer αvβ3 over the α5β1. 
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 Over the time course of the experiment, the most marked difference found in 
this study was the increased expression of ITGA1 in hOS-ADSC, which was found to 
be highly up-regulated after 7 days and then declined by 21 days. The same was not 
observed in hADSC at any time-point or on any surface; expression levels remained 
unaltered. Surprisingly, the production of ITGB1 in hADSC and hOS-ADSC decreased 
over time, which contradicts current thinking. It was expected the expression of ITGB1 
to be up-regulated at least in the first 7 days of culture like ITGA1. The α1 and α2 
subunits are known to each form a dimer with β1 and modulate the production of 
collagen I (Heino, 2014). Collagen I is a marker for early osteoblastic differentiation 
(zur Nieden et al., 2003).  
 I also evaluated whether hADSC and hOS-ADSC would express the osteogenic-
related proteins Runx-2 and Osteocalcin on titanium. Runx-2 is a master transcription 
factor for osteogenesis (Komori, 2002). The results showed similar protein expression 
of Runx-2 by hOS-ADSC on all substrates at 7 days (including glass). Even cells in 
SFM (hADSC) expressed this “osteogenic marker” at the same level as hOS-ADSC on 
all substrates. A few cellular events could explain this expression. Runx-2, through an 
interaction with mitotic genes, has an active role determining the phenotype of progeny 
cells during mitosis (Young et al., 2007). Runx-2 has also been shown to repress self-
renewal genes such as TERT, in BMSC (Isenmann et al., 2007). TERT was not 
expressed in either hADSC or hOS-ADSC at any time-point on any surface. This is in 
line with previous data that TERT is turned off by Runx-2. Therefore, Runx-2 may be 
responsible for MSC pre-committing to a non-terminal differentiated state (pre-
osteoblast/chondroblasts) (Komori, 2010, Isenmann et al., 2007).  
 Osteocalcin is the most abundant non-collagenous protein found in bone and 
produced by osteoblasts (Neve et al., 2013). The gene encoding this protein (BGLAP) is 
known to interact with RUNX2 in order to determine the maturation of hADSC into 
hOS-ADSC (Qi et al., 2003). The immunofluorescence results showed pronounced 
protein expression of Osteocalcin by hOS-ADSC on all substrates after 21 days. 
However, gene expression of Osteocalcin in hOS-ADSC on any of the surfaces did not 
increase over time. Egusa and collaborators (2007) also reported stable expression over 
time for BGLAP. This may be rather explained by the translation efficiency, which is 
more related to protein production then mRNA levels (Schwanhausser et al., 2011). 
Also, this could be due to variations in the differentiation/maturation state of hOS-
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ADSC in cells sourced from different individuals. In support of this theory, I found 
similar cell line variability in the gene expression of MSX2 in hOS-ADSC. This gene 
interacts with RUNX2 during the osteogenic differentiation of MSC and is essential for 
the osteoblastic maturation process (Satokata et al., 2000, Qi et al., 2003).  
 hOS-ADSC had a slower proliferation rate when compared to hADSC. This was 
possibly related to the differentiation process itself (Filipak et al., 1989). These results 
were expected since proliferation arrest and differentiation induction are closely 
associated. This is associated with MSC undergoing a growth arrest at a distinct cell 
cycle state (GD, which is part of G1) prior to differentiation (Filipak et al., 1989, Scott et 
al., 1982). Also, some specific serum-free media have been shown to promote the 
proliferation of hADSC when compared to those that contains serum (Patrikoski et al., 
2013, Lund et al., 2009).  
 The differentiation mechanism of hADSC into hOS-ADSC greatly affected the 
production of a mineralised matrix. As expected, this was clearly prominent in 
differentiated cell cultures (hOS-ADSC) (Lim et al., 2009). Also, the substrates 
themselves did not promote significant variation in the matrix production quantities. 
These results are in agreement with a previous report (Hacking et al., 2008). 
Conversely, the matrix deposition has been shown by others to increase along with 
increased surface roughness (Wall et al., 2009). This could be explained by the 
difference in culture conditions (SFM versus serum-containing media), titanium surface 
characteristics (alumina-blasted titanium versus sand-blasted/acid etched - SLA), and 




 The differentiation of hADSC into hOS-ADSC had more effect on cell 
proliferation, mineralised matrix production, and gene expression than the topography 
and characteristics of the titanium surfaces on which they were cultured. Gene 
expression also provides clues in the mechanisms involved with cell adhesion and 
differentiation of hADSC cultured on MTi and ABTi in SFM. To my knowledge this is 
the first report of the influence of titanium substrates on hADSC cultured in a clinical 
grade serum-free medium. Finally, this study has shown that multipotent hADSC grown 
in SFM and committed to an osteogenic phenotype demonstrate potential for bone 












The previous chapter investigated the osteogenic in vitro capacity of human 
ADSC grown in serum-free conditions on titanium substrates. The human cells showed 
the capacity to synthesise a mineralised matrix on different titanium substrates. 
Ultimately, the results demonstrated that hADSC have the potential to be used in the 
rehabilitation of individuals requiring bone regeneration around titanium implants. 
However, the safe and predictable clinical use of ADSC for bone regeneration cannot be 
performed directly in humans without further in vivo testing preferably in large animal 
models. For this reason, this chapter aimed to investigate the in vivo use of autologous 
ovine ADSC cultured in SFM condition to generate de novo bone in defects containing 
titanium discs with different surfaces. In addition these cells were characterised in vitro 
to allow a better understanding of their behaviour and its usefulness as a model for 
human ADSC. 
The introduction of this chapter contains information already presented in the 
previous chapter, but will help orient the reader presenting relevant information like 
those found in the introduction of a manuscript. The reader will find detailed methods 
and raw data in the appendices section. 
3.1 Introduction 
 Titanium implants are often used in dental and medical rehabilitations requiring 
bone anchorage. A lack of bone to support the implant can compromise the viability and 
long-term stability of such treatments. For this reason a diversity of bone grafts have 
been used to regenerate bone around these devices with limited success (Esposito et al., 
2009, Beswick and Blom, 2011). 
The surface topography and roughness of titanium implants are known to 
influence the biological response of bone. Compared to smooth surfaces (Ra < 1), the 
micro-rough ones (Ra = 1.0 to 2.0µm) have been demonstrated to improve bone 
deposition on its surfaces (Boyan et al., 2002, Le Guehennec et al., 2007, Herrero-
Climent et al., 2013).  
 The use of mesenchymal multipotent progenitor cells also known as 
mesenchymal stem cells (MSC) have been advocated as an alternative to regenerate 
bone (Kon et al., 2012). These cells are found in the adipose tissue, so-called adipose 
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derived stem cells (ADSC), contributing to the maintenance of tissue homeostasis and 
repair (Zuk et al., 2001). The ability of these cells to differentiate into multiple effector 
cells, such as osteoblasts, is recognised as a potential tool for bone regeneration 
(Romagnoli and Brandi, 2014). Recent work has demonstrated that these cells can 
regenerate bone in vivo (Gu et al., 2014). Also, the de novo formation/regeneration of 
bone on titanium substrates has been demonstrated. Pieri and collaborators (2010) have 
shown that the association of anorganic bovine bone with ADSC led to a significantly 
more new de novo bone formation/regeneration and higher bone-to-implant contact 
(BIC) than the anorganic scaffold alone. 
 Culturing cells in serum-free conditions has been regarded as paramount for the 
safe clinical use of these cells. Serum-free culturing conditions avoid the drawbacks of 
the use of animal serum such as the contamination risk by mycoplasma, prions, and 
viruses, batch-to-batch variability, and its unpredictable effect in cell growth and 
differentiation (Shahdadfar et al., 2005, Brunner et al., 2010, Santos et al., 2011, Wang 
et al., 2012). Therefore, pre-clinical animal studies would benefit from the use of 
serum-free media. 
 According to Pearce and collaborators (2007), there are a number of animal 
models used for orthotopic bone regeneration studies.  In this study we used sheep as a 
large animal model due to its size, weight, and bone remodelling similarities to humans 
(Pearce et al., 2007). Other animal models have also been considered highly similar to 
humans such as dogs, pigs, and non-human primates (Pearce et al., 2007). However, 
dogs and non-human primates have been involved in ethical debates and highly rejected 
by the general society. Pigs in particular have been extensively used for the study of the 
implantation of titanium devices (Manzano et al., 2014). Pigs would make a good 
alternative to sheep but the latter is easier to source in New Zealand. Pigs in particular 
have been extensively used for the study of the implantation of titanium devices. Also, 
sheep have been extensively used for testing the implantation of titanium devices into 
bone and regenerative techniques (Peric et al., 2014).  
I hypothesised that autologous ovine adipose-derived stem cells (oADSC), 
grown under serum-free conditions, would regenerate bone when placed in contact with 
alumina-blasted (ABTi) and machined (MTi) titanium devices. Moreover, the rougher 
surface of (ABTi) would increase the amount of bone formed compared to MTi. To test 
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this hypothesis, this study aimed to evaluate in a sheep femur epicondyle model the in 
vivo capacity of oADSC, grown in SFM, to regenerate bone on ABTi and MTi titanium 
discs. 
3.2 Materials and Methods 
 The Animal Ethics Committee of the University of Otago approved this study 
(Approval No. 12/13) (Appendix 10). 
3.2.1 	Titanium	discs	
 Pure titanium discs ASTM-F67-95 grade IV, measuring 10mm x 1.5mm 
(diameter x thickness) were purchased from Southern Implants (Irene, South Africa). 
The surface of the discs was rutile titanium with either machined titanium (MTi) 
(Ra=0.45) or a surface blasted with alumina (Al2O3) particles (ABTi) (Ra=2.06). The 
manufacturer sterilised the discs by gamma irradiation. A detailed characterisation of 
the titanium discs can be found in Chapter II. 
3.2.2 	Animals	
 All surgeries were carried out at the Hercus Taieri Research Unit at the 
University of Otago (HTRU, Dunedin, New Zealand). The study was performed in 7 
mature female Perendale sheep (Ovis aries). The animals weighted on average 56.06kg. 
Before each surgical procedure the animals were anaesthetised with sodium thiopentone 
10mg/kg (IV) (Jurox New Zealand, Cat# G9046). General anaesthesia was maintained 
with halothane 1-2% to effect (Piramal Healthcae Ltd, Cat# DNH22021). The operative 
site was shorn and prepared with 2% chlorhexidine (Riotane®, Orion Laboratories Pty 
Ltd, Cat# R1002191F) and 10% povidone-iodine solution (Betadine®, Pfizer, Cat# 
61035065) and the body draped with sterile disposable drapes. Aseptic technique and 
sterile instruments were used at all times. Local anaesthetic infiltration with 
Scandonest® 2% containing adrenaline 1:100,000 (Septodont, Cat# 09821172700) was 
administered adjacent to the operative site to control bleeding. 
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3.2.3 	Isolation	and	primary	oADSC	culture	
 All cell culture procedures were performed at the Molecular Biosciences 
Laboratory from the School of Dentistry of the University of Otago. The isolation of 
oADSC followed, with slight modifications, a previously published protocol (Niemeyer 
et al., 2010a). A detailed method on the primary isolation and culture of oADSC 
including SFM adaptation can be found in Appendix 11. All media used are described 
in Appendix 17. Detail on the surgical procedure can be found in Appendix 12. Briefly, 
under general anaesthesia, approximately 10g of adipose tissue were obtained through 
surgical dissection with a scalpel blade No. 15 (Swann-Norton, Cat# 0305) from the fat 
deposits at the hip region of each animal. Blood was also collected and the autologous 
sheep serum (SS) obtained to be used for the culture of the primary cell line. The tissue 
was transferred immediately after surgery to the cell culture facility for processing. 
The tissue was transported in a PBS solution containing 20mg/mL of BSA 
(Sigma Aldrich, Cat# 05470) and 1% antibiotic-antimycotic (Life Technologies, Cat# 
15240) at room temperature. The tissue was washed in the transportation solution a 
number of times, cut into small pieces (approximately 1mm3), and digested for 90 
minutes at 37ºC under light agitation in a 0.6mg/mL collagenase II solution (Sigma 
Aldrich, Cat# C6885). The enzyme activity was neutralised with a serum-free medium 
(SFM) (StemPro MSC SFM Xeno-free KIT, Life Technologies, Cat# A1067501) 
supplemented with 2.5% autologous sheep serum (SS). The SFM was also 
supplemented with 1% GlutaMAX-I CTS (Life Technologies, Cat# A12860), 0.05% 
gentamycin, and 1% antibiotic-antimycotic. The cells were resuspended and strained 
through a 70µm cell strainer to remove cell clumps and endothelial aggregates. The 
cells were washed and resuspended in SFM with 2.5% SS. Cells were plated at a full 
concentration into a T75 coated with 1µg/cm2 bovine fibronectin (Sigma Aldrich, Cat# 
F1141) and gently washed after 1 hour with PBS to remove non-adherent cells 
(Griesche et al., 2010). The cells were kept in a humidified atmosphere at 37°C and 5% 
CO2. The medium was replaced every 48hrs following a serum-free adaptation protocol 
(below). The cells were passaged with TrypLE Express (Life Technologies, Cat# 
12604012) at 80-90% confluence and plated at a concentration of 5x103 cells/cm2. Cells 
at 4th passage with a minimum viability of 96% were used at this study.  
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3.2.4 	Serum-free	adaptation	of	oADSC	
 Cells cultured in SFM with 2.5% SS were adapted to a complete SFM system 
supplemented only with 1% GlutaMAX-I CTS, 0.05% gentamycin, and 1% antibiotic-
antimycotic. Briefly, cells in P0 (passage 0) were cultured in SFM with 2.5% SS. If the 
cell yield was poor, the concentration of SS was increased to 20% (only necessary for 
cells from 1 animal). The use of SS was halted at P1 (passage 1) and they were 
exclusively cultured in SFM thereafter. If 20% SS was used, cells were passaged to 
2.5% on P1 and then to complete SFM at P2. After the adaptation, cells were cultured 
according to the adapted SFM manufacturer’s protocol detailed in Chapter 2 and 
Appendix 3. 
3.2.5 	oADSC	tri-lineage	differentiation	
 To confirm oADSC multipotency, a tri-lineage differentiation assay 
(osteogenesis, adipogenesis, and chondrogenesis) was performed on 8-well glass slides 
(Labtek, Cat# NUN154534). A detailed method on the tri-lineage differentiation of 
oADSC can be found in Appendix 4. Each well was coated with 2µg/cm2 bovine 
fibronectin for 1 hour. Cells at the 4th passage were used in all experiments. For the 
osteogenesis assay, osteogenic medium (oOM) was used. The oOM contained complete 
SFM supplemented with 10% autologous SS, 500µM of 2-phospho-L-ascorbic acid 
trisodium salt (Sigma Aldrich, Cat# 49752), 10nM of dexamethasone (Sigma Aldrich, 
Cat# D2915), and 10mM of ß-glycerophosphate (Sigma Aldrich, Cat# G9422). Cells 
were plated at a concentration of 1x104 cells/cm2 in complete SFM. The oOM replaced 
the SFM after 24 hours and was subsequently replaced every 3 days. Cells were 
cultured in osteogenic conditions for 21 days. 
 The culture conditions for chondrogenesis and adipogenesis assays (Life 
Technologies, Cat# A10071-01 and A10070-01 respectively) followed the 
manufacturer’s recommendations. Both differentiation media were also supplemented 
with 0.05% gentamycin and 1% antibiotic-antimycotic. Cells were plated on each slide 
at a concentration of 1x104 cells/cm2 in complete SFM for the osteogenesis and 
adipogenesis assays. For the chondrogenesis assay, cells were plated in a single 5µL 
droplet at a concentration of 8x104 cells/droplet (micromass). The micromass was 
cultured in 100% humidity for 2 hours and then the chondrogenesis medium (CD) was 
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added. In the adipogenesis assay, an adipogenic differentiation medium (AD) replaced 
the SFM after 24 hours and was subsequently replaced every 3 days. Cells were 
cultured in chondrogenic and adipogenic conditions for 14 days. 
 After the given culture periods for each of the assays, cells were washed in PBS 
and then fixed in 10% formalin for 30 minutes. Osteogenesis, chondrogenesis, and 
adipogenesis were assessed through staining with alizarin red S, alcian blue, and oil red 
O respectively (Sigma Aldrich, Cat# A5533, A3157, and O0625). Alizarin red S and 
Alcian Blue staining methods followed the protocol found at the differentiation kit’s 
manual. Oil red O followed the protocol proposed by Lillie and Ashburn in 1943 (Ellis, 
2014). 
3.2.6 	In	vitro	experiments	with	oADSC	and	titanium	discs	
 Cell lines at the 4th passage from three animals were used in these experiments. 
The in vitro experiments were performed in tissue culture polystyrene (TCPS) 48-well 
plates with a well diameter of 1.2cm (Cellstar, Cat# 677180, Greiner Bio-one, 
Germany). Undifferentiated oADSC cultured in SFM and oADSC grown in osteogenic 
differentiation medium (oOS-ADSC) were used in these experiments. MTi or ABTi 
discs and oADSC or oOS-ADSC were randomly allocated to the wells. TCPS was used 
as a control surface. Each well was coated with bovine fibronectin at a concentration of 
2µg/cm2 for 1 hour prior to cell plating. Cells were plated at a concentration of 5x103 
cells/cm2. Appropriate medium (SFM or OM) was replaced after 24 hours and then 
every 3 days. 
3.2.7 	Proliferation	of	oADSC	on	titanium	
 oADSC proliferation on titanium was evaluated at 2, 6, 12, and 24 hours using 
the AlamarBlue assay (Life Technologies, Cat# DAL1025) according to the 
manufacturer’s instructions. A detailed method can be found in Appendix 5. Briefly, at 
baseline (24 hours after plating) the culture medium (SFM) was replaced by SFM or 
OM containing 10% AlamarBlue. Controls included a 100% reduced alamarBlue (no 
cells, SFM or OM with 10% alamarBlue autoclaved at 121°C for 15 minutes) and 0% 
reduced alamarBlue (no cells, SFM or OM with 10% alamarBlue). At each of the time-
points, 100µL of medium with alamarBlue from each sample was retrieved, placed in a 
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96-well plate, and read. The fluorescent signal was measured in a Synergy 3 microplate 
reader (Biotek Instruments, USA) at 530-560nm excitation and 590nm emission 
wavelength. The reduction of alamarBlue (%) was calculated using the formula: 
 
Equation 4 – %Reduction of alamarBlue 
% Reduction of alamarBlue = Fx – F0% red / F100% red – F0% red. 
Fx = fluorescence signal from sample  
F0% red = fluorescence signal from 0% reduced alamarBlue control 
F100% red = fluorescence from 100% reduced alamarBlue control 
3.2.8 	oADSC	mineralised	matrix	deposition	on	titanium	
 The mineralised matrix assay was an adaptation of previously published 
protocols (Gregory et al., 2004, Stanford et al., 1995). A detailed method on the 
mineralised matrix assay can be found in Appendix 7. Mineralised matrix deposition by 
oADSC and oOS-ADSC was evaluated measuring the absorbance of alizarin red S 
staining extracted with cetylpyridinium chloride (Puchtler et al., 1969, Stanford et al., 
1995). Briefly, cells were stained for 10 minutes with 500µL of 40mM alizarin red S, 
pH 4.2 (Sigma-Aldrich, Cat# A5533) at RT with gentle shaking. Stained cells were 
washed with PBS and then incubated with 1mL of 10% (w/v) cetylpyridinium chloride 
in 10mM sodium phosphate, pH 7.0, for 20 minutes at RT with gentle shaking. 
Duplicate aliquots (200µL) from each sample were transferred to a 96-well plate and 
read with a Synergy 3 microplate reader. Absorbance was measured at a wavelength of 
570nm. An alizarin red S standard curve was generated to determine the actual 
concentration according to the protocol from Millipore - Osteogenesis assay kit (Cat# 
ECM815). Briefly, a 2-fold serial dilution with a range between 2000 and 1.8µM was 
constructed. 
3.2.9 	Animal	model	
 The in vivo experiment used seven animals, from which the oADSC were 
isolated. Cells at the 4th passage were used. A detailed method on the animal model can 
be found in Appendix 12. The model was performed in the medial femoral epicondyles 
of both legs of all animals (Figure 20). Four groups were included in the experiment 
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(Table 7). All groups were randomly allocated to both legs of each animal. Four 10mm 
x 7mm (width x depth) defects, two in each leg, were drilled into the femur epicondyle 
with a 10mm trephine bur (Predictable Surgical Technologies, Cat# 1315-9.0) followed 
by an 8mm ablative bur (Meisinger, Cat#DD207). Titanium discs (ABTi and MTi) were 
placed in the bottom of each defect. The remaining osseous defects measuring 10mm x 
5.5mm were subsequently filled with the carrier material. Autologous blood clot was 
used as a carrier to an average of 9x106 autologous oADSC per defect in the test groups 
MTi/oADSC and ABTi/oADSC. At the time of surgery, cells in SFM were pelleted, 
resuspended, and mixed 3:1 with fresh blood. The blood was left to clot at RT before 
use. The two control groups MTi/control and ABTi/control were filled with autologous 
blood clot made up in the same fashion as the test groups, but without cells. An extra 
bone defect hereafter called “sentinel defect” was also created for the in vivo tracking of 
cells (see following content 3.2.10). 
 
Table 7 – Experimental groups. The groups included the type of titanium surface (MTi - machined 
titanium and ABTi - alumina-blasted titanium) and the presence or not of ovine adipose-derived 
stem cells (oADSC). 
 Group	  Titanium	disc	used	  oADSC/defect	
 No	of	
animals	
 MTi/oADSC	  MTi	  9x106	cells	  7	
 MTi/control	  MTi		  -	  7 
 ABTi/oADSC	  ABTi	  9x106	cells	  7	
 ABTi/control	  ABTi	  -	  7	
 
The soft tissues were sutured in layers; periosteum using horizontal mattress 
with 3-0 Vicryl (Ethicon, Cat# J497H), muscle and skin using continuous suture with 2-
0 Maxon (Covidien, Cat# 88866267-51). A long-acting local anaesthetic Marcain® 
0.5% with 1:200,000 adrenaline (Astra Zeneca, Cat# PH043) was injected around the 
surgical wound to control immediate post-operative pain. The sheep were housed at the 
HTRU for three days postoperatively to allow close monitoring of the post-surgical 
recovery. Postoperative antibiotics and anti-inflammatory agents were administered 
daily, consisting of Amphoprim 30mg/kg (Virbac Animal Health, Cat# 1PZ0010/2) and 
Carprofen 5mg/kg (Norbrook, Cat# 215672c04) subcutaneously. The immediate post-
operative care lasted three days and included a daily subcutaneous administration of 
antibiotic and anti-inflammatory drugs, consisting of Amphoprim (30mg/kg) and 
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Carprofen (5mg/kg) respectively. After recovery, the animals were returned to the farm 
for the remainder of the one-month experimental period. An experienced caretaker 
checked the animals daily. After the experimental period the animals were sacrificed, 
under general anaesthesia, by overdose of Sodium thiopentone (Jurox New Zealand, 
Cat# G9046) and subsequently carotid perfused with water for injection and then 10% 
neutral buffered formalin. The femur epicondyles were resected en bloc, stored in 10% 
neutral buffered formalin, and subsequently prepared for histology. 
3.2.10 In	vivo	cell	tracking	
A sentinel defect measuring 5mm x 8mm (width x depth) made with a 5.0mm 
cylindrical implant drill and containing no titanium disc but only blood clot with 
PKH26 (Sigma Aldrich, Cat#PKH25GL) labelled oADSC was also created in two 
sheep (Figure 20B). As described by the manufacturer, PKH26 is lipophilic cell 
membrane dye that contains a yellow-orange fluorescent dye with long aliphatic tail. 
The labelling protocol followed the recommendations from Ude and collaborators 
(2012). A detailed method on the labelling procedure can be found in Appendix 13. 
Briefly, 3x106 autologous oADSC were labelled with 2x10-6 M of PKH26 following the 
manufacturer’s protocol. Autologous SS was used to stop the labelling procedure. Cells 
were pelleted, resuspended, and mixed 3:1 with blood prior to use. The blood with 
labelled cells was left to clot and then placed into the sentinel defect. The defect was 
covered with Spongostan® (Ethicon, Cat#MS0005) to prevent the dislodgement of the 
clot containing labelled cells. Custom-made 1mm diameter tantalum beads were used to 
mark the outline of the defect (Figure 20D). The beads allowed an easier post mortem 




Figure 20 – Femoral epicondyle model in sheep. The surgeries were performed in the medial 
portion of the femoral epicondyle (A). The groups, two per leg, were randomly distributed between 
both legs. The bone defects were prepared with a trephine followed by an ablative bur (B). A 
sentinel defect was also prepared with a 5.0mm cylindrical implant drill to accommodate the 
PKH26 labelled oADSC used in the cell tracking experiment (blue arrow – B). The titanium discs 
were placed in the bottom of the defects (C). The blood containing on not oADSC was placed into 
each bone defect (D). The sentinel defect was filled with blood clot containing PKH26 labelled cells 
(D). Note the presence of custom made 1mm diameter tantalum beads outlining the sentinel defect 
(blue arrows – D). A post-mortem radiograph shows the titanium discs in relation to the medial 
femoral epicondyle (E). Note the location where the sentinel defect was placed (blue circle – E).  
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3.2.11 Histological	preparation	
 En bloc specimens were reduced in size using a dovetail hand saw, dehydrated 
in ascending grades of alcohol, and then embedded in methyl-methacrylate resin as 
previously described by Duncan and collaborators (Duncan et al., 2008). A detailed 
method on the undemineralised histology can be found in Appendix 14. 
Undemineralised ground sections were cut from the test and control bone defects 
containing titanium discs. The sections were mounted, grounded, polished, and stained 
with MacNeals tetrachrome with toluidine blue and acid fuschin for counterstaining. 
The sections were histologically and histomorphometrically analysed. Sections were 
viewed using a Nikon Eclipse Ti-U microscope at 30x and 150x magnification (Nikon, 
Model Ti-HD). Digital images were captured using a TCC-5.0ICE colour camera. Two 
sections per site were analysed. 
The sentinel defects were trephined and stored in 10% neutral buffered formalin 
in the dark. The bone cylinders (x2) were cut in half parallel to its long axis. Each 
portion was allocated to either fluorescence histological analysis or paraffin embedded 
histology. The fluorescent detection of PKH26 was performed in the surface of the 
allocated half cylinders using a Leica M205 FA dissection microscope with a colour 
camera DFC490. A Zeiss LSM 710 confocal microscope at 75x magnification was also 
used to three-dimensionally localise the PKH26 labelled cells within the tissues. The 
other half cylinders were demineralised in 10% EDTA solution containing 10% formic 
acid. The completion of the demineralisation process was checked with the ammonium 
oxalate test and radiographs. The specimens were embedded in paraffin, cut into 5µm 
sections, mounted on glass slides, and stained with Accustain® Masson's trichrome 
(Sigma Aldrich, Cat#HT15) following the manufacturer instructions (Appendix 15). 
The histological sections were viewed using an Olympus Vanox-T microscope at 200x 
magnification (Olympus Australia Pty Ltd, Australia) and images were captured using a 
Diagnostic Instruments SPOT RT colour camera (SciTech Pty Ltd, Australia). 
3.2.12 Histomorphometric	and	histological	analysis	
 A detailed method on the histomorphometric analysis including the inter-rater 
reliability test can be found in Appendix 16. A single evaluator (DGZ) was calibrated 
and performed all measurements. The inter-rater reliability was calculated using the 
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Pearson’s correlation coefficient. The histomorphometric analysis was carried out using 
the image analysis program FIJI (Schindelin et al., 2012). Images taken at 30x 
magnification were montaged using the software Photoshop CS6 Extended (Adobe) in a 
juxtaposed fashion to allow the analysis of new mineralised bone fill within the defect 
(Figure 21). The titanium discs were used to delimitate the area of tissue to be 
measured. The percentage of mineralised bone within the defect was measured 
subtracting the new bone formed from the total tissue volume. The formula used to 
calculate the percentage of mineralised bone was (Equation 5): 
Equation 5 – % Mineralised bone 
% Mineralised bone = (fraction area of mineralised bone) x 100   




Figure 21 – Method used for the histomorphometric analysis. A juxtaposed montage of images 
taken at 30x magnification was used for the calculation of bone fill within the defect (A). The tissue 
area delimited by the titanium disc (red box - B) was used in the analysis. The area of interest was 
threshold to isolate the mineralised tissue and subsequently used to subtract it from the total tissue 
volume (B). Two montages of two distinct sections from each group of each animal were used in the 
analysis. 
 
The percentage of bone-to-implant contact (BIC) was also evaluated. BIC was 
calculated on the full length of the titanium discs as the percentage of mineralised bone 
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in contact with the titanium surface. The qualitative histological analysis was performed 
at 200x magnification to describe the characteristics of the tissues within the defect of 
all groups. Duplicate sections of all groups determined measurement error. 
3.2.13 Statistical	methods	
 Biological triplicates were performed for all in vitro experiments using oADSC 
from three animals (n=3). For the in vivo experiments the animals were also used as 
statistical units (n=7). One-way ANOVA statistical testing was used for multiple group 
comparison. Tukey post hoc test was used to correct the results for multiple 





 oADSC were successfully isolated and adapted to a serum-free culture system. 
The potential of oADSC (n=7), grown in specialised medium (osteogenic, adipogenic, 
and chondrogenic), to successfully differentiate into osteoblast-like, chondroblast-like, 
and adipocyte-like cells was confirmed (Figure 22). However, a tri-lineage 
differentiation was not achieved in cells from all animals (Table 8). Cells grown in SFM 
did not differentiate 
 
 
Figure 22 – Images are representative of oADSC from all animals. oADSC (n=7) were isolated and 
adapted to SFM (A). oADSC at the 4th passage were differentiated into osteoblast-like (B), 
chondroblasts-like (C), and adipocyte-like (D) cells. Cells were stained with Alizarin Red (B); 
Alcian Blue (C), and Oil Red O (D).  The controls are shown in the small squares within each 




Table 8 – Tri-lineage differentiation of oADSC (n=7). oADSC was successfully differentiated into 
osteoblast-like, chondroblast-like, and adipocyte-like cells; however, the differentiation potential 
varied between animals. ✔  = positive differentiation and ✗  = negative differentiation. 
 Animal	code	  Osteogenesis	  Chondrogenesis	  Adipogenesis	
 364	  ✗	  ✔	  ✔	
 366	  ✔	  ✗	  ✔ 
 369	  ✔	  ✗	  ✔	
 370	  ✔	  ✔	  ✔	
 372	  ✔	  ✔	  ✔ 
 375	  ✗	  ✔	  ✔ 
 380	  ✔	  ✗	  ✔ 
 
3.3.2 	In	vitro	oADSC	on	titanium	
 A detailed method and raw results on the proliferation and the mineralisation 
assays can be found in Appendices 5 and 7 respectively. The proliferation assay showed 
a lower proliferation of oOS-ADSC grown on ABTi compared to oADSC grown on 
ABTi at 24 hours (p<0.05) (Figure 23). There was no significant difference at the same 
time point between oADSC and oOS-ADSC grown on MTi and TCPS.  
The production of a mineralised matrix was evaluated by Alizarin red S staining 
at 21 days of culture. There was no statistically significant difference between groups. 
However, there was a tendency of increased mineralisation in the groups containing 
oOS-ADSC on titanium substrates (Figure 24). This trend was clearly present for one of 
the animals (sheep 366).  
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Figure 23 – Proliferation assay. There was a statistically significant increased proliferation only for 
oOS-ADSC compared to oADSC both on ABTi. Undifferentiated cells - oADSC (Blue) and 
osteogenically differentiated cells – oOS-ADSC (Red) cultured on TCPS (1st and 2nd bars), MTi (3rd 
and 4th bars), and ABTi (5th and 6th bars) surfaces (n=3). Repeated measures (RM) ANOVA - 
*p<0.05. Error bars (SEM). 
 
 
Figure 24 – Mineralisation assay results. To determine the quantity of mineralised matrix produced 
the concentration of alizarin red S (ARS) was measured at 21 days of the culture of oADSC 
(undifferentiated cells) and oOS-ADSC (osteogenically differentiated cells) grown on TCPS (tissue 
culture polystyrene), MTi (machined titanium), and ABTi (alumina (Al2O3)-blasted titanium) 
surfaces (n=3). Each connecting line represents an individual animal (number inside the box). No 
statistical significant difference was found between groups; however, there was a tendency of 
increased mineralised matrix production by oOS-ADSC on MTi and ABTi. Symbols = 
TCPS/oADSC ( ), TCPS/oOS-ADSC ( ), MTi/oADSC ( ), MTi/oOS-ADSC ( ), ABTi/oADSC 
(☐), and ABTi/oOS-ADSC (n). 

















































































3.3.3 	In	 vivo	 cell	 tracking	 and	 histological	 analysis	 of	 the	
sentinel	defects	
 PKH26 labelled cells (oADSC/PKH26) were used to check whether cells placed 
into the sentinel defects would remain at the site of implantation after the experimental 
period of one month. The presence of oADSC/PKH26 was confirmed at the sentinel 
defect sites (Figure 25). The cells were mostly localised at the central top half of the 
defect. The histological evaluation of the sentinel defects showed a dense collagenous 
matrix at the top third of the defect and the de novo formation of bone from the sides of 
the defect (Figure 26). 
 
Figure 25 – In vivo cell tracking experiment. A radiograph of the sentinel defects shows the location 
where PKH26/oADSC were found (blue square - A). In yellow is the area correspondent to the 
defect site. Note that most cells were found at the central top half of the defect as shown by the 
dissection microscope’s fluorescence images (blue arrows - B and C). A 3D rendering of the 
confocal images of PKH26/oADSC found at the sentinel defect (D). Augmentations of 25x and 50x 
were used at B and C respectively. Bone trabeculae (green), PKH26/oADSC (red), and DAPI/cell 




Figure 26 – Histological analysis of the sentinel defects. A montage of the sentinel defect shows the 
location of the areas of interest (A – green boxes). The histological analysis showed the de novo bone 
formation from the sides of the defect (B). Note the presence of osteoid tissue that was synthesised 
by osteoblasts (B – arrow a) and the old trabeculae that underwent remodelling (B – arrow b). A 
dense collagenous matrix was deposited at the top of the defect (C – arrows b). A cell rich fibrous 
connective tissue characterised by the presence of fibroblasts (D – red) and a collagenous matrix (D 
– blue) was noted throughout the defect. Note the remnants of blood clot that still were present at 
the defect after 1 month (C – arrow a and E – arrow a). Scale bar = 100µm. 
 
3.3.4 	Histomorphometric	evaluation	
 The Pearson’s’ correlation coefficient calculated for inter-rater reliability was 
0.95 (p=0.00003). The percentage of BIC for all samples was zero, meaning no bone 
was found in contact with the titanium discs in any of the groups. The evaluation of the 
percentage of mineralised tissue within the defect showed no statistically significant 
difference between groups (Figure 27). However, there was a tendency of increased de 
novo bone formation in the control groups compared to the test groups. Also, the ABTi 
surface appeared to stimulate the de novo bone formation at a higher rate than MTi. 
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Figure 27 – Histomorphometric analysis. The histomorphometric analysis of the percentage of 
mineralised tissue (bone) within the bone defects showed no statistically significant difference 
between groups. There was a trend of increased mineralisation at the control sites. Symbols = 
MTi/control ( ), MTi/oADSC ( ), ABTi/control (☐), and ABTi/oADSC (n).  
 
3.3.5 	Histological	analysis	
 There was no difference in the histological characteristics between the groups 
(Figure 28). The histological analysis showed de novo bone formation from the sides of 
the defect. The top half and side of the defects showed the initial stages of an osteoid 
formation. The central bottom half of the defects was characterised by fibrous tissue. 
The remnants of blood clot and the presence of Vicryl® suture were found in all groups. 








































Figure 28 – Histological analysis of bone defects with titanium discs. Images are representative of 
all groups. A montage of the defect, containing the titanium disc, shows the location of the areas of 
interest (A – green boxes). The de novo formation of bone (A) was found to be from the sides of the 
defect. Note the de novo formation of new trabeculae (B – arrow a). A fibrous tissue was found at 
most of the central bottom half of the defect (D). The organization of osteoblasts and initial stages 
of formation of an osteoid (C – arrow a) were found at the top half and side of the defect. The 
presence of Vicryl® suture was noted in all specimens (E – arrow a). A fibrous tissue encapsulated 




There is nothing in the current literature addressing the in vivo behaviour of ovine 
ADSC grown in serum-free conditions used in the presence of titanium devices. This 
study investigated the in vivo use of SFM grown autologous oADSC for de novo bone 
formation/regeneration on machined and alumina-blasted titanium surfaces. The main 
findings of this thesis were that the osteogenic differentiation of oADSC in vitro was 
not as efficient as expected and that oADSC did not improve de novo bone formation 
after a healing period of one month in vivo. 
Before testing the hypothesis, oADSC were tri-lineage differentiated to verify its 
multipotency. I observed a distinct differentiation potential between cell lines. Only 
cells from two animals successfully differentiated into all three lineages (osteogenic, 
chondrogenic, and adipogenic). Cell lines from two animals did not differentiate 
towards an osteogenic lineage and the remaining three differentiated into osteogenic 
and adipogenic lineages. I believe that the induction factors presented in the 
differentiation medium used in this study were designed for human ADSC 
differentiation and may not be appropriate for the differentiation of oADSC. 
Kalaszczynska and co-workers (2013) investigated the use of osteogenic media, 
containing dexamethasone, ascorbic acid, and β-glycerolphosphate, on the 
differentiation of oADSC. They found that osteogenic medium containing β-
glycerolphosphate did not stimulate the osteogenic differentiation of oADSC. Also, 
these results could be due to variability in the differentiation potential between 
individual animals (Huang et al., 2005). 
3.4.1 	In	vitro	response	of	oADSC	on	titanium	surfaces	
 I tested in vitro the proliferative and osteogenic capacity of oADSC seeded on 
different titanium substrates. The proliferation assay showed that oOS-ADSC did not 
present a decrease in the proliferation rate over time compared to oADSC as expected. 
Others showed that ovine MSC proliferate at a significantly higher rate than ovine 
osteoblasts (Reichert et al., 2010). Moreover, it has been suggested that undifferentiated 
cells are expected to slow down their proliferation rate upon differentiation; MSC have 
been shown to undergo growth arrest prior to differentiation (Filipak et al., 1989, Scott 
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et al., 1982). In my experiment the only significant decrease in the oOS-ADSC 
proliferation rate was found for cells grown on ABTi (p<0.05). This is in agreement 
with another study where human MSC decreased in number on roughened surfaces 
(Olivares-Navarrete et al., 2010). 
The mineralisation assay presented an unexpected result in which no significant 
difference was found between any of the groups. However, there was a tendency of 
increased production of mineralised matrix on the oOS-ADSC titanium groups. I could 
not identify any other work with ovine stem cells showing similar results. I believe the 
lack of an increased matrix production by oOS-ADSC was due to the varied ability of 
cells from different animals to differentiate into osteoblast-like cells. Also, the 
differentiation medium (OM) may have had an impact in the osteogenic differentiation 
of oADSC as previously discussed. 
3.4.2 	In	 vivo	 response	 of	 labelled	 oADSC	 in	 the	 sentinel	 bone	
defects	
The results showed that oADSC remained within the bone defect after one 
month of healing. This was in agreement with other reports using PKH26 labelled 
MSC. Ude and co-workers (2012) detected in vivo PKH26 labelled oADSC and ovine 
bone marrow stem cells (oBMSC) for up to 49 days. Interestingly, the cells were mainly 
present at the top centre portion of the defect where they were associated with the 
presence of a dense collagenous matrix and the remnants of blood clot. This shows that 
the cells did not migrate out to the surrounding tissue. These results are in agreement 
with a previous report showing the presence of PKH26 labelled oADSC within the neo-
cartilage formed in the knee joint of sheep (Ude et al., 2012). Also, CM-Dil-labelled 
BMSC were found after 16 weeks in bone defects surrounding titanium dental implants 
in the jaw of dogs (Kim et al., 2009). The number of cells used in the sentinel defect 
(3x106 cells/defect) was insufficient to cover the whole defect and might have had an 
impact in the contribution of oADSC towards the de novo bone formation in the bone 
defect. Pieri and collaborators (2010) showed that anorganic bovine bone loaded with 3 
x 105, 3 x 106, or 3 x 107 cells per graft presented a dose-dependent de novo bone 
formation; greater de novo bone formation was found in the animals where a higher 
concentration of ADSC was used. 
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3.4.3 	In	 vivo	 response	 of	 oADSC	 in	 bone	 defects	 containing	
titanium	devices	
This study tested the in vivo de novo bone formation/regeneration of bone 
defects with titanium discs using autologous oADSC cultured in SFM. There was no 
difference in the amount of new bone generated within the defect between groups. In 
fact, there was a trend of reduced de novo bone formation in the oADSC groups 
compared to the controls (blood clot only). The histological characteristics of bone in all 
groups were identical. Previous reports on bone de novo bone formation/regeneration in 
animal models using stem cells presented conflicting results. Niemeyer and co-workers 
(2010a) showed that oADSC loaded into mineralised collagen scaffolds performed 
similarly to the scaffold alone when regenerating bone in critical size defects in sheep. 
In contrast, the same research group showed in another study also in sheep that collagen 
matrix loaded with autologous oADSC outperformed the unloaded scaffold in 
regenerating bone (Niemeyer et al., 2010b). When titanium was brought into the 
equation, MSC loaded into HA/TCP particles did promote greater bone de novo bone 
formation around titanium dental implants than the scaffold alone (Kim et al., 2009). 
Others also showed improved bone de novo bone formation using BMSC associated 
with fibrin compared to fibrin alone in bone defects around titanium dental implants (Ito 
et al., 2006).  
 The effect of surface roughness in the in vivo de novo bone 
formation/regeneration of bone defects using stem cells of mesenchymal origin remains 
unclear. The results showed that surface roughness did not impact significantly in the de 
novo formation of bone. However, there was a trend for slightly greater de novo bone 
formation in defects containing roughened titanium. In fact, roughened surfaces are 
shown to have a positive effect over the osteogenic differentiation of MSC (Olivares-




Although present at the defect site, autologous oADSC cultured in SFM did not 
promote the de novo formation of bone in defects containing titanium discs. Moreover, 
the titanium roughness did not significantly impact in the amount of bone generated at 
the defects after the experimental period of one month. Longer experimental periods 
may be necessary to evaluate the in vivo impact of ADSC in the de novo 
formation/regeneration of bone in defects containing titanium devices. Also, an 
optimised osteogenic culture condition for oADSC should be developed. There is a 
need to further develop this animal model in order to appropriately address whether 











4.1 Final discussion 
This thesis investigated the hypothesis that ADSC grown in serum-free conditions 
on titanium devices would promote an increased de novo formation/regeneration of 
bone. Moreover, titanium with micro-rough surfaces would further improve the de novo 
bone formation. To address this hypothesis, experimental work was undertaken to 
answer two main questions: 
1. Do ADSC grown in serum-free conditions have the potential to form/regenerate bone 
in the presence of titanium devices? 
2. Does surface topography/roughness of titanium devices influence the amount of bone 
produced by ADSC grown in serum-free conditions? 
 Before answering the two main questions of this study, it is important to 
consider the relevance of the work done in a clinical context. Such justification puts in 
perspective the selection of materials and techniques used in this thesis. As pointed out 
in the introduction of this thesis, the regeneration of bone around titanium devices is 
challenging. In dentistry, this challenge is often due to severe bone loss around titanium 
implants caused by natural resorption, iatrogenic complications, and infection. This 
thesis was done to test ADSC in the most challenging conditions and using materials 
that could be used clinically, in order to provide clues on whether these cells would 
promote bone regeneration around dental implants.  
ADSC were selected for their easy access, abundant source, and great numbers 
in the human body, which makes them a great avenue for their use in bone regenerative 
procedures. SFM was an obvious choice of culture medium, for its safety and clinical 
applicability, when considering the use of ADSC for human therapeutical use.  
The selection of machined and sandblasted titanium surfaces was due to the fact 
that these surfaces are the most commonly available in the dental implant market 
around the world. Also, the scientific literature has plenty of research demonstrating 
that these titanium surfaces have distinct behaviours in vitro and in vivo as discussed 
throughout this thesis.   
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In order to understand how ADSC grown in SFM would behave in the presence 
of titanium, I first developed an in vitro study designed to test the direct interaction 
between ADSC and titanium in a well-controlled environment. This provided me with 
important knowledge on the impact that commercially available titanium surfaces have 
on ADSC, excluding variables that contain unknown components such as blood serum. 
Once I understood the impact that titanium has on ADSC, either osteogenically 
differentiated or not, it was time to progress to the in vivo model. The in vivo animal 
model selected was chosen to represent the challenges faced by ADSC in regenerating 
bone in the presence of titanium devices in the complex environment of a large 
mammal. The design of the experiment aimed to mimic the complex scenario of severe 
bone loss commonly found clinically. The regenerative challenge of the bone defect 
used is often found in sites where immediate implant placement was done post 
extraction and in periimplantitis defects.  
The use of only undifferentiated ADSC was designed to mimic the direct 
clinical use of ADSC for bone regeneration, which ultimately requires stem cells with 
more capabilities than simply depositing bone matrix. These capabilities include the 
recruiting of native stem cells, immunomodulation, angiogenesis, osteogenesis, etc. 
The blood clot was used as a carrier for the ADSC to prevent the influence on 
regeneration provided by other materials such as collagen and calcium phosphate 
scaffolds. The idea was to provide a scaffold that would be “relatively inert” since 
blood clot is always present in any post surgical wound.  
The in vivo experimental time of 1 month was selected to test whether these 
cells would clearly boost the de novo formation of bone. In clinical situations, clear 
signs of de novo bone formation around titanium implants are usually found after 8 
weeks of healing. However, if evidence of de novo bone formation were found as early 
as in 1 month, this would demonstrate the great capacity ADSC in promoting de novo 
bone formation.  
4.1.1 	Addressing	question	1	
Answering the first question this thesis has demonstrated that human ADSC 
grown in serum-free conditions have the potential, when osteogenically-induced, to be 
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used for de novo bone formation/regeneration procedures in the presence titanium 
devices. The in vitro experiments using hADSC showed that osteogenically induced 
cells generate large amounts of mineralised extracellular matrix compared to 
undifferentiated cells. Moreover, the titanium substrates stimulated the deposition of 
mineralised matrix compared to tissue culture plastic. However, the in vitro and in vivo 
experiments using ovine ADSC did not confirm this regenerative potential. oADSC 
failed to produce significant amounts of mineralised extracellular matrix in vitro and to 
improve or accelerate the de novo formation of bone in vivo. There are a number of 
possible reasons why this regenerative potential hasn’t been confirmed. The fact that 
these cells were cultured in a serum-free environment may have reduced their 
osteogenic potential. However, our in vitro experiments demonstrated that the 
osteogenic potential was preserved. The osteogenic culture conditions used for oADSC 
were exactly the same as those used for hADSC. These conditions may have not been 
appropriate for the osteogenic induction of oADSC. The use of β-glycerolphosphate, 
which in hADSC stimulates osteogenic differentiation, apparently did not have the same 
effect on oADSC. Monosodium phosphate (NaH2PO4) has been shown to be a better 
source of phosphate ions, which are necessary for the formation of hydroxyapatite 
crystals (Ca10(PO4)6(OH)2), in promoting osteogenesis of oADSC in culture 
(Kalaszczynska et al., 2013). The complete biological mechanism explaining why β-
glycerolphosphate is not a good source of phosphate ions in oADSC osteogenic cultures 
is currently unknown. Conflicting data indicates the lack of alkaline phosphatase (ALP) 
enzymatic activity in oADSC cultures as a possible reason for its impaired osteogenic 
differentiation capacity. ALP, which is essential for the degradation of β-
glycerolphosphate (Ahlers, 1975), was shown to be undetected in oBMSC. However, 
the lack of ALP activity did not interfere with the osteogenic differentiation of these 
cells (Rentsch et al., 2010). Others not only found ALP activity in osteogenically 
differentiated oBMSC cultured in medium containing β-glycerolphosphate but also had 
increased mineralised nodule formation compared to ovine osteoblasts (Reichert et al., 
2010). Thus the lack of optimisation of the oOS-ADSC culture seems to explain the 
variability on the osteogenic differentiation potential found between animals and also 
compared to hOS-ADSC. For these reasons I believe that an optimisation of the 
osteogenic culture conditions would benefit future experiments using osteogenically 
induced oADSC.  
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Another sign of impaired osteogenesis on ovine cells was the similar 
proliferation rate of osteogenically differentiated oADSC compared to undifferentiated 
oADSC. A decreased proliferation upon differentiation is a well-known phenomenon 
(Scott et al., 1982, Filipak et al., 1989). Therefore, it was expected that oOS-ADSC 
would present a similar proliferative behaviour to osteogenically differentiated hADSC 
in which the proliferation rate decreased significantly compared to undifferentiated 
hADSC. This difference was even more pronounced between hADSC and hOS-ADSC 
grown on titanium substrates. 
It is important to observe that only one month was given for the bone defect to 
regenerate. The relatively wide and shallow cylindrical characteristics of the defect 
(10mm diameter x 7mm deep) associated with the presence of a titanium disc (1.5mm 
thick) on its floor may have partially impaired the de novo bone formation. De novo 
bone formation in cylindrical defects occurs from the sides and bottom of the defects. 
The presence of the titanium disc prevented the de novo bone formation from the 
bottom of the defect. Aaron and Skerry (1994) studied the histological characteristics of 
the regeneration of 10mm bone defects in the iliac crest of sheep after a healing period 
between 5 days and 3 months. These authors have clearly shown that after three weeks 
there was only limited mineralised bone within 10mm diameter defects; though clear 
sites of osteoid were found at all sides of the defect and below the thickened 
periosteum. These findings are very similar to what has been found in the histological 
results from this thesis in vivo experiment. Aaron and Skerry (1994) also demonstrated 
that it took another nine weeks for the defect to be 50% filled with mineralised bone 
trabeculae. It is likely therefore that not enough time was given for the bone 
regeneration of the defects to happen; showing some, if any, difference between 
oADSC loaded and unloaded defects. 
I acknowledge the fact that carriers/scaffolds other than clot could benefit the de 
novo formation of bone using oADSC in vivo. A number of stem cell carriers including, 
calcium phosphates, calcium carbonates, collagen I, synthetic polymers, etc., have been 
used for bone regeneration with no clear advantage in using any particular material 
(Dahl et al., 2014). There is however, a growing body of knowledge supporting the 
association of carriers and stem cells. In a study in sheep, collagen matrix loaded with 
autologous oADSC regenerated more bone than the unloaded scaffold (Niemeyer et al., 
2010b). However, my work aimed to evaluate the effect of ADSC independently of any 
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carriers. For this reason blood clot seemed to be the material of choice. The benefit of 
using other carriers should be addressed in future experiments using similar models. 
Although the immunoregulatory properties of ADSC were not investigated in this 
thesis, it is important to consider its likely influence on the de novo bone formation 
process. During bone healing an early inflammation phase is known to be an important 
part of this process (Schmidt-Bleek et al., 2014). Its modulation using MSC could 
further benefit the regenerative process (Bunnell et al., 2010). Interestingly, the bone 
defects that were filled with blood clot containing oADSC showed a slight trend to 
present lower amounts of mineralised tissue compared with those containing only blood 
clot. It is important to point out that caution is advised in interpreting these results 
because of the small sample size. One possible explanation is the fact that ADSC 
regulates the immune response through the inhibition of the proliferation and pro-
inflammatory cytokines (i.e. IL-12, TNF-α, and INF-γ) production by peripheral blood 
mononuclear cells (PBMC) (Melief et al., 2013). Also, ADSC were shown to impair the 
maturation and differentiation of dendritic cells and the proliferation of T-lymphocytes 
mediated by interleukin-10 and prostaglandin-E2 (PGE2) (Ivanova-Todorova et al., 
2009, Yanez et al., 2010). These expected immunosuppressive effects from oADSC 
could have reduced the inflammation phase of healing; therefore delaying/preventing 
the de novo bone formation process within the bone defects investigated. 
Despite the high osteogenic potential showed by hADSC in vitro, another factor 
could also have contributed to the lack of de novo bone formation at the sites where 
oADSC were used. The number of cells used (9x106 cells/defect) could be considered 
modest in regenerating bone since there is a dose-dependent regenerative effect from 
ADSC (Pieri et al., 2010). Hence it is expected that a higher dose of oADSC would 
stimulate more pronounced de novo bone formation. 
The importance of using pre-differentiated ADSC needs further investigation. In 
this thesis I decided to use only undifferentiated oADSC for the in vivo de novo bone 
formation model instead of osteogenically differentiated oADSC. Whether oADSC or 
oOS-ADSC should be used for the regenerative procedure is a matter of debate. The 
benefit of using stem cells for bone regeneration lies in its numerous biological 
properties such as direct differentiation, neovascularisation, and immunoregulation 
(Raynaud and Rafii, 2013). The use of pre-committed MSC for bone regeneration 
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would cancel a number of the biological properties found in its undifferentiated 
counterparts. Some authors have shown no difference between undifferentiated and 
osteogenically committed MSC in regenerating critical size bone defects in rats (Peters 
et al., 2009). Also, others have shown a higher bone generation by oBMSC compared to 
ovine osteoblasts in an ectopic bone generation model in immunocompromised 
NOD/SCID mice (Reichert et al., 2010). Conversely, the same study found a higher in 
vitro osteogenic potential for oBMSC compared to ovine osteoblasts (Reichert et al., 
2010). Another study using osteogenically committed MSC showed that these cells 
have higher osteogenic potential when cultured for short periods of time; four days 
compared to 10 and 16 days (Castano-Izquierdo et al., 2007). Thus it is likely that a co-
culture system using undifferentiated and osteogenically committed MSC would greatly 
benefit pre-clinical in vitro and in vivo experiments for de novo bone 
formation/regeneration (Lettry et al., 2010). Co-culture of MSC with other somatic cells 
would also be beneficial (Usami et al., 2009, Koob et al., 2011).  
4.1.2 	Addressing	question	2	
Addressing the second question this study found that the difference in 
topography/roughness of MTi and ABTi did not have a significant effect on the 
osteogenic potential of either human or ovine ADSC either in vitro or in vivo. Though it 
was noticeable that the osteogenic effect of cells grown on titanium was in fact higher 
than those grown on TCPS. The foremost explanation for the similar behaviour between 
ADSC grown on MTi and ABTi remains elusive. One of the accepted mechanisms 
associating the osteogenic differentiation behaviour of ADSC to different titanium 
surfaces is the interaction of cells with extracellular matrix proteins bound to the 
substrate (e.g. fibronectin). The surface characteristics of the titanium substrates 
determine the adsorption kinetics of proteins, and are believed to influence the 
differentiation process of cells (Yang et al., 2013). In this study the adsorption pattern 
of fibronectin to MTi and ABTi was different but without any significant effect on the 
osteogenic differentiation of either hADSC or oADSC. To clarify these findings more 
research should be conducted on the interaction between ADSC grown in serum-free 
conditions, osteogenically induced ADSC, and different titanium substrates. 
Supporting the limited effect of the surface characteristics on osteogenic 
differentiation, the gene expression analysis performed in this thesis showed that the 
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titanium surface characteristics played a limited role on the differentiation of hADSC. 
The integrins ITGA5 and ITGB1 were highly up-regulated at baseline (24 hours of 
culture) in both MTi and ABTi. These integrins form the heterodimer α5β1 that binds to 
fibronectin and are closely related to osteogenesis in MSC (Moursi et al., 1997, 
Hamidouche et al., 2009). Intriguingly these integrins expressed in hOS-ADSC grown 
in both titanium substrates were down-regulated over time. Meanwhile two other 
integrins ITGAV and ITGB3 that form the heterodimer αvβ3 got up-regulated over 
time. Apparently once hOS-ADSC matured as osteoblasts they reduce the need of using 
α5β1 integrin; apparently there was a shift towards the use of αvβ3. The αvβ3 
heterodimer has been associated with the inhibition of the differentiation of MSC into 
osteoblasts (Martino et al., 2009, Li et al., 2013). 
The in vivo animal model also supported that the surface characteristics had little 
effect on the osteogenic behaviour of ADSC. There was no difference at all in the de 
novo bone formation of defects containing MTi and ABTi. These results should be 
interpreted with caution, since only one month was given for the de novo bone 
formation/regeneration of the bone defects as previously discussed. Animal models with 
longer experimental periods should be performed to allow the identification of 




Considering the limitations previously discussed, it is unclear whether ADSC 
grown in serum-free conditions have the potential to regenerate bone in defects 
containing titanium devices.  
The optimization of the in vitro osteogenic culture condition appears to be 
necessary for the ovine cells; assuring their osteogenic behaviour to be similar to those 
from human cells. Additionally, the time allowed (i.e. one month) for the in vivo de 
novo bone formation used in this thesis should be reconsidered. Multiple and/or longer 
periods of time should be considered to complement the proposed evaluation of de novo 
bone formation/regeneration in sheep. 
The behaviour of ADSC was not significantly influenced by the different surface 
characteristics of MTi and ABTi. In general these cells performed similarly on both 
surfaces. The osteogenic differentiation of ADSC was the most important factor 
determining the behaviour of these cells, particularly in vitro. 
4.3 Future directions 
A number of findings of this thesis deserve further investigation: 
1. A thorough investigation of oADSC grown in serum-free conditions is 
necessary, especially in relation to its multipotency. This would bring new insights on 
whether it is appropriate to use sheep and its oADSC on pre-clinical models for bone de 
novo bone formation/regeneration. 
2. The use of methods to select a population of ADSC with higher osteogenic 
potential could boost the de novo bone formation of these cells. 
3. A comparison between the use of ADSC cultured in serum-free and serum 
containing environments is necessary to address any differences in the in vitro and in 
vivo de novo formation of bone between these two distinct types of cell.  
4. The expression and function of the OCT-4 gene in hOS-ADSC should be 
investigated. The expression of OCT-4 gene in hOS-ADSC was intriguing. Research on 
this topic would cast light on a possible new role for one of the OCT-4 isoforms. 
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5. The effect of the surface characteristics on ADSC grown in serum-free 
conditions should be further investigated since little difference in the cellular behaviour 
was seen on cells grown on MTi and ABTi. This should include the adhesion 
mechanism of ADSC grown in serum-free medium on titanium substrates. 
6. The expression of genes associated with self-renewal, adhesion, and 
osteogenesis in oADSC grown in serum-free conditions should be investigated to allow 
the same level of understanding of the cellular behaviour of hADSC. 
7. A multiple time-point assessment (five or more) for up to one month on the 
osteogenic genes expressed in ADSC grown in serum-free and osteogenic conditions on 
titanium substrates should be performed. This would provide information on the over 
time expression of osteogenic genes and associate this with ongoing cellular events. 
8. Future research would benefit from the use of more animals. However, the 
ethical implications and benefits of such approach should be carefully considered. Also, 
longer in vivo experimental periods including multiple time-point analysis should be 
considered. 
9. Other carriers should be evaluated for the loading of serum-free cultured 
ADSC. Carriers are known to modulate the behaviour and fate of stem cells. Therefore, 
appropriate carriers would potentialise the osteogenic effect of ADSC cultured in 
serum-free conditions. Additionally, carriers with the capacity to slowly release growth 
factors would likely have an important impact on the regenerative potential of these 
cells. 
10. In order to take full advantage of the regenerative potential of serum-free 
cultured ADSC, the use of three-dimensional (3-D) bioprinters should be evaluated for 
the production of better and personalised bone substitute scaffolds made of complex 
structures containing multiple materials. 
11. A 3-D dynamic serum-free culture of ADSC would benefit in vitro 
experiments in providing these cells with a more realistic environment in an attempt to 
mimic its in vivo behaviour. Scaffolds used for de novo bone formation/regeneration in 
vivo would also take advantage of the more efficient incorporation of serum-free ADSC 
using 3-D dynamic culture systems. 
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12. The in vivo tracking of serum-free cultured ADSC should be further explored 
using other labelling and localisation techniques. This would clarify a number of 
questions on the behaviour and fate of these cells and their progeny. 
13. Further pre-clinical studies using ADSC cultured in serum-free conditions 
should consider the use of co-cultured ADSC and osteogenically committed ADSC to 
improve de novo bone formation/regeneration. Also, co-cultures using ADSC and other 
somatic cells could be an effective way of improving the regenerative capacity of these 
cells. 
14. The use of immunodeficient animal models such as immunodeficient nude 
mouse/rat should be considered in the future. These models could take advantage of the 
use of human ADSC for bone regeneration and therefore, provide results more similar 
to what would happen with these cells in humans. 
15. In order to improve the understanding on the quality of adhesion of ADSC to 
different titanium surfaces, the adhesive force of ADSC attached to titanium should be 
tested. 
16. The use of cells in early cell passages such as P0 and P1 would most likely 
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*These settings (Figure 29) were used to determine the surface roughness of the 
titanium discs. 
 





Figure 30 – SurfCharJ settings used for roughness analysis 
 
Surface	roughness	raw	results	
Table 9 – ABTi surface roughness raw results. 
ABTi Rq (rms) Ra Rsk Rku Rv Rp Rt Rc SA 
1 2.94 2.14 -1.71 2.38 -10.49 7.65 18.14 0.00 1.50 
2 2.87 2.06 -1.80 2.89 1.02 19.60 18.58 11.92 1.52 
3 3.08 2.12 -2.05 3.92 1.00 19.32 18.31 13.11 1.53 
4 3.16 2.29 -1.73 2.40 1.00 17.96 16.96 11.85 1.54 
5 2.80 2.02 -1.72 2.54 1.00 19.46 18.46 10.95 1.48 
6 2.47 1.72 -1.93 3.93 1.01 18.64 17.63 11.35 1.41 
Mean 2.89 2.06 -1.82 3.01 -0.91 17.10 18.01 9.86 1.50 




Table 10 – MTi surface roughness raw results.  
MTi Rq	(rms) Ra Rsk Rku Rv Rp Rt Rc SA 
1 0.44 0.22 -2.71 26.98 7.79 18.26 10.47 15.98 1.02 
2 1.10 0.64 -4.15 26.02 3.18 19.78 16.60 15.65 1.10 
3 0.53 0.32 -3.02 30.17 7.24 19.00 11.76 16.08 1.03 
4 0.87 0.49 -4.16 32.69 4.08 22.53 18.44 17.86 1.08 
5 0.56 0.31 -7.36 106.69 4.76 21.26 16.50 18.82 1.02 
6 1.27 0.72 -3.84 20.98 2.95 19.54 16.60 14.87 1.11 
Mean 0.80 0.45 -4.21 40.59 5.00 20.06 15.06 16.54 1.06 
St.	Dev. 0.34 0.20 1.66 32.63 2.06 1.56 3.17 1.49 0.04 
 
Contact	angle	raw	results	
Table 11 – Contact angle raw results 





1 69.05 85.52 60.31 82.06 
2 67.04 81.17 64.81 87.17 
3 72.72 78.83 61.32 79.79 
Mean 69.60 81.84 62.14 83.00 





























*All cell culture experiments were conducted using aseptic techniques in a class II 
biosafety cabinet. 
Coating	culture	flasks	with	CELLstartTM	CTS	
1. CELLstart CTS (Life Technologies, Cat# A1014201) was diluted 1:100 with sterile 
PBS (Life Technologies, Cat# SALB010) (i.e., 100µL CELLstart into 10mL of PBS). 
Solution was gently pipetted to mix prior to the coating as per volumes in Table 12.  
2. Culture flasks with CELLstart were placed in the incubator at 37ºC in a humidified 
atmosphere of 5% CO2 for 60 minutes. 
3. After incubation, flasks were temporarily placed in a laminar flow hood until use. 
Immediately before use, CELLstart solution was removed and replaced with complete 
medium. 
Note: CELLstart was prepared fresh before each use. 
 
Table 12 – Cell start solution 
Vessel CELLstart solution 1:100 (mL) 






StemPro® MSC SFM Basal Medium (Life Technologies, Cat# A13829-01) required 
supplementation with StemPro® MSC SFM XenoFree Supplement (Life Technologies, 
Cat# A11577-01) and GlutaMAX-CTS (Life Technologies, Cat# A12860). 
1. For 500mL complete medium, 5mL of StemPro® MSC SFM XenoFree supplement 
was aseptically added to StemPro® MSC SFM basal medium (500mL). 
2. 5mL of GlutaMAX was added to the medium before use. 
3. 250µL of 10mg/mL Gentamicin reagent solution (Life Technologies, Cat# 15710064) 
was added to the medium to give a final concentration of 0.05%. 
4. 5mL of antibiotic-antimycotic (Life Technologies, Cat# 15240) was also added to the 
medium to give a final concentration of 1%. 
Recovering	cryopreserved	hADSC	
1. A frozen vial of hADSC was rapidly thawed in a 37°C water bath until a small 
amount of ice remained. 
2. 0.5mL of complete medium was added into the cryovial. 
3. The entire content of the cryovial was transferred into a 50mL conical tube. 
4. 3.5mL of pre-warmed (37°C) StemPro® MSC SFM XenoFree complete medium was 
carefully added to the conical tube at an approximate rate of 3 to 5 drops per 5 seconds 
and gently swirled after every addition. 
5. The tube was centrifuged at 150×g (~1200 rpm) for 5 minutes at room temperature. 
6. The supernatant was removed and the cell pellet was resuspended in pre-warmed 
(37°C) StemPro® MSC SFM XenoFree complete medium and the cell suspension 
added to an appropriate CELLstart-coated flask at a density of ≥ 5×104 cells/cm2 after 
counting with a haemocytometer. 
7. Cells were incubated at 37ºC in a humidified atmosphere of 5% CO2 (Sanyo, Cat# 
MCO-19AIC UV). 
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8. 24hrs was given for the cells to adhere to the flask prior to the medium replacement. 
9. Medium was subsequently replaced every 2 days. 
Table 13 – Medium replacement 
Vessel 
 
Surface area (cm2) Complete medium (mL) 
 35mm dish 9.62 3 
T25 25 7 
T75 75 15 
Passaging	ADSC	
*Procedures used for a T75 culture vessel. Smaller vessels had the solution volumes 
adjusted. 
1. Cultures were observed under the microscope and cells were confirmed ready to be 
sub-passaged when 80-90% confluent. 
2. TrypLE reagent (Life Technologies, Cat# 12604021) and SFM were pre-warmed to 
37°C before use. 
3. 10mL of pre-warmed SFM was added to a 50mL conical tube. 
4. Spent medium from the flask was discarded. 
5. Cells were briefly washed with 10mL of sterile PBS and then discarded. 
6. 3mL TrypLE was added to the flask. The flask was tilted in all directions to evenly 
distribute the reagent. Cells were incubated in TrypLE for 3 minutes in the incubator at 
37ºC.  
7. After incubation, the flask was checked under the microscope for cell detachment. 
The flask was firmly tapped to facilitate complete cell detachment. 
8. 7mL of pre-warmed SFM was added to each flask and the cell suspension collected 
and transferred to the 50mL conical tube containing SFM. The flask was firmly tapped, 
re-washed with 10mL SFM, and the suspension collected to the 50mL conical tube 
containing the remaining of the cell suspension. 
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9. The conical tube was centrifuged at 150xg for 5 minutes at room temperature. 
10. The supernatant was removed and the cells were resuspended in a minimal volume 
of pre-warmed SFM for cell counting. 
11. Cells were stained 1:1 with Trypan blue solution and counted with a 
haemocytometer. 
12. The CELLstart solution (1:100) was discarded from each T-75 coated flask and 
10mL of SFM was added.  
13. Enough cell suspension was added to each flask to provide ≥ 5×104 cells/cm2 (i.e. 
3.75×106 cells per T-75 flask). The cell suspension was gently swirled to ensure even 
distribution. 
14. The culture flask was placed in the incubator at 37ºC with a humidified atmosphere 
of 5% CO2. 
15. The culture medium was replaced every 2 days with pre-warmed SFM. 
Cryopreservation	
1. Cryopreservation solution (2X) was prepared by supplementing SFM with 20% 
Dimethyl Sulfoxide (DMSO) (Sigma Aldrich, Cat# D4540). The solution was made 
fresh. 
2. The harvested cell pellet was resuspended to twice the desired final cell concentration 
(i.e. 2×106 cells/mL) in pre-warmed SFM. 
3. Cryopreservation solution was slowly added to the cell suspension, and gently mixed 
to ensure homogeneity. 
4. Immediately the desired volume of cell suspension (i.e. 1mL) was added to the sterile 
cryovials (CRYO.S, Greiner Bio-one, Lot# E130600R) at RT. 
5. The cryovials were placed at -70°C in a cryogenic freezing container (“Mr Frosty” (-
1°C/min) Freezing Container). 
6. After 24 hours the frozen cells were transferred to liquid nitrogen (vapour phase). 
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 Appendix	 4	 –	 Tri-lineage	 differentiation	
culture	method	and	staining	
1. Cells were obtained following the passaging protocol in Appendix 2. 
2. Cell viability was determined (at least 90%) and total cell density counted using 
Trypan blue (i.e., haemocytometer). 
3. ADSC were seeded into fibronectin coated (2µg/cm2) eight-well chamber slides 
(Labtek, Cat# NUN154534) or wells at 1×104 cells/cm2 (Osteogenesis and Adipogenesis 
assays). For the chondrogenesis assay, cells were plated at the centre of the slide in a 
single 5µL droplet at a concentration of 8x104 cells/droplet (micromass). A total of 
400µL was used per well. 
Fibronectin	coating:	
- A solution of either human or bovine fibronectin (Sigma Aldrich, Cat# F0895 and 
Cat# F1141) was prepared using sterile PBS at a concentration of 2µg/cm2. 
- The wells of an eight-well chamber slide were coated with 50µL/well fibronectin 
solution for 1hour. 
- The fibronectin solution was discarded and the slides allowed to dry for approximately 
1hour in the class II safety cabinet. 
- The slide was ready to use once the fibronectin coating was just dry. 
 
4. Cells were incubated in SFM at 37°C in a humidified atmosphere of 5% CO2 for 24 
hours (Osteogenesis and Adipogenesis assays). The micromass was cultured in 100% 
humidity for 2hours and then the chondrogenesis medium was added. 
5. Medium was replaced with pre-warmed SFM or complete differentiation medium 
(Osteogenic, Chondrogenic, or Adipogenic) every 3 days. ADSC continued to expand 
under SFM or differentiation conditions until the end of the experiment.  
Osteogenesis assay – 21 days of culture. 
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Chondrogenesis assay – 14 days of culture. 
Adipogenesis assay – 14 days of culture. 
 
Osteogenic	culture	
- Complete Osteogenesis Differentiation Medium (hADSC) 
StemPro® Osteocyte/Chondrocyte Differentiation Basal Medium (Life Technologies, 
Cat# A10069-01) required supplementation with StemPro® Osteogenesis Supplement 
(Life Technologies, Cat# A10066-01). 
1. For 100mL complete medium, 10mL of StemPro® Osteogenesis Supplement was 
aseptically added to 90 mL of StemPro® Osteocyte/ Chondrocyte Differentiation Basal 
Medium. 
2. 50µL of 10mg/mL (0.05%) Gentamicin reagent solution (Life Technologies, Cat# 
15710064) and 1mL of antibiotic-antimycotic (Life Technologies, Cat# 15240) were 
added to the medium. 
- Complete Osteogenesis Differentiation Medium (OM) (oADSC) 
1. For 50mL complete medium, complete SFM (Appendix 3) was supplemented with 
500µM 2-phospho-L-ascorbic acid trisodium salt (Sigma Aldrich, Cat# 49752), 10nM 
dexamethasone (Sigma Aldrich, Cat# D2915), and 10mM β-glycerophosphate (Sigma 
Aldrich, Cat# G9422). 
2. 25µL of 10mg/mL (0.05%) Gentamicin reagent solution (Life Technologies, Cat# 
15710064) and 0.5mL of antibiotic-antimycotic (Life Technologies, Cat# 15240) were 




*Chamber slide cassette was removed from the slide prior to staining. 
Alizarin red S binds ~ 2 mol of Ca++/mol of dye in solution. 
40mM Alizarin Red S (ARS) (Sigma-Aldrich, Cat# A5533) solution was used for final 
staining. 
Required: pH 4.2 at RT. 
FW = 342.26. 
- 100mM stock solution of ARS was prepared: 
3.42g of Alizarin red S in 100mL of dH2O. 
- 40mM (pH 4.2, RT) working solution was prepared: 
40mL (100mM stock solution) + 60mL (dH2O). 
*Stirred to mix. 
*pH was corrected to 4.2 with hydrochloric acid solution (HCl) (BDH, Cat# 1256J) 
under stirring. 
 
1. Cells were washed in PBS for 30 seconds. 
2. Fixed in ice-cold 70% ethanol in dH2O for 1hour. 
3. Rinsed with mH2O. 
4. Stained for 10 minutes with Alizarin red 40mM (pH 4.2) at RT under gentle shaking. 
5. Rinsed 5x with mH2O and then 2x PBS for 5 and 15 minutes under gentle shaking (to 
reduce unspecific bounding of Alizarin red). 
6. Slides were dehydrated in a series of ethanol, cleared in xylene, and mounted with 




- Complete Chondrogenesis Differentiation Medium 
StemPro® Osteocyte/Chondrocyte Differentiation Basal Medium (Life Technologies, 
Cat# A10069-01) required supplementation with StemPro® Chondrogenesis 
Supplement (Life Technologies, Cat# A10064-01). 
1. For 100mL complete medium, 10mL of StemPro® Chondrogenesis Supplement was 
aseptically added to 90mL of StemPro® Osteocyte/Chondrocyte Differentiation Basal 
Medium. 
2. 50µL of 10mg/mL (0.05%) Gentamicin reagent solution (Life Technologies, Cat# 
15710064) was added to the medium. 
3. 1mL of antibiotic-antimycotic (Life Technologies, Cat# 15240) was also added to the 
medium 
Alcian	Blue	staining	
*Chamber slide cassette was removed from the slide prior to staining. 
3% Acetic Acid Solution was prepared with 3mL of glacial acetic acid and 97mL of 
dH2O. 
Alcian Blue Solution (pH 2.5) was prepared with 1g of Alcian blue 8GX (Sigma 
Aldrich, Cat# A3157) in a 3% acetic acid solution. The solution was mixed well and the 
pH adjusted to 2.5 using glacial acetic acid to a final volume of 100mL. 
1. After 14 days under differentiating conditions the medium was discarded, the cells 
were rinsed once with PBS, and fixed with 10% neutral buffered formalin for 30 
minutes. 
2. After fixation, the slide was rinsed with PBS and the cells stained with 1% Alcian 
Blue solution prepared in 0.1N HCl for 30 minutes. 
3. The slide was rinsed three times with 0.1N HCl and dH2O was added to neutralise the 
acidity. 
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4. Slides were dehydrated in a series of ethanol, cleared in xylene, and mounted with 
DPX® (Sigma Aldrich, Cat# 06522) 
Adipogenic	culture	
- Complete Adipogenesis Differentiation Medium 
StemPro® Adipogenesis Differentiation Basal Medium (Life Technologies, Cat# 
A10410-01) required supplementation with StemPro® Adipogenesis Supplement (Life 
Technologies, Cat# A10065-01). 
1. For 100mL complete medium, 10mL of StemPro® Adipogenesis Supplement was 
aseptically added to 90mL of StemPro® Adipogenesis Differentiation Basal Medium. 
2. 50µL of 10mg/mL (0.05%) Gentamicin reagent solution (Life Technologies, Cat# 
15710064) was added to the medium. 
3. 1mL of antibiotic-antimycotic (Life Technologies, Cat# 15240) was also added to the 
medium. 
Oil	Red	O	staining	
Oil red O stock stain was made with 0.5g of Oil Red O dye (Sigma Aldrich, Cat# 
O0625) in 100mL of isopropanol. The dye was dissolved in the isopropanol at 37ºC 
(water bath).  
Oil Red O working solution was prepared for immediate use: 30ml of the stock stain 
was diluted with 20ml of distilled water and allowed to stand for 10 minutes. The 
solution was filtered with a 0.22µm filter into a conical tube and covered immediately. 
1. Cells were fixed in 10% neutral buffered formalin for 30 minutes. Cells were briefly 
washed with running tap water for 10min. 
3. Rinsed with 60% isopropanol. 
4. Stained with freshly prepared Oil Red O working solution for 15 minutes. 
5. Rinsed with 60% isopropanol. 
6. Stained for 1 minute with Gill’s haematoxylin (Sigma Aldrich, Cat# GHS232). 
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7. Rinsed with distilled water 






- Phase 1 (preparing 100% reduced AlamarBlue) 
1. AlamarBlue and SFM were pre-warmed. 
2. 450µL of SFM was added into a 1.5mL conical tube with screw cap (Neptune, Cat# 
3744.S.X). 
3. 50µL of AlamarBlue was added into the conical tube. 
4. Steps 2 and 3 were repeated three extra times (quadruplicate). 
5. The solution was sterilised by autoclaving at 121ºC for 15 minutes. 
*The same steps were used to prepare AlamarBlue with OM (Osteogenic media). 
 
- Phase 2 (experiment with randomised groups) 
*All groups were conducted in quadruplicate; including the controls. 
1. Titanium discs were aseptically placed into the wells of a 48-well plate accordingly 
to the allocation determined by the group’s randomisation.  
2. The designated wells were coated with fibronectin (2µg/cm2) (see Appendix 4). 
3. Cells were plated in each well at a concentration of 1x104 cells/cm2 in 900µL of 
SFM. 
4. After 24 hours (adherence period), 900µL of medium was replaced and 100µL of 
AlamarBlue added to each well to make a total of 1ml/well.* 
*For the hOS-ADASC wells, medium was replaced with 900µL of OM instead of SFM 
before introducing AlamarBlue. 
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5. Cells were incubated at 370C and 5% CO2. 
6. Fluorescence was read at 2, 6, 12, and 24 hours.* 
*100µL in duplicate for each time point in a 96-well plate (totalising quadruplicates for 
each group). 
*100% AlamarBlue was read in the same 96-well plate in quadruplicate. 
*The fluorescent signal was measured in a Synergy 3 microplate reader (Biotek 
Instruments, USA) at a wavelength of 530-560nm excitation and 590nm emission. The 
reduction of AlamarBlue (%) was calculated using the formula: 
 
% Reduction = Fx – F0% red / F100% red – F0% red. 
Fx = fluorescence signal from sample  
F0% red = fluorescence signal from 0% reduced AlamarBlue 
F100% red = fluorescence from 100% reduced AlamarBlue control 
- Standard curve 
 

















Table 14 – Proliferation assay raw data hADSC (% reduction of AlamarBlue). 
 
 
Table 15 – Proliferation assay raw data oADSC (% reduction of AlamarBlue). 
 
Time%(Hrs)
2 2.332199 1.156887 1.118455 2.231102 1.676657 2.737643 -0.24549 0.751838 0.940519
6 8.148024 4.328462 4.669703 9.214619 7.41223 10.45776 3.611436 3.164927 4.049608
12 25.23204 14.31727 14.4473 35.15358 22.17275 28.00306 15.51165 11.42323 12.33933
24 67.61658 41.19607 43.90789 73.45438 58.26985 61.50557 52.10133 33.33717 39.32895
2 0.888001 1.544071 2.268694 0.200859 0.707449 0.927809 1.555992 1.073133 2.446135
6 6.365252 5.738591 8.687405 4.257928 3.326375 4.036952 8.20535 5.233438 9.42084
12 27.46601 18.3326 23.73119 16.41137 13.24121 10.65553 32.61393 17.47083 24.8151
24 64.98105 48.36071 57.98134 55.58434 38.3926 32.30263 71.98917 48.74155 60.06738
OM / TCPS SFM / TCPS OM / RT
SFM / RT OM / ST SFM / ST
Time%(Hrs)
2 0.240855 1.064339 1.891192 1.026531 1.427242 0.86468 0.858576 0.246886 -1.45323
6 5.53165 4.675697 5.372725 9.374557 5.40726 5.033771 4.557808 2.02789 0.530428
12 22.3439 15.93574 19.89227 33.13508 17.2858 19.87099 18.65122 9.153499 9.252556
24 68.51124 51.57064 67.36839 84.51561 51.94995 58.33065 64.35069 35.84819 37.74333
2 1.174396 0.876151 -0.21785 4.785923 0.840523 -0.76501 3.483874 1.010755 0.464214
6 6.753652 3.889364 3.440002 11.36904 3.894661 2.292819 11.71823 5.106713 5.678316
12 25.76919 14.40329 16.64751 32.75159 14.58239 14.00191 33.43468 17.62205 20.95301
24 71.74706 44.64677 48.33153 96.87812 49.9914 50.65034 82.92277 50.67325 60.43945
OM / TCPS SFM / TCPS OM / RT






Immunofluorescence for Runx-2 and Osteocalcin on TCPS and titanium discs 
(MTi and ABTi)* 
*Titanium discs were glued to a glass slide with epoxy glue (Selleys, Araldite, Cat# 04-
683) prior to the procedure below. 
*All solutions were used at 70µL/cm2 or disc. 
- DAY 1 
1. Fixation 
Cells were washed with PBS for 5 minutes at RT. 
Fixed in ice-cold acetone for 10 minutes. 
Slides were stored in the fridge at 4ºC. 
 
- DAY 2 
1. Rehydrate 
Cells were rehydrated in PBS for 5 minutes. 
A wax pen (Dako, Cat# S2002) was used around sections. 
2. Antigen retrieval (detergent wash) – only for Runx-2 
Cells were incubated for 10 min in PBS containing 0.25% Triton X-100. 
Cells were washed in PBS once for 30 seconds and once for 2 minutes. 
3. Blocking 
Blocking was performed with 20% goat serum (Sigma Aldrich, Cat# G9023) in 1% 
BSA/PBS (dilutant) (BSA, Sigma Aldrich, Cat# 05470) for 30 minutes at RT. 
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4. Primary antibody 
Primary antibody (see Chapter 2) diluted in PBS/1%BSA with 5% goat serum was 
added. 
5. IgG Control 
IgG Control diluted in PBS/1%BSA with 5% goat serum was added at a matched 
concentration to the primary antibody of interest. 
Cells were incubated overnight at 40C in a sealed container containing PBS to keep the 
inside humidity elevated. 
 
- DAY 3 
1. Skim milk solution 
The primary antibody was removed by tapping the slide. 
Cells were washed in 1% (w/v) skim milk solution in PBS under gentle shaking for 2 
minutes. 
Cells were washed with PBS twice for 10 minutes. 
2. Secondary antibody (in the dark) 
Secondary antibody (see Chapter 2) diluted in PBS/1%BSA with 5% goat serum was 
added. 
Cells were incubated for 1 hour at RT in the dark. 
3. Wash (in the dark) 
Cells were washed with PBS once for 2 minutes and twice for 10 minutes. 
4. DAPI counterstaining and coversliping (in the dark) 
Cells were counterstained with Vectashield mounting medium containing DAPI (Vector 






- Staining protocol for Alizarin red-S (Stanford et al, 1995; Gregory et al, 2004) 
*A 40mM Alizarin red S solution was prepared (see Appendix 4). 
*48-well plates containing wells with or without titanium were used. 
Phase 1 – Alizarin red S (ARS) staining 
1. Cells were washed in PBS at RT for 30 seconds. 
2. Fixed in ice-cold 70% ethanol for 1 hour. 
3. Rinsed with ultrapure H2O (Simplicity with UV, Millipore). 
4. Stained for 10 minutes with 40mM ARS, pH 4.2 at RT under gentle shaking. 
5. Rinsed 5 times with ultrapure H2O and washed twice in PBS for 10 then 15 minutes 
under shaking (to reduce unspecific binding of ARS). 
 
Phase 2 – Mineralised matrix quantitation 
*Sodium phosphate buffer 10mM at pH7.0 was made (Sambrook and Russell, 2001) 
1. To resuspend the ARS, cells were incubated with 1mL of 10% (w/v) cetylpyridinium 
chloride (358.0gmol-1, Sigma-Aldrich, Cat# C0732-100G) in 10mM sodium phosphate 
buffer, pH7.0, for 20 minutes at RT under gentle shaking 
2. 200µL ARS extract was collected in duplicate for the absorbance reading 
3. ARS extract was transferred to a flat bottom 96-well plate (Greiner Bio-one, Cat# 
655-180) and read by absorbance at 570nm 
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4. An ARS standard curve was generated as follows (Millipore - Osteogenesis assay kit, 
cat No. ECM815): 
• ARS 2mM was prepared 1:20 in dilution buffer (10% CPC in 10mM sodium 
phosphate buffer)  
• A high range set was constructed by diluting the 2mM working stock in 2-fold 
serial dilutions in 1.5mL micro-centrifuge tubes 
• A low range set was constructed by diluting the 2mM stock 1:66 in 10% CPC in 
10mM sodium phosphate buffer to achieve a 30µM working stock. The 30µM 
working stock was diluted in 2-fold dilutions in 1.5mL micro-centrifuge tubes 
• The blank consisted of dilution buffer (10% CPC in sodium phosphate buffer) 
only. 
5. Dilutions were transferred to a 96-well plate and read by absorbance at 562nm along 




Figure 32 – Standard curve Alizarin red S 
  


























Table 16 – Mineralisation assay raw data hADSC 
 
 
Table 17 – Mineralisation assay raw data oADSC 
 
Concentration*(µM)
2000 3.291 3.32 2.99 3.025 2.99 3.025
1000 1.646 1.624 1.537 1.531 1.537 1.531
500 0.784 0.779 0.764 0.767 0.764 0.767
250 0.382 0.381 0.382 0.388 0.382 0.388
125 0.201 0.18 0.192 0.193 0.192 0.193
30 0.04 0.036 0.042 0.041 0.042 0.041
15 0.019 0.012 0.021 0.02 0.021 0.02
7.5 0.012 0.006 0.009 0.008 0.009 0.008
3.75 0.003 0.003 0.003 0.005 0.003 0.005
1.875 0.51 0.445 0.001 0.002 0.001 0.002
hADSC / TCPS (Unknown) 0.087 0.062 0.052 0.053 0.029 0.058
hOS-ADSC / TCPS (Unnknown) 0.302 0.373 0.217 0.125 0.104 0.092
hADSC / Mti (Unknown) 0.085 0.078 0.048 0.06 0.057 0.057
hOS-ADSC / Mti (Unknown) 0.689 0.686 0.988 0.53 0.454 0.409
hADSC / ABTi (Unknown) 0.118 0.117 0.033 0.043 0.054 0.048
hOS-ADSC / ABTi (Unknown) 0.561 0.667 0.256 0.49 0.236 0.282
hADSC A hADSC B hADSC C
Concentration*(µM)
2000 2.891 2.918 2.891 2.918 2.891 2.918
1000 1.494 1.481 1.494 1.481 1.494 1.481
500 0.742 0.737 0.742 0.737 0.742 0.737
250 0.371 0.367 0.371 0.367 0.371 0.367
125 0.185 0.183 0.185 0.183 0.185 0.183
30 0.043 0.044 0.043 0.044 0.043 0.044
15 0.022 0.018 0.022 0.018 0.022 0.018
7.5 0.012 0.008 0.012 0.008 0.012 0.008
3.75 0.002 0.002 0.002 0.002 0.002 0.002
1.875 -0.002 0.005 -0.002 0.005 -0.002 0.005
oADSC / TCPS (Unknown) 0.096 0.107 0.15 0.121 0.252 0.097
oOS-ADSC / TCPS (Unnknown) 0.198 0.015 0.086 0.232 0.092 0.249
oADSC / Mti (Unknown) 0.066 0.082 0.16 0.093 0.234 0.078
oOS-ADSC / Mti (Unknown) 0.175 0.193 0.167 0.117 0.082 0.306
oADSC / ABTi (Unknown) 0.008 0.067 0.09 0.247 0.087 0.202
oOS-ADSC / ABTi (Unknown) 0.255 0.216 0.076 0.172 0.28 0.089






*RNA was extracted using TRIzol reagent (Invitrogen, Cat#15596-026) and a Purelink 
RNA mini kit (Life technologies, Ambion, Cat# 12183018A). The experiment followed 
the protocol proposed by the manufacturer 
*Only nuclease-free water (Applied Biosystems, Ambion, Cat# AM9930) was used 
*Only molecular biology grade ethanol (Absolute for analysis, Merk, Cat# K40869283-
011) was used 
- Preparation 
1. Working surface was cleaned with 70% ethanol and RNase AWAY (Invitrogen, Cat# 
10328-011) 
2. 70% ethanol was prepared in nuclease-free water for the experiment 
- Phase separation with TRIzol  
3. Medium was discarded from the cell culture; the cells were rinsed with PBS and 
lysed directly by adding TRIzol Reagent accordingly to the table below. The cell lysate 
was passed through a RNase-free pipette tip until cells were no longer observed on the 
surface using an inverted microscope. The content was transferred to the next well until 
the content of all 3 wells were collected.* 
*Every group was cultured in 3x wells of a 48-well plate (Greiner Bio-one, Cat# 
677180) to allow the retrieval of enough RNA to perform the gene expression 
experiment. 
Table 18 – Phase separation with TRIzol  
Quantity TRIzol (each well) Chloroform (each well) 
3 wells/sample 166µL 33µL 
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4. The lysate was incubated with TRIzol® Reagent at room temperature for 5 minutes 
to allow complete dissociation of the nucleoprotein complexes. 
5. 100µL of chloroform (GR for analysis, Merk, Cat# K32975445-408) to 500µL 
TRIzol® Reagent was used. The tube was shake vigorously by hand for approximately 
15 seconds. 
6. The sample was incubated at room temperature for 2–3 minutes. 
7. The sample was centrifuged at 12,000×g for 15 minutes at 4oC. 
Note: After centrifugation, the mixture was separated into a lower, red phenol-
chloroform phase, an interphase, and a colourless upper aqueous phase, which 
contained the RNA. The volume of the aqueous upper phase was approximately 300µL 
(200µL retrievable). 
8. Approximately 200µL of the colourless, upper phase containing the RNA was 
transferred to a fresh RNase–free tube. 
9. An equal volume 70% ethanol was added to obtain a final ethanol concentration of 
35% (~200µL). Sample was vortex to mix well (IKA MS 3 digital, IKA). 
10. The tube was inverted to disperse any visible precipitate that may form after adding 
ethanol. 
- Binding, washing, and elution 
11. Approximately 400µL was transferred of a sample to a Spin Cartridge (with a 
Collection Tube). 
12. Samples were centrifuged at 12,000×g for 15 seconds at room temperature. The 
flow-through was discarded and the Spin Cartridge reinserted into the same Collection 
Tube. 
13. Steps 11–12 were repeated until the entire sample was processed. 
14. On-column PureLink® DNase treatment (Life Technologies, Cat# 12185010) was 
prepared accordingly to the table below. 
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Table 19 – DNase treatment 
Component Volume 
10x DNase I Reaction Buffer 8µL 
Resuspended DNase (~3U/µL) 10µL 
RNase Free Water 62µL 
Final Volume per sample 80µL 
 
15. 350µL Wash Buffer I was added to the Spin Cartridge containing the bound RNA 
and centrifuged at 12,000 ×g for 15 seconds at room temperature. The flow-through and 
the Collection Tube were discarded. The Spin Cartridge was inserted into a new 
Collection Tube. 
16. 80µL PureLink® DNase mixture (prepared as described previously) was added 
directly onto the surface of the Spin Cartridge membrane. 
17. The sample was incubate at room temperature for 15 minutes. 
*Recovery tubes were labelled 
18. 350µL Wash Buffer I was added to the Spin Cartridge and centrifuged at 12,000xg 
for 15 seconds at room temperature. The follow-through and the Collection Tube were 
discarded and the Spin Cartridge inserted into a new Collection Tube. 
19. 500µL Wash Buffer II with ethanol (*ethanol was added and the box and checked) 
was added to the Spin Cartridge. 
20. The sample was centrifuge at 12,000xg for 15 seconds at room temperature. The 
flow-through was discarded and the Spin Cartridge reinserted into the same Collection 
Tube. 
21. Steps 19–20 were repeated once. 
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22. The Spin Cartridge was centrifuged at 12,000×g for 1 minute to dry the membrane 
with bound RNA. The Collection Tube was discarded and the Spin Cartridge inserted 
into a Recovery Tube. 
23. 100µL RNase–free water was added to the centre of the Spin Cartridge 
24. Sample was incubated at room temperature for 1 minute.  
25. The Spin Cartridge with the Recovery Tube was centrifuged for 1 minute at 
12,000×g at room temperature. 
26. RNA Yield and Quality was analysed with a spectrophotometer (NanoVue, GE 
Healthcare). Samples were kept on ice. 
*2µL of RNA was used for analysis 




Table 20 – RNA extraction results 















Baseline 1.814 17.2* 1.841 11.6* 1.905 16.0* 
hADSC/MTi 
Baseline 1.830 16.4* 1.840 12.4* 1.770 16.0* 
hADSC/ABTi 
Baseline 1.767 16.4* 1.807 10.1* 2.080 10.4* 
hADSC/TCPS 
7 days 1.952 64.8 2.044 74.4 2.043 56.4 
hADSC/MTi 
7 days 1.758 64.0 2.033 78.8 2.068 48.8 
hADSC/ABTi 












1.841 32.4* 2.061 24.4* 2.075 22.0* 
hADSC/TCPS 
21 days 1.956 71.2 2.069 59.6 2.045 54.8 
hADSC/MTi 
21 days 1.957 72.8 2.075 77.2 2.058 70.8 
hADSC/ABTi 












1.976 64.8 2.042 117.6 2.072 126.8 
1. The samples were considered to have a good quality RNA when A260/280 was 
higher than 1.700  




*Where RNA sample to be used was too diluted, an RNA precipitation step was 
performed 
- Preparation 
70% Ethanol was made in DNase-free water 
- Protocol 
1. The sample was thawed.  
2. 10% (v/v) of ice-cold 3M Sodium acetate (pH=5.5) (RNase-free, DPEC treated) was 
added and vortex shortly. 
- Sodium acetate (Merk, Cat# 1.06267.0500): 
MW 136.08 
40.82g (NaOAc) in 100mL dH2O. 
*pH was corrected with glacial acetic acid. 
100µL of DPEC (Sigma Aldrich, Cat# D5758) was added under stirring. 
Solution was autoclaved at 121ºC for 20min. 
 
3. 2.5 fold ice-cold ethanol (Molecular Biology Grade) was added and vortex to mix 
well. 
4. Sample was place at -200C for 1 hour 
5. Sample was centrifuged for 20min at 10,000xg at 40C. 
The hinge of the eppendorf was positioned at the outer end of the centrifuge and an 
exact balance was used. Most of the times pellet was not clearly visible as it was crystal 
(glassy whitish). By putting the eppendorf at correct position in the centrifuge was very 
helpful to localize the RNA pellet at the bottom outer end of the tube. 
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6. The supernatant was carefully removed with only a small amount left behind to 
protect the pellet from disruptions. 
7. 500 µL of ice-cold 70% ethanol was added and the sample centrifuged again for 5min 
at 10,000xg at 4ºC. 
8. The supernatant was carefully removed tilting the eppendorf to avoid pellet 
disruptions. 
9. The sample was air dried (until just dry) in a drier at 55ºC. 
10. 12 µL of RNase free water was added to resuspend the precipitated RNA and put on 
ice for 15min. 
11. The RNA concentration and quality were checked with a spectrophotometer 
(NanoVue, GE Healthcare). 




Table 21 – RNA precipitation results 















Baseline 1.814 51.2 1.841 35.6 1.905 54.0 
hADSC/MTi 
Baseline 1.830 44.8 1.840 42.0 1.770 65.6 
hADSC/ABTi 
Baseline 1.767 36.0 1.807 31.6 2.080 40.0 
hADSC/ABTi 












1.841 42.0 2.061 170.4 2.075 16.0 
hADSC/ABTi 




*High-capacity cDNA RT kits (Cat# 4368814) was used 
*A single reaction per sample of 500ng was prepared. If the sample had less than 
500ng, the total amount was used instead (e.g. 430ng). 
*The kit components were thawed on ice 
*The RT master mix was prepared on ice 
1. A 2x RT master mix was prepared (20µL reaction) as follows: 
 
Table 22 – Master mix preparation 
Component Kit without RNase 
inhibitor (µL) 
RT (1) NO RT (2) 
1st 10x RT buffer 2.0 2.0 
3rd 25x dNTP mix (100mM) 0.8 0.8 
4th 10x RT Random primers 2.0 2.0 
5th Multiscribe RT 1.0 - 
2nd Nuclease-free H2O 4.2 5.2 
TOTAL 10.0 10.0 
 
2. The 2x RT master mix was placed on ice and mixed gently 
3. cDNA RT reaction was prepared 1:1 (sample to master mix) to make a 20µL reaction 
4. Sample was centrifuged to spin down the contents and eliminate air bubbles 
5. The tube was placed on ice until ready to load the thermal cycler 
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4. The reverse transcription reaction was performed following the program of the 
thermal cycler conditions in PTC-100 MJ Programmable Thermal Controller machine 
(Research, Inc.) 
Table 23 – Thermal cycler conditions for reverse transcription 
 Step 1 Step 2 Step 3 Step 4 
Temperature 
(ºC) 
25 37 85 4 
Time 10min 120min 5sec ∞ 
*The reaction volume was set to 20µL 





1. Create a plate document for the 7500 Fast system (see RT2 SYBR Green ROX qPCR 
Master Mix (2x), QIAGEN, Cat# 330520). 
2. Complete the setup of the plate document. 
3. Set up the thermal cycler protocol and save the document. 
4. Make it up cDNA stock from each sample. 
*Thaw cDNA samples on ice. 
*Vortex to mix content and spin briefly. 
5. Make it up PCR reaction stocks accordingly to the table below: 
 
Table 24 – PCR reaction 
RT2 SYBR Green ROX qPCR reaction 1x reaction (µL) 
Master mix 12.5 
SYBR Green RT2 qPCR assay 1 
RNase-free water 7.5 
cDNA template (5ng)* 4 
TOTAL 25 
*The cDNA template was paced directly into the wells. 
*The RT2 SYBR Green Master Mix was mixed and centrifuged thoroughly by swirling 
before use. 
*The SYBR Green gene expression assay was vortexed and spun briefly before use. 
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6. Samples were mixed by gentle inversion, and then spun briefly. 
7. The plate was prepared (25µL reaction per well). 
*21µL of reaction mix was transferred to the wells of a MicroAmp® Fast Optical 96-
Well Reaction Plate with Barcode, 0.1 mL (Applied Biosystems, Cat# 4346906). 
*The 4µL cDNA, from stocks, was placed at the assigned wells for each sample. No 
Reverse Transcriptase and No Template control samples were also included. 
8. The plate was sealed with an optical adhesive cover, and then centrifuged briefly at 
1000xg for 1min to spin down the contents and eliminate air bubbles. 
9. The plate document was opened; the reaction plate loaded into the 7500Fast System, 

















































*Samples were loaded into a 96 well-plate in duplicate. A 10-fold serial dilution was 
used where the highest concentration was 10ng of cDNA per reaction and the lowest 
0.001ng of cDNA per reaction. 
*Samples and reactions were prepared as per abovementioned method. 
*Cq (also called Ct) cut-off was established at 33. Very weak signals between 33 and 35 
disrupted the efficiency slope. If the values above 33 did not interfere with the curve 
slope they were maintained. 
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Figure 44 – Standard curve PGK1 SYBR green assay 
  
PGK1 Standard Curve
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Y = -3.428*X + 24.31
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Figure 45 - Standard curve OCT4 SYBR green assay 
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Figure 46 - Standard curve TERT SYBR green assay 
  
TERT Standard Curve Ref. cDNA
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Y = -3.255*X + 32.67
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Figure 47 - Standard curve MSX2 SYBR green assay 
  
MSX-2 Standard Curve
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Y = -3.095*X + 28.57
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Figure 48 - Standard curve RUNX2 SYBR green assay 
  
RUNX-2 Standard Curve
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Y = -3.244*X + 26.44
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Figure 49 - Standard curve BGLAP SYBR green assay 
  
BGLAP Standard Curve
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Y = -3.431*X + 29.41
 185 
 
Figure 50 - Standard curve ITGA1 SYBR green assay 
  
ITGA1 Standard Curve
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Y = -3.312*X + 28.39
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Figure 51 - Standard curve ITGA5 SYBR green assay 
  
ITGA5 Standard Curve
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Y = -3.288*X + 24.67
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Figure 52 - Standard curve ITGAV SYBR green assay 
  
ITGAV Standard Curve
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Y = -3.123*X + 25.44
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Figure 53 - Standard curve ITGB1 SYBR green assay 
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Figure 54 - Standard curve ITGB3 SYBR green assay 
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- 2% Agarose gel (Life Technologies, Cat# 15510-027) was used. 
- Gels were run at 100V for 5 minutes and then 80V. 
- Samples from 10ng cDNA standard curve reactions. 
- cDNA used were Baseline / hADSC / TCPS, 7 Days / hADSC / TCPS, 21 Days / hOS-
ADSC / TCPS, and reference human cDNA (Takara Clontech, Cat# 639653) 
- Post-staining was performed with 150µL ethidium bromide in 500mL of dH2O for 15 
minutes and then washed for 15 minutes in dH2O. 
- Each lane contained 10µL of sample (10ng/25µL) plus 2µL of dye (GelPilot Loading 
Dye, 5x; Qiagen, Cat# 239901 and GeneRuler 100bp plus DNA Ladder 0.1µg/µL, 
Fermentas Life Sciences). No template controls were used as controls. 





Figure 55 – Gel electrophoresis of the 10ng standard curve products for PGK1, BGLAP, RUNX2, 
MSX2, POU5F1, and TERT. Note the presence of no template controls (NTC). 
 
 
Figure 56 - Gel electrophoresis of the 10ng standard curve products for ITGA1, ITGA5, ITGAV, 
ITGB1, and ITGB3. Note the presence of no template controls (NTC).  
 192
Gene	expression	raw	results	(Cq	values)	






Baseline(/(hADSC(/(TCPS 24.935 24.095 23.42 30.785 30.86 30.505 28.655 26.84 26.52
Baseline(/(hADSC(/(MTi 23.005 26.75 24.95 29.93 32.64 32.315 27.47 28.27 27.71
Baseline(/(hADSC(/(ABTi 23.23 24.33 24.06 29.995 30.25 30.645 27.72 27.075 27.07
7(Days(/(hADSC(/(TCPS 23.345 23.16 23.39 30.19 29.85 30.23 27.615 25.54 25.955
7(Days(/(hADSC(/(MTi 23.325 25.54 23.48 30.035 31.285 30.4 27.595 27.74 26.23
7(Days(/(hADSC(/(ABTi 23.485 24.33 23.935 30.395 31.08 30.655 27.995 26.74 26.545
7(Days(/(hOS?ADSC(/(TCPS 24.175 23.92 24.08 30.655 30.61 30.575 27.965 26.385 26.665
7(Days(/(hOS?ADSC(/(MTi 24.225 23.735 24.14 30.89 31.145 31.095 28.305 27.12 27.085
7(Days(/(hOS?ADSC(/(ABTi 25.165 24.535 23.45 31.265 31.735 30.41 28.53 27.525 26.76
21(Days(/(hADSC(/(TCPS 22.765 23.31 23.365 29.595 31.305 30.61 27.715 27.205 26.845
21(Days(/(hADSC(/(MTi 22.865 22.73 23.355 29.595 30.96 30.375 28.03 27.28 26.995
21(Days(/(hADSC(/(ABTi 23.145 24.06 24.34 29.87 31.285 31.125 27.7 27.725 27.07
21(Days(/(hOS?ADSC(/(TCPS 24.61 23.58 23.85 29.68 30.885 30.16 28.3 27.2 26.37
21(Days(/(hOS?ADSC(/(MTi 24.36 22.84 23.445 29.195 30.235 30.085 28.055 26.985 26.195
21(Days(/(hOS?ADSC(/(ABTi 23.99 23.225 23.14 29.025 30.73 30.555 28.05 27.41 26.255
PGK1 BGLAP RUNX?2
Baseline(/(hADSC(/(TCPS 34.1 32.245 31.945 35.185 33.515 32.375 39.145 40 38.815
Baseline(/(hADSC(/(MTi 32.42 33.31 33.34 34.375 35.815 35.86 38.425 40 39.035
Baseline(/(hADSC(/(ABTi 32.99 32.54 32.765 33.445 33.75 33.405 39.13 39.885 39.165
7(Days(/(hADSC(/(TCPS 33.38 31.495 31.86 33.515 32.71 33.76 38.255 39.655 40
7(Days(/(hADSC(/(MTi 32.96 32.95 31.85 33.44 37.345 34.3 38.615 39.065 39.175
7(Days(/(hADSC(/(ABTi 33.21 31.8 32.065 33.465 34.27 34.61 38.1 38.43 40
7(Days(/(hOS?ADSC(/(TCPS 33.22 31.65 32.51 33.03 32.85 32.935 40 38.625 40
7(Days(/(hOS?ADSC(/(MTi 33.26 32.26 31.985 32.125 34.495 33.06 40 40 40
7(Days(/(hOS?ADSC(/(ABTi 34.665 33.16 31.68 33.42 34.275 33.14 40 39.705 39.405
21(Days(/(hADSC(/(TCPS 32.445 32.13 31.825 33.93 34.395 34.025 37.86 36.65 40
21(Days(/(hADSC(/(MTi 32.51 31.865 32.13 33.785 34.125 33.995 37.615 39.26 40
21(Days(/(hADSC(/(ABTi 32.625 30.885 31.195 32.565 34.535 34.17 36.615 40 40
21(Days(/(hOS?ADSC(/(TCPS 32.415 31.685 30.735 32.35 33.26 32.355 40 40 40
21(Days(/(hOS?ADSC(/(MTi 31.915 30.855 30.53 32.665 32.895 32.315 39.325 40 40
21(Days(/(hOS?ADSC(/(ABTi 32.025 31.595 31.23 32.195 32.455 32.265 39.435 40 40
TERTMSX?2 POU5F1
Baseline(/(hADSC(/(TCPS 29.445 28.27 27.32 26.215 24.01 23.67 25.285 25.17 24.595
Baseline(/(hADSC(/(MTi 28 29.67 28.535 24.395 25.315 24.865 24.955 26.6 25.805
Baseline(/(hADSC(/(ABTi 28.01 28.33 27.925 24.535 23.88 24.08 24.76 25.215 25.05
7(Days(/(hADSC(/(TCPS 27.36 26.82 26.73 24.3 24.65 24.75 24.125 22.93 23.145
7(Days(/(hADSC(/(MTi 27.39 29.635 26.765 24.32 27.475 25.485 24.195 25.27 23.35
7(Days(/(hADSC(/(ABTi 27.43 27.125 26.835 24.4 25.295 25.14 24.45 23.82 23.405
7(Days(/(hOS?ADSC(/(TCPS 25.875 24.53 24.67 24.945 25.335 25.21 24.25 23.095 23.435
7(Days(/(hOS?ADSC(/(MTi 25.975 25.135 24.885 24.28 25.095 25.06 24.37 23.46 23.31
7(Days(/(hOS?ADSC(/(ABTi 26.62 25.77 24.8 25.215 25.85 24.975 25.415 24.075 23.16
21(Days(/(hADSC(/(TCPS 26.99 27.445 26.99 24.78 25.135 28.335 24 23.755 23.585
21(Days(/(hADSC(/(MTi 27.29 27.4 27.05 25.025 25.135 29.005 24 23.695 23.665
21(Days(/(hADSC(/(ABTi 27.215 27.395 27.455 24.795 25.48 27.17 24.23 23.535 23.68
21(Days(/(hOS?ADSC(/(TCPS 27.305 26.155 25.315 24.95 24.745 29.75 25.285 22.94 22.725
21(Days(/(hOS?ADSC(/(MTi 27.07 26.015 25.64 24.755 29.925 30.09 25.19 22.885 23.065
21(Days(/(hOS?ADSC(/(ABTi 27.02 26.195 25.335 24.67 30.135 29.48 25.26 23.005 22.78
ITGA1 ITGA5 ITGAV
Baseline(/(hADSC(/(TCPS 23.18 22.055 21.505 29.03 26.9 27.69
Baseline(/(hADSC(/(MTi 21.495 23.88 22.72 28.54 28.43 28.68
Baseline(/(hADSC(/(ABTi 21.675 22.305 21.9 27.875 25.21 27.175
7(Days(/(hADSC(/(TCPS 21.65 23.255 23.31 29.98 21.305 21.065
7(Days(/(hADSC(/(MTi 21.475 25.46 23.565 29.9 23.855 21.045
7(Days(/(hADSC(/(ABTi 21.6 24.36 23.975 28.9 21.575 21.375
7(Days(/(hOS?ADSC(/(TCPS 22.435 23.705 23.97 30.855 21.51 21.855
7(Days(/(hOS?ADSC(/(MTi 22.55 23.89 24.075 31.145 21.82 21.95
7(Days(/(hOS?ADSC(/(ABTi 23.39 24.52 23.88 31.455 22.365 21.935
21(Days(/(hADSC(/(TCPS 21.245 24.355 24.255 28.45 21.44 21.41
21(Days(/(hADSC(/(MTi 21.63 24.34 24.475 28.86 21.3 21.5
21(Days(/(hADSC(/(ABTi 21.395 25.07 24.88 28.445 21.46 21.975
21(Days(/(hOS?ADSC(/(TCPS 23.23 24.765 24.455 31.03 22.14 22.12
21(Days(/(hOS?ADSC(/(MTi 23.155 24.74 24.7 31.17 22.03 22.395
21(Days(/(hOS?ADSC(/(ABTi 23.195 24.865 24.805 31.145 22.03 22.24
ITGB1 ITGB3
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Table 26 – Raw Cq values of no template controls (NTC) from experiments using cell lines 1, 2, and 




Detector Sample,type Plate,1 Plate,2 Plate,3 Plate,4 Plate,5 Plate,1 Plate,2 Plate,3 Plate,4 Plate,5
BGLAP NTC 40 40 36.93 40 39.82 40 39.76 40 40 40
BGLAP NTC 40 40 40 39.98 40 40 40 40 40 40
ITGA1 NTC 38.36 40 40 40 40 40 40 40 37.52 40
ITGA1 NTC 40 40 40 40 40 40 40 40 40 39.48
ITGA5 NTC 40 40 40 40 40 40 37.92 40 39.7 40
ITGA5 NTC 40 40 40 40 40 40 38.89 40 40 40
ITGAV NTC 40 40 40 40 40 40 40 40 40 38.64
ITGAV NTC 40 40 40 40 40 37.16 40 40 40 39.73
ITGB1 NTC 40 40 40 40 40 40 39.57 40 40 40
ITGB1 NTC 40 40 40 40 40 40 40 40 39.31 40
ITGB3 NTC 40 40 40 40 40 40 40 40 36.11 35.54
ITGB3 NTC 40 40 40 39.74 40 40 40 40 35.48 35.1
MSXE2 NTC 39.05 39.04 38.29 35.62 36.15 40 35.34 38.64 38.96 39.47
MSXE2 NTC 39.3 38.56 40 35.77 35.82 38.83 36.14 38.14 39.4 40
PGK1 NTC 40 39.04 40 36.87 37.98 39.43 35.76 38.25 38.78 40
PGK1 NTC 40 39.34 40 36.55 38.32 39.71 37.14 38.12 38.5 40
POU5F1 NTC 40 40 40 40 40 40 40 40 40 40
POU5F1 NTC 40 40 40 40 40 40 40 40 40 40
RUNXE2 NTC 40 40 40 40 40 40 40 40 40 40
RUNXE2 NTC 40 40 40 40 40 40 40 40 40 40
TERT NTC 38.88 38.61 40 35.18 36.03 40 36.67 40 40 40
TERT NTC 39.63 40 40 35.48 37.06 40 36.36 40 39.07 40
Experiment,1 Experiment,2
Detector Sample,type Plate,1 Plate,2 Plate,3 Plate,4 Plate,5
BGLAP NTC 40 40 40 40 40
BGLAP NTC 40 40 40 39.37 40
ITGA1 NTC 40 40 36.77 40 40
ITGA1 NTC 40 40 40 40 40
ITGA5 NTC 40 40 40 40 40
ITGA5 NTC 40 40 40 40 40
ITGAV NTC 40 40 40 40 40
ITGAV NTC 40 40 40 40 40
ITGB1 NTC 40 40 40 38.81 39.88
ITGB1 NTC 40 40 38.15 38.44 39.33
ITGB3 NTC 40 40 40 35.31 35.42
ITGB3 NTC 40 40 40 35.86 35.59
MSXE2 NTC 37.25 39.88 38.56 37 40
MSXE2 NTC 36.9 40 40 37.07 40
PGK1 NTC 36.87 38.73 38.2 37.54 40
PGK1 NTC 36.65 39.24 39.54 37.49 40
POU5F1 NTC 40 40 40 40 40
POU5F1 NTC 40 40 40 40 40
RUNXE2 NTC 39.78 40 40 40 40
RUNXE2 NTC 40 40 40 40 40
TERT NTC 38.28 40 39.79 39.18 40
TERT NTC 37.86 40 39.98 39.53 40
Experiment,3
 194
Table 27 – Raw Cq values of no reverse transcriptase controls (NORT) from experiments using cell 





Figure 57 – Raw Cq clusters.  
*Cq values above the threshold of 35 were considered undetected.  
Detector Sample Experiment01 Experiment02 Experiment03
PGK1 Baseline0/0hADSC0/0TCPS0NORT 40 C 37.9
PGK1 Baseline0/0hADSC0/0TCPS0NORT 40 C 40
PGK1 Baseline0/0hADSC0/0MTi0NORT 40 C 40
PGK1 Baseline0/0hADSC0/0MTi0NORT 40 C 40
PGK1 Baseline0/0hADSC0/0ABTi0NORT 37.39 C C
PGK1 Baseline0/0hADSC0/0ABTi0NORT 40 C C
PGK1 70Days0/0hADSC0/0TCPS0NORT 40 38.88 40
PGK1 70Days0/0hADSC0/0TCPS0NORT 40 38.69 40
PGK1 70Days0/0hADSC0/0MTi0NORT 40 36.33 40
PGK1 70Days0/0hADSC0/0MTi0NORT 40 37.51 40
PGK1 70Days0/0hADSC0/0ABTi0NORT 40 40 40
PGK1 70Days0/0hADSC0/0ABTi0NORT 40 40 40
PGK1 70Days0/0hOSCADSC0/0TCPS0NORT 40 37.36 37.65
PGK1 70Days0/0hOSCADSC0/0TCPS0NORT 40 38.16 40
PGK1 70Days0/0hOSCADSC0/0MTi0NORT 38.53 40 40
PGK1 70Days0/0hOSCADSC0/0MTi0NORT 40 40 37.71
PGK1 70Days0/0hOSCADSC0/0ABTi0NORT 40 40 40
PGK1 70Days0/0hOSCADSC0/0ABTi0NORT 40 40 40
PGK1 210Days0/0hADSC0/0TCPS0NORT 37.99 36.82 36.7
PGK1 210Days0/0hADSC0/0TCPS0NORT 39.1 37.49 36.65
PGK1 210Days0/0hADSC0/0MTi0NORT 38.62 40 40
PGK1 210Days0/0hADSC0/0MTi0NORT 38.11 37.78 40
PGK1 210Days0/0hADSC0/0ABTi0NORT 38.75 40 40
PGK1 210Days0/0hADSC0/0ABTi0NORT 38.93 39.4 40
PGK1 210Days0/0hOSCADSC0/0TCPS0NORT 38.47 40 40
PGK1 210Days0/0hOSCADSC0/0TCPS0NORT 39.58 40 40
PGK1 210Days0/0hOSCADSC0/0MTi0NORT 39.5 40 40
PGK1 210Days0/0hOSCADSC0/0MTi0NORT 38.87 36.7 40
PGK1 210Days0/0hOSCADSC0/0ABTi0NORT 39.03 40 40











































Table 28 – Relative gene expression in both cell lines grown on TCPC, MTi, and ABTi at 7 and 21 
days compared to cells grown on its matched surface at baseline (24hrs after plating). Mean 2-ΔΔCq 








- Samples cDNA 
hADSC / TCPS / Baseline 
hADSC / TCPS / 21 days  
hOS-ADSC / TCPS / 21 days  
*Samples were prepared as per Appendix 8 
*Cells from 3x wells from a 48-well plate were necessary from each sample to retrieve 
sufficient RNA 
*TaqMan® Express Human Endogenous Control 96-well plate, Fast, ABI, Cat# 
4426700) 
- Fast plate protocol (Plate No. 4426691) 
1. The document template was prepared in the 7500 Fast system software. 
2. For each cDNA sample, 5µL of cDNA (1ng/µL) was combined 1:1 with 5µL of 
TaqMan Fast Universal PCR master mix (Life Technologies, Cat# 4352042) for each 
reaction; total volume equals 10µL. An individual reaction was correspondent to the 
volume needed to each well. In total, 32 reactions were made for each cDNA since there 
were 32 target genes in the plate. 
3. The solution was gently vortexed and spun to mix the components. 




Figure 58 – Endogenous control fast plate layout 
*Note 3 sets of 32 candidate reference genes (different grey colour wells) 
6. The plate was sealed with MicroAmp Optical adhesive film (Life technologies, Cat# 
4360954) and centrifuged at 1000xg for 1 minute. 
7. The run was performed using the 7500 Fast system. 
Step 1 (Repeat 1x): Hold (Polymerase activation) 950C for 20 seconds 
Step 2 (Repeat 40x): Melt (Denaturation) 950C for 3 seconds 
Annealing / Extension 600C for 30 seconds 




*Data collection: stage 2, step 2 600C @ 0:30 
 
8. After run, data was saved and exported for analysis. 
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Endogenous	control	plate	raw	results	




Sample'Name Detector Task hADSC'/'TCPS'/'Baseline hADSC'/'TCPS'/'21'days hOS>ADSC'/'TCPS'/'21'days Mean'Cq Qbase'geNorm'(M) StDev.'Cq
18S DJ'HKG Unknown 13.59 14.1 13.44 13.71 0.274 0.3459772
GAPDH DJ'HKG Unknown 19.75 21.58 19.65 20.32667 0.322 1.08657
HPRT1 DJ'HKG Unknown 25.45 28.08 26.95 26.82667 0.711 1.31933
GUSB DJ'HKG Unknown 27.06 27.92 25.02 26.66667 0.642 1.489474
ACTB DJ'HKG Unknown 20.34 22.16 19.89 20.79667 0.372 1.201929
B2M DJ'HKG Unknown 21.41 22.39 20.95 21.58333 0.080 0.735481
HMBS DJ'HKG Unknown 26.95 28.74 27.93 27.87333 0.414 0.8963439
IPO8 DJ'HKG Unknown 26.74 28.58 26.3 27.20667 0.390 1.209518
PGK1 DJ'HKG Unknown 23.33 24.11 22.85 23.43 0.147 0.6359247
RPLP0 DJ'HKG Unknown 21.08 23.49 20.22 21.59667 0.593 1.695121
TBP DJ'HKG Unknown 27.84 30.26 28.03 28.71 0.439 1.345697
TFRC DJ'HKG Unknown 24.57 26.05 24.6 25.07333 0.189 0.8459507
UBC DJ'HKG Unknown 22.51 23.98 21.06 22.51667 0.546 1.460011
YWHAZ DJ'HKG Unknown 30.63 33 28.23 30.62 0.793 2.385016
PPIA DJ'HKG Unknown 20.29 21.53 20.13 20.65 0.119 0.7662902
POLR2A DJ'HKG Unknown 26.42 27.43 25.93 26.59333 0.077 0.7648748
CASC3 DJ'HKG Unknown 25.27 27.03 24.25 25.51667 0.493 1.406319
CDKN1A DJ'HKG Unknown 24.62 24.8 22.95 24.12333 0.616 1.020114
CDKN1B DJ'HKG Unknown 27.44 28.48 27.26 27.72667 0.132 0.6585839
GADD45A DJ'HKG Unknown 27.42 28.67 27.1 27.73 0.096 0.8296384
PUM1 DJ'HKG Unknown 25.22 27.38 23.83 25.47667 0.664 1.788863
PSMC4 DJ'HKG Unknown 25.96 27.49 26.24 26.56333 0.219 0.8146372
EIF2B1 DJ'HKG Unknown 26.45 29.49 26.13 27.35667 0.686 1.854436
PES1 DJ'HKG Unknown 25.55 26.6 25.86 26.00333 0.249 0.5394755
ABL1 DJ'HKG Unknown 24.83 26.23 25.4 25.48667 0.297 0.7040122
ELF1 DJ'HKG Unknown 27 28.85 24.78 26.87667 0.746 2.037801
MT>ATP6 DJ'HKG Unknown 19.5 22 19.09 20.19667 0.518 1.57513
MRPL19 DJ'HKG Unknown 25.48 27.83 25.17 26.16 0.466 1.454545
POP4 DJ'HKG Unknown 25.21 27.15 25.85 26.07 0.345 0.9885345
RPL37A DJ'HKG Unknown 23.05 23.84 21.4 22.76333 0.570 1.245004
RPL30 DJ'HKG Unknown 28.73 27.72 28.6 28.35 0.848 0.5494546
RPS17 DJ'HKG Unknown 21.43 22.13 21.05 21.53667 0.164 0.5478441
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Endogenous	control	plate	data	analysis	
- Selection of the reference gene to be used in the RT2qPCR experiments 
*The selection of the reference gene followed a set of 3 criteria. The selected reference 
gene was the one respecting all criteria. 
1. First criteria: Genes with Cq values between 22 and 25 were selected. 
 
Figure 59 – Graph of the mean Cq values of the endogenous control plate. 
































































































2. Second criteria: Genes with a standard deviation of the mean Cq lower than 1. 
 
Figure 60 – Graph of the standard deviation of the mean Cq values of the endogenous control plate. 
*The genes selected were 18S, PES1, RPS17, RPL30, PGK1, CDKN1B, ABL1, B2M, 
POLR2A, PPIA, PSMC4, GADD45A, TFRC, HMBS, and POP4. 
3. Third criteria: Genes with a geNorm (M) value below 0.5 were selected. 
 
Figure 61 – Graph of the M values of the endogenous control plate. 
*The genes selected were POLR2A, B2M, GADD45A, PPIA, CDKN1B, PGK1, 
RPS17, TFRC, PSMC4, PES1, 18S, ABL1, GAPDH, POP4, ACTB, IPO8, HMBS, 
TBP, MRPL19, and CASC3. 
4. Selection of gene: The only gene respecting all the criteria was PGK1. Hence, this 
gene was selected as the reference gene. 
PGK1 mean Cq = 23.43; Standard Deviation = 0.63; and M = 0.14.   








































































































































































































Thank you for your reply to the provisos requested for protocol
l2ll3. These were considered at the most recent meeting of
the Otago University Animal Ethics Committee and I am
pleased to advise that your protocol has now been approved in
full.
Yours sincerely
/"-/? /.'##\ , -&{*-nffi5;{} *,*r- $-*".-o'
BarbaraLee
Secretary




 Appendix	 11	 –	 Ovine	 adipose-derived	 stem	
cells	isolation	and	culture	
Sheep	serum	preparation	
*Volume obtained was approximately 50% of whole blood after clotting. 
1. 100mL of whole blood was retrieved, and placed into DB vacutainer tubes containing 
gel for serum separation (Cat# 0268396). 
2. The blood was let to clot inside a fridge for 20 – 30min. 
3. Spun at 2000xg for 10 min at 40C. 
*The gel separated the serum from the whole blood. 
4. The serum was filtered with 45 and 22µm filters. 
5. The serum was transferred to 50mL Falcon flasks. 
6. Heat inactivation was performed for 30 min at 560C (see below). 
7. Sheep serum (SS) was stored at -200C. 
Heat	inactivation	of	SS	
*Protocol from Serum Source International (International, 2014) 
1. The SS was allowed to acclimate at RT for a minimum of 10 minutes. 
2. The water bath was prepared to a controlled temperature to 56°C for the heat 
inactivation process. There was enough water to submerge the entire contents of the 
bottle. 
3. A control bottle was filled with water to monitor the water bath temperature. The 
control bottle was identical to the bottle being heat inactivated and the temperature of 
the water within the control bottle was the same as that of the SS. 
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4. The control bottle and SS were placed into the 56° C water bath. A suspended glass 
thermometer was used to monitor the temperature inside the control bottle. The 
thermometer was not allowed to touch the sides or bottom of the bottle. 
5. The timer was set to 30 minutes once the temperature of the control bottle reached 
56°C. The same temperature was maintained for the entire duration of the process. 
6. The bottles were gently swirled every 4 minutes to make certain the SS remained 
uniform throughout heating. 
7. The heat-inactivated SS was removed after 30 minutes and gently swirled once again.  
8. The bottle was allowed to cool down to RT. 
9. The heat-inactivated SS was stored at -20°C. 
Cell	culture	
* This method was modified from Niemeyer and co-workers (Niemeyer et al., 2010a). 
*Approximately 10g of processed adipose tissue was enough for a T75. 
*T75 was coated with 1µg/cm2 of bovine fibronectin and incubated in a humidified 
atmosphere at 37ºC and 5% CO2 for 1 hour. 
* Krebs–Ringer buffer (K4002-1L, use at 9.5g/L) containing HEPES was made up as 
follows: 
10mL of Krebs-Ringer buffer with 100µL (10mmol/L) of HEPES (1M) 
1. Approximate starting quantity of adipose tissue was 10g 
2. The adipose tissue was washed twice with PBS containing 20mg/ml BSA and 1% 
antibiotic-antimycotic. The solution was discarded and the adipose tissue kept with a 
barrier (tweezers were used). 
*PBS containing BSA was made as follows: 
30ml of PBS 
600mg (20mg/mL) BSA (bovine serum albumin) 
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0.3mL (1%) antibiotic-antimycotic (penicillin/streptomycin) 
3. The tissue was placed in a Petri dish and reduced to portions approximately 1mm2 in 
size (chopped with two scalpels blades No. 15). The fibrous material and blood vessels 
were removed. 
4. A 0.6 mg/ml collagenase solution (collagenase type II – Sigma Aldrich, derived from 
Clostridium hydrolyticum, Cat# C6885) diluted with Krebs–Ringer buffer containing 
HEPES was prepared as follows: 
10mL of Krebs-Ringer buffer with HEPES 
6mg of collagenase type B 
*Filter sterile 0.22µm 
5. The adipose tissue was incubated with an equivalent volume of collagenase solution 
(1:1) and lightly agitated at 37ºC for 90 minutes.  
6. The SFM containing 2.5% of autologous sheep serum was prepared. 
7. The cells were centrifuged at 600xg for 10 minutes at RT, the supernatant was 
discarded together with the lipid layer, and cell pellet kept. 
8. The cell pellet was washed with warmed 10mL PBS with EDTA 1mM (Sigma-
Aldrich Enzyme Explorer - Metalloproteinase inhibitors). 
9. Cell clumps and endothelial cell aggregates were largely removed by subsequent 
filtration through a 70µm cell strainer.  
10. The cells were centrifuged at 600xg for 10 minutes at room temperature, the 
supernatant discarded, and the cell pellet kept. 
11. The cell pellet was washed with warmed 10mL PBS. 
12. The cells were centrifuged at 600xg for 10 minutes at room temperature, the 
supernatant discarded, and cell pellet kept. 
 13. The cells were resuspended in 10mL of SFM containing autologous SS and then 
adapted to serum-free conditions as follows: 
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Table 30 – Serum-free medium adaptation 
Passage Sheep Serum* Sheep Serum 
P0 20% 2.5% 
P1 2.5% 0% 
P2 0% 0% 
*Only required for cell line from sheep 372 due to low initial attached cell number 
 
13. The cells were centrifuged at 600xg for 10 minutes at room temperature and the 
supernatant discarded. The cells were resuspended in 10mL of SFM with SS (see table 
above).  
*This step was important to remove the remaining collagenase from the cell suspension. 
14. The oADSC were plated at full concentration into T75 tissue culture flask in a 
humidified atmosphere at 37ºC and 5% CO2.  
15. After 1 hour the cells were washed with warmed PBS to remove non-adherent cells 
(Griesche et al., 2010) and a new medium was placed.  
16. The medium was replaced after 24 hours and every 48 hours subsequently until 
reaching 90% confluence and ready for passage. 
17. The passage protocol and subsequent culture in complete serum-free conditions was 
performed according to the methods found in Appendix 3. 
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 Appendix	 12	 –	 Obtainment	 of	 adipose	 tissue	
and	animal	model	surgery	
Surgical	procedures	
*Ewes (Perendale sheep – Ovis aries), weighting on average 56.06Kg were used. 
*All surgeries were performed at the Hercus Taieri Research Unit (HTRU), University 
of Otago 
*An experienced veterinary technician performed all drug administrations and 
antisepsis. 
*All experiments were performed in aseptic conditions. 
Preparation	
1. The animals were sedated with Diazepam 0.2mg/kg (IV) (Ceva Animal Health Pty 
Ltd, Cat# PAMLAB02) and Ketamine 2mg/kg (IV) (Phoenix Pharm Distributors Ltd, 
Cat# DS06/11). 
2. The analgesic and antibiotic coverage were also started with Carprofen 5mg/kg (SC) 
and Amphoprim 30mg/kg (SC) respectively. 
3. General anaesthesia (GA) was induced with Sodium Thiopentone 2.5% 10mg/Kg 
(IV). The GA was maintained over-time with inhalation of halothane (1-2% to effect). 
4. The operative site was shorn and prepared with 2% Chlorhexidine (Riotane®) and 
10% povidone-iodine solution (Betadine®) and the body draped with disposable surgical 
drapes (Convertor, Tiburon, Cat# 08KAH738, 8476, and 29494). 
Obtainment	of	adipose	tissue	
1. An approximately 15cm long skin incision was made with a scalpel blade No. 22 
(Swann-Norton, Cat# 0308) to expose the subcutaneous fat (Figure 62). 
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Figure 62 – Approximately 15cm long skin incision. 
 
2. The adipose tissue was dissected and removed with a scalpel blade No. 15 (Swann-
Norton, Cat# 0305) and tissue scissors (Figure 63). 
 
Figure 63 – Dissection of adipose tissue. 
 
3. The adipose tissue was collected in labelled 50ml sterile falcon tubes (Figure 3). 
*Approximately 10g of adipose tissue were removed from each animal. 
* Each falcon flask contained a filtered sterile (0.22µm) solution: 
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20ml of PBS 
400mg (20mg/mL) BSA (bovine serum albumin) 
0.2mL (1%) antibiotic-antimycotic (penicillin/streptomycin) 
 
Figure 64 – The adipose tissue was collected into a falcon flask. 
 
4. The wound was closed in a single layer with 2-0 Maxon suture. 
5. The animal was taken to an individualised paddock for recovery. 
6. The tissue was taken to cell culture facility of the Molecular Biosciences Laboratory 




1. A local anaesthetic Scandonest® 2% with 1:100,000 adrenaline (Septodont, Cat# 
09821172700) was injected in the region of the femur epicondyle (Figure 65). 
 
Figure 65 – Local anaesthetic injection. 
 
2. An approximately 15cm long incision on the skin was made at the femur epicondyle 
region with an electrosurgical blade (Figure 66). 
 
Figure 66 – Skin incision to access the femur epicondyle. 
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3. An incision of the underlying tissues was made with a scalpel blade No. 22.  
4. The periosteum was elevated to expose the bone surface of the femur epicondyle 
(Figure 6). 
 
Figure 67 – The periosteum was elevated to expose the bone surface. 
 
5. A 10mm trephine bur (Predictable Surgical Technologies, Cat# 1315-9.0) was used 
outline the position, depth, and length of the defects (Figure 68). 
 
Figure 68 – Outline of the osseous defects created by a 10mm trephine bur. 
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6. A 8mm ablative bur (Meisinger, Cat#DD207) was subsequently used to prepare the 
defects to a depth of 7mm (Figure 69). A bone chisel was used at the bottom of the 
defects to assure that a flat and smooth surface was achieved. The depth was checked 
with a periodontal probe (Williams markings). 
 
Figure 69 – A 8mm ablative bur was used to prepare the defect to a depth of 7mm. 
 
7. The titanium discs measuring 10mm x 1.5mm (diameter x thickness) were randomly 
allocated and placed inside the defects (Figure 70). 
 
Figure 70 – Discs positioned inside the defects. 
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8. An extra defect called sentinel was prepared with a cylindrical implant drill with 
markings. Tantalum beads were use to mark the location of the sentinel defect (see 
Chapter III).  
 
9. The blood clot with or without cells was randomly allocated and placed into the 
defects (Figure 71). 
 
Figure 71 – Blood clot with or without cells was placed into the defects. 
 
10. The periosteum was repositioned and sutured using a horizontal mattress suture with 
3-0 Vicryl. 
11. The muscle, fibrous tissue, and skin were sutured using a continuous suture with 2-0 
Maxon (Figure 72 and Figure 73). 
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Figure 72 – Continuous suture of the muscle and fibrous tissues using a continuous suture. 
 
 
Figure 73 – Continuous suture of the skin. 
 
12. Once sutured, the skin was cleaned and a long-acting local anaesthetic Marcain® 
0.5% with 1:200,000 adrenaline was injected around the surgical wound. 
13. The animal was taken to an individualised paddock for recovery. 
Euthanasia	
*Euthanasia was performed after the experimental period of one month. 
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1. The animals were euthanised under GA as per previous protocol (for GA see 
“Preparation” above). 
2. Bilateral incisions beside the trachea were made and the carotid artery dissected and 
exposed. 
3. Catheters (Jelco Optiva - Smiths Medical, IV catheter 14G x2inch, Cat# 5068) were 
inserted into the carotids and secured using ligatures with a 3-0 mononylon suture. The 
catheters were connected to lines connected to 1L bag of saline.  
4. The animals were bilaterally perfused with saline containing 5,000 I.U. of heparin 
sodium (DBL Heparin Sodium Injection BP, Hospira, Cat# 218070) via gravitational 
pressure. 
5. Once the water was finished, 1L of 10% formalin was introduced bilaterally into the 
bags for perfusion via gravitational pressure. 
6. Once the fixation was performed, the femur epicondyles were dissected and removed 







*2x T75 or 1x T175 were used. 
*Cell used were between 80 to 90% confluent. 
- Protocol for T75. 
1. Cells were observed in a monolayer from basal cultures of oADSC expanded in SFM 
to ensure mid-log growth phase confluence (80-90%). Medium and floating cells from 
culture flask were discarded. 
2. 10mL of PBS was added and the cell monolayer rinsed gently. 
3. PBS was discarded and 3mL of pre-warmed TrypLE Express was added to flask 
completely coating the culture surface; incubated for 3 minutes. 
4. The cell suspension was collected into a centrifuge tube and pelleted down at 150×g 
for 5 minutes. 
5. The cells were resuspended in minimal volume SFM and the cell viability and total 
cell density were determined using Trypan Blue stain and manual cell counting method 
(haemocytometer). 
PKH26	Labelling	procedure	
*The following protocol followed the manufacturers method. 
*The following procedure used a 2mL final staining volume, containing final 
concentrations of 0.6x10–6 M of PKH26 and 3x106 cells/mL. 
*The following steps were performed at RT. 
1. A suspension of oADSC containing 6x106 single cells was placed in a 50mL falcon 
flask and washed once using SFM (1mL). 
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*Serum proteins and lipids also bind the dye, reducing the effective concentration 
available for membrane labelling. Best results were obtained by washing the cells once 
with SFM (step 1) prior to resuspension in Diluent C for labelling (step 4). 
2. The cells were centrifuged at 400×g for 5 minutes into a loose pellet. 
*The PKH26 ethanolic dye solution was not added directly to the cell pellet. This would 
result in heterogeneous staining and reduced cell viability. 
3. After centrifuging cells, the supernatant was carefully aspirated leaving no more than 
25µL of supernatant. 
*For reproducible results, it was important to minimise the amount of residual SFM 
present when cells are resuspended in Diluent C.  
4. A 2x Cell Suspension was prepared by adding 1 mL of Diluent C (Cat# G8278) to the 
cell pellet and resuspended with gentle pipetting to insure complete dispersion. The 
cells were not vortex and not let stand in Diluent C for long periods of time. 
*The presence of physiologic salts would cause the dye to form micelles compromising 
the staining efficiency. Therefore, it was important that the cells were suspended in 
Diluent C at the time the dye was added, not in SFM or buffered salt solutions. 
5. Immediately prior to staining, a 2x Dye Solution (4x10–6 M) was prepared in Diluent 
C by adding 4µL of the PKH26 ethanolic dye solution (Cat# P9691) to 1mL of Diluent 
C in a falcon flask and mixed well to disperse. 
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Table 31 – PKH26 staining preparation. 
Method Molarity of Dye Dye volume Cell number 
Manufacturer 
protocol 
4x10–6 M 4µL 1x107 cells/mL 
My protocol 1.2x10–6 M 4µL (new stock*) 0.5x107 cells/mL 
*Equation 6 – To make new stock: 
4M - 4µL 
2M – X 
X = 2µL of dye + 2µL of ethanol (add in 1mL of diluent C) 
 
* If a final dye concentration < 2x10–6 M is desired, the most reproducible results will 
be obtained by diluting the PKH26 ethanolic dye solution provided in the kit with 100% 
ethanol to make an intermediate dye stock (see table and equation above). 
*To minimize ethanol (MOB grade) effects on cell viability, the volume of dye added in 
step 5 resulted in no more than 1–2% ethanol at the end of step 6. 
6. 1 mL of 2x Cell Suspension (step 4) was rapidly added to 1mL of 2x Dye Solution 
(step 5) and the sample immediately mixed by pipetting. Final concentration after 
mixing the indicated volumes was 2.5x106 cells/mL and 1x10–6 M PKH26. 
*Because staining was nearly instantaneous, rapid and homogeneous dispersion of cells 
in dye solution was essential for bright, uniform, and reproducible labelling. Following 
the manufacturer recommendations, the following measures have been found to aid in 
optimizing results: 
a. Ethanolic PKH26 dye was not added directly to the 2x Cell Suspension in 
Diluent C.  
b. Equal volumes of 2x Cell Suspension (step 4) and 2x Dye Solution (step 5) were 
added.  
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c. 2x cell and 2x dye concentrations were adjusted to avoid staining in very small 
(< 100µL) or very large (> 5mL) volumes.  
d. Pipetman was used for rapid addition of cells and admixing with dye. 
Serological pipettes were not used because they are slower and give less uniform 
staining. Mixing by “racking” or vortex was not used because they are also 
slower and gives less uniform staining. 
e. Volumes were dispensed as precisely as possible in order to accurately 
reproduce both cell and dye concentrations from sample to sample.  
7. The cell/dye suspension was incubated for 2.5 minutes with periodic mixing. Because 
staining was so rapid, longer times provided no advantage. 
*Cells were exposed to dye solution and Diluent C for the minimum time needed to 
achieve the desired staining intensity. Since Diluent C lacks physiologic salts, longer 
exposure could cause reduced cell viability. 
8. The staining was stopped by adding an equal volume (2mL) of autologous SS and 
incubated for one minute to allow binding of excess dye. 
*Autologous SS was preferred as the stop solution. 
*SFM or buffered salt solutions (i.e. PBS) were not used as stop solution, because they 
would cause the formation of cell-associated dye aggregates. Dye aggregates would act 
as slow-release reservoirs of unbound dye that were not efficiently removed by washing 
and could be transferred to unlabelled cells present in the experiment (i.e. surrounding 
tissues). 
9. The cells (PKH26/oADSC) were centrifuged at 400xg for 10 minutes at 20-25°C and 
the supernatant carefully removed, being sure not to remove cells. The cells were 
resuspended in 10mL of SFM, transferred to a fresh sterile falcon flask tube, 
centrifuged at 400xg for 5 minutes at 20-25°C, and washed two more times with 10mL 
of SFM to ensure removal of unbound dye. 
*Transferring to a new flask increased washing efficiency by minimising carryover of 
residual dye bound to the flask walls. 
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10. After the final wash, the cell pellet was resuspended in 10mL SFM for assessment 
of cell recovery, viability, and fluorescence intensity. Cells were centrifuge and 
resuspended to the desired final concentration of viable cells. 
*Staining was typically at least 100-1,000 times brighter than background (auto-
fluorescence). Intensity distributions were symmetrical and as homogeneous as 
possible. 





 Appendix	 14	 –	 Undemineralised	 tissue	
histology	
Resin	embedding	protocol	
*This protocol was adapted from the protocol of Ms Monika Aeberhard, School of 
Dentistry, Berne University, Berne, Switzerland. 
1. The animals were perfused through the carotid arteries bilaterally using 1L of 
heparinised saline per side followed by 1L formalin per side. The tissues were resected 
en bloc.  
2. The hard tissue was specimens were fixed in 10% formalin at RT for 7 days inside a 
fume hood.  
3. The tissue containing the sentinel defect was trephined and stored in 10% formalin in 
the dark (see Chapter 3 – Histological preparation).  
4. Radiographs were taken at this point (Figure 74). 
 
Figure 74 – Radiograph of the femoral head.  
 
5. Specimens were reduced in size to approximately 10mm3. 
6. The specimens were transferred to histology cassettes, accompanied by paper label 
marked in pencil.  
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7. The 10% formalin was discarded (“Hazardous Waste”).  
8. Specimens were placed in 20% alcohol - ultrasonic treated for 15 minutes and then 
left for 24 hours on oscillating platform in the fume hood at RT.  
9. Specimens were placed in 40% alcohol - ultrasonic treated for 15 minutes and then 
left for 24 hours on oscillating platform in the fume hood at RT. 
10. Specimens were placed in 75% alcohol - ultrasonic treated for 15 minutes and then 
left for 24 hours on oscillating platform in the fume hood at RT. 
11. Specimens were placed in 95% alcohol - ultrasonic treated for 15 minutes and then 
left for 24 hours on oscillating platform in the fume hood at RT. 
12. Specimens were placed in 100% alcohol - ultrasonic treated for 15 minutes and then 
left for 24 hours on oscillating platform in the fume hood at RT. 
13. Specimen were washed in xylene and discarded (“Hazardous Waste”).  
14. Specimens were placed in xylene - ultrasonic treated for 15 minutes and then left for 
24 hours on oscillating platform in fume hood at RT. Glass jars were used as xylene 
dissolves plastic containers. 
15. Specimens were washed in methyl methacrylate (MMA) monomer (the jar labelled 
“MMA wash” was used; this was the  discarded MMA I – see step 17). MMA wash 
liquid was discarded into an appropriate container. Could not be tipped down the drain 
as it would set solid.  
16. The cassettes were transferred to MMA I for two days, on an oscillating platform in 
the fume hood. Specimens were kept covered to avoid excessive MMA evaporation.  
17. The cassettes were transferred to MMA II (Table 32) for two days on an oscillating 
platform in the fume hood. Specimens were kept covered to avoid excessive MMA 
evaporation. Discarded  MMA I was placed into a jar marked “MMA wash”. 
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Table 32 – Method for MMA II (2L). 
Product Quantity 
4 parts of Methyl methacrylate 99% with 130ppm of 
hydroquinone inhibitor (Sigma Aldrich, Cat# M55909) 
1.6L 
1 part of Dibutyl phthalate 99% (Sigma Aldrich, Cat# 524980) 400mL 
0.5% of Benzoyl peroxide 75%, Luperox® A75 (Sigma Aldrich, 
Cat# 517909) 
20g 
Total Approximately 2L 
 
18. The specimens were removed from the cassettes and transferred to individual jars 
with tight-sealing lids, having pre-set bases of approximately 10mm thick MMA III 
(Table 33). This base acted as an initiator for the setting reaction, and also ensured that 
the sample was positioned in the middle of the resin block. 
 
Table 33 – Method for MMA III (1.85L, enough for 70 jars). 
Product Quantity 
4 parts of Methyl methacrylate 99% with 130ppm of 
hydroquinone inhibitor (Sigma Aldrich, Cat# M55909) 
1.48L 
1 part of Dibutyl phthalate 99% (Sigma Aldrich, Cat# 524980) 370mL 







19. Each specimen was accompanied with labelled paper ID tag that stayed with the 
specimen throughout dehydration and embedding. Specimens were oriented flat on 
bottom of the jar – did not touched the sides of the jar. 
20. The jars were placed in a water bath at RT in the fume hood and left undisturbed for 
3 weeks. If not set after 3 weeks, the specimens were place in a warm place under direct 
sun light. 
21. Once specimen was set, the glass was fractured away from sample by clamping in 
the vice; inside a plastic bag to catch glass fragments. The glass jars were wrapped in a 
towel to protect the operator against flying debris. Safety glasses and gloves were used. 
22. The bulk of resin block was reduced and the margins grinded flat using a lab model 
grinder. 
23. Porosities in the block were removed using Struers Clarocit Universal cold 
mounting acrylic, made up as a runny solution and poured into porosities. This was set 
in a pressure pot with warm water for 15 minutes. 
24. The blocks were polished using a Struers grinder with waterproof Struers Silicon 
Carbide Paper in grit sizes 1200 and 2400. This allowed an unobstructed viewing of the 
specimen prior to cutting. Struers TegraPol-21 was used with polishing papers fit 
directly. 
25. The blocks were mounted in a Struers Accutom-50 either by super-gluing to a pre- 
cut acrylic block within the chuck. 
26. The water in the machine was checked and lubricant (Struers Additive for Cooling 
Fluid, Cat. No 49900002 ADDUN) added. 
27. Sections were cut using Struers diamond saw with factory settings on Accutom-50. 
The specimens were cut using the smaller blade 330CA (Struers, Cat# M0D13, 127mm 
x 400µm x 12.7mm) at 3500 RPM. Three 700µm thick sections were cut from the 
middle of the block. 
28. Each lowermost side of the cut sections was briefly polished for 20 seconds with 
4000 paper, then wiped with acetone on gauze and glued to an acrylic slide using 
cyanoacrylate glue and a custom-designed section press with a plastic sheet as 
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separating medium. The bases were labelled of the acrylic plate on both sides using a 
diamond drill. 
29. Prior to grinding, the thickness of each section was checked using a digital 
micrometre. 
30. Thick sections were ground to 100µm ± 20µm semi-thin sections using an 
automated grinding and polishing machine (TegraPol-21, Struers). Slides were held 
using a custom designed specimen holder and manually pressed against the sand paper. 
The specimens were often rotated to ensure uniform grinding of the slide. 
31. Specimens were ground using 500 grit paper to approximately 300 - 400µm, then 
1200 grit to approximately 120 - 150µm, then polished using 2400 and 4000 grit to 80 – 
120µm final thickness. 
32. Polished sections were stained using MacNeils Tetrachrome and Toluidine blue 
with acid fuschin counterstain (see method below). 
33. Once stained the sections were ready for microscopic analysis. 
Staining	protocol	
*The stain used was MacNeals’ Tetrachrome combined with Toluidine Blue solution. 
*The stain was made fresh for optimum results. 
Preparing	the	MacNeals’	Tetrachrome	dye	with	Toluidine	blue	
1. Solution A was prepared by mixing all the ingredients below with a magnetic stirrer 
until clear and no precipitate. The solution was left for 12 hours at 50ºC then 3 days at 
37ºC. The solution was filtered and stored in the dark in a bottle covered with 
aluminium foil. 
0.5 g Methylene blue (Merck 15943) 
0.8g Azur II (Merck 9211) 
0.1g Methyl violet 2B (Sigma M 0527) 
250 ml Methanol 
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250 ml Glycerol 
2. Solution B was prepared combining 1g of Toluidine blue in 100mL of distilled water 
with 1g of borax. The solution was stored in the dark in a bottle covered with 
aluminium foil. 
3. Solutions A and B were combined 2:1 respectively. 10ml of solution A mixed with 
5mL of solution B were made up to 100mL with distilled water, mixed well, and stored 
in the dark in a bottle covered with aluminium foil. 
Staining	protocol	
1. Sections were placed in 40% Ethanol in a staining (Coplin) jar. 
2. Placed in ultrasonic bath for 5 minutes. 
3. Without rinsing the sections, ethanol was replaced with 0.1% Formic acid for 5 
minutes in ultrasonic bath. 
4. The sections were washed with tap water. 
5. Section were covered on with MacNeals’ Tetrachrome plus Toluidine blue solution 
(solutions A + B) using an eyedropper and stained for 5 minutes. 
6. Sections were rinsed with distilled water for 5 minutes. 
7. Sections were covered with 0.05% acid Fuschin (in water) for 10 minutes. 
8. Sections were cleaned with distilled water and air-dried. 






The following reagents were mixed well: 
75mL of picric acid (saturated). 
25mL of formaldehyde (37-40%). 
5mL of glacial acetic acid. 
Weigert’s	Iron	Hematoxylin	solution	
1. Stock solution A was prepared mixing the following reagents: 
1g of hematoxylin (Sigma Aldrich, Cat# H3136). 
100mL of 95% alcohol. 
2. Solution B was prepared mixing the following reagents: 
4mL of ferric chloride (29g/100mL of iron (III) chloride FeCl3, Sigma Aldrich, Cat# 
57740). 
 95mL of distilled water. 




*The staining was performed using the kit Accustain Trichrome Stains (Masson) 
(Sigma Aldrich, Cat# HT15). 
*The kit provided all the reagents apart from the above ones. 
1. Tissue sections were deparaffinised and hydrated to deionised water. 
2. Sections were mordant in Bouin’s solution at 56°C for 15 minutes. 
3. Sections were washed in running tap water until the yellow colour was removed. 
4. Sections were stained in Weigert’s Iron Hematoxylin solution for 5 minutes. 
5. Sections were washed in running tap water for 5 minutes and then rinsed in deionised 
water. 
6. Sections were stained in Biebrich Scarlet Acid Fuchsin solution for 5 minutes. 
7. Rinse in deionised water. 
8. Sections were placed in Phosphotungstic-Phosphomolybdic Acid solution for 5 
minutes. 
9. Sections were stained in Aniline Blue solution for 5 minutes. 
10. Sections were placed in 1% Acetic Acid solution for 2 minutes. 
11. Sections were rinsed, dehydrated through alcohol, cleared in xylene, and coverslip 
with DPX (Sigma Aldrich, Cat# 06522). 
12. Interpretation of staining as follows: 
Nuclei – Black  
Collagen – Blue  







1. The image was opened in the FIJI software. 
2. The image was converted to 8bit grey scale. Image > Type > 8Bit (Figure 75). 
 
Figure 75 – Image conversion to 8bit grey-scale. 
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3. The area of interest was selected (yellow) and cropped using the titanium disc as 
reference (Figure 76). 
 
Figure 76 – Selection and cropping of the area of interest (yellow) using the titanium disc as 
reference. 
 
4. The brightness and contrast were adjusted to facilitate the later thresholding of the 
image. Image > Adjust < Brightness/Contrast (Figure 77). 
 
Figure 77 – Adjustment of brightness/contrast. 
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5. The measurements used in the analysis were set to calculate the area fraction limited 
to threshold. Analise > Set measurements (Figure 78). 
 
Figure 78 – Measurements were set for the analysis. 
 
6. The image was threshold to select the whole tissue and analysed. Analyse > Measure 
(Area value was between 0 and 100. This value was equivalent to 100% of the tissue, 
the remaining was just background) (Figure 79). 
 
Figure 79 – Thresholding of the whole tissue. 
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7. The image was threshold again, now selecting only the mineralised portion of the 
bone. Analise > Measure (Figure 6). The area fraction value was converted using the 
100% whole tissue equivalent. 
 
Figure 80 – Thresholding of mineralised bone. 
 
8. The final percentage of mineralised bone was calculated using the following 
equation: 
Equation 7 – Percentage of mineralised bone 
Percentage of mineralised bone (%) = fraction area of mineralised bone threshold x 100 









*The percentage of mineralised bone was measured independently from 10 sections 
randomly selected. The principal evaluator (Diogo Godoy Zanicotti – DGZ) had its 
measurement checked against the ones independently performed by Dr Carolina Loch 
Santos da Silva (CL). 
 




























A complete list of media used in all experiments (in order of appearance) follows: 
1. StemPro MSC SFM Xeno-free kit (Serum-free medium - SFM), commercial, serum-
free. Designation for cells grown in this medium: hADSC (human adipose-derived stem 
cells) and oADSC (ovine adipose-derived stem cells)*. 
*For oADSC adaptation to a serum-free environment, the cells were initially cultured in 
autogenous sheep serum (see page 75, section 3.2.4) 
2. StemPro Osteogenic differentiation kit (Osteogenic differentiation medium – OM), 
commercial, contain serum. Designation for cells grown in this medium: hOS-ADSC 
(osteogenically differentiated human adipose-derived stem cells). 
3. StemPro Adipogenesis differentiation kit (Adipogenic differentiation medium – AD), 
commercial, contain serum. Used for adipogenic differentiation of both hADSC and 
oADSC. 
4. StemPro Chondrogenesis differentiation kit (Chondrogenic differentiation medium – 
CD), commercial, serum-free. Used for chondrogenic differentiation of both hADSC 
and oADSC. 
5. Ovine osteogenic differentiation medium (oOM), own production as described in 
chapter 3.2.5, contain autologous ovine serum. Designation for cells grown in this 
medium: oOS-ADSC (osteogenically differentiated ovine adipose-derived stem cells). 
